,date,information,related
0,2022-07-20,"Headline: Stock Market Today: Track Market Trends And The Best Stocks To Watch, source:Yahoo, summary: Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.",VRTX
1,2022-09-23,"Headline: 7 Growth Stocks to Buy During a Stock Market Crash, source:InvestorPlace, summary: A stock market crash will only strengthen the outlook of these companies, making them good growth stocks to buy., Headline: Dow Jones Sells Off Ahead Of Powell Comments As Recession Fears Mount, source:Yahoo, summary: The Dow Jones Industrial Average sold off Friday ahead of Fed chief Powell's comments at a Federal Reserve event in Washington D.C., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $283.45 in the latest trading session, marking a -1.01% move from the prior day.",VRTX
2,2022-09-24,"Headline: Recession Fears Increasing: Here's the Best Stock to Buy Right Now, source:Yahoo, summary: Here's my pick for the best stock to buy right now with recession fears rising.  Vertex Pharmaceuticals (NASDAQ: VRTX) has soared close to 30%, absolutely trouncing the S&P 500.  How has Vertex seemingly defied gravity?, Headline: S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market, source:Yahoo, summary: S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market.",VRTX
3,2022-09-25,"Headline: Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 86%, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying..., Headline: Is Now the Right Time to Be Buying Growth Stocks?, source:Yahoo, summary: There are plenty of fierce headwinds in play, but that doesn't mean you should sit on the sidelines.",VRTX
4,2022-09-26,"Headline: Can Healthcare Stocks Continue To Outperform? , source:TalkMarkets, summary: Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis., Headline: Dow Jones Continues To Fall As Stock Market Correction Worsens; Treasury Yields Surge, source:Yahoo, summary: The Dow Jones Industrial Average dropped Monday, as the stock market correction worsened. The 10-year Treasury yield surged to new highs., Headline: 4 Stocks To Watch In Today's Stock Market: Hostess, J.M. Smucker, Toro, Vertex, source:Yahoo, summary: Hostess Brands, J.M. Smucker, Toro and Vertex Pharmaceuticals are stocks to watch, as the current stock market correction continues., Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 2.35% to $276.78 Monday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Dow Jones Hits Bear Market After Today's Sell-Off; What To Do Now, source:Yahoo, summary: Dow Jones futures were little changed ahead of Tuesday's open. The Dow Jones Industrial Average finished in a bear market Monday., Headline: Vertex Pharmaceuticals Moves Up In Market Cap Rank, Passing Analog Devices, source:The Online Investor, summary: the online investor,VRTX,ADI,",VRTX
5,2022-09-27,"Headline: The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market., Headline: Why Low Volatility ETFs Are Beating The Market, source:TalkMarkets, summary: Low volatility investing is back in vogue since the market environment remains extremely challenging., Headline: Vertex, Crispr announce regulatory submissions for exagamglogene autotemcel, source:Thefly.com, summary: Vertex Pharmaceuticals (V... VRTX, CRSP, Headline: IN BRIEF: Vertex Pharmaceuticals granted US rolling review for exa-cel, source:Alliance News, summary: No summary, Headline: CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy , source:MarketWatch, summary: CRISPR Therapeutics Inc. undefined and Vertex Pharmaceuticals Inc. undefined said Tuesday that the Food and Drug Administration granted a rolling review to..., Headline: S&P 500 Bear Market: Where to Invest $10,000 Right Now, source:Yahoo, summary: After an all-too-short bounce, the S&P 500 is again in a bear market.  The Nasdaq Composite Index has been firmly in bear market territory for weeks.  Arguably the smartest place to park $10,000 right now is in the U.S. Treasury's Series I savings bonds., Headline: Why Is Crispr Therapeutics (CRSP) Stock Up Today?, source:InvestorPlace, summary: Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review., Headline: Vertex exa-cel filing timeline 'better than feared,' says Morgan Stanley, source:Thefly.com, summary: After Vertex Pharmaceutic... VRTX, CRSP, BLUE, Headline: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022, source:Yahoo, summary: BOSTON & ZUG, Switzerland, September 27, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rol, Headline: CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy, source:Yahoo, summary: CRISPR Therapeutics Inc. and Vertex Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%. Vertex said it plans to a submit an application to the FDA in November, with plans to complete the submission in the first quar, Headline: NEW YORK MARKET CLOSE: Nasdaq breaks into green, Dow and S&P still red, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 2.88% to $284.74 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug, source:Yahoo, summary: Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped., Headline: Why Vertex Pharmaceuticals Stock Triumphed On Tuesday, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on Tuesday thanks to news about one of its pipeline programs., Headline: S&P 500 Undercuts Bear Market Low As Treasury Yields Race Toward Key Level; What To Do Now, source:Yahoo, summary: The S&P 500 joined the Dow Jones in undercutting bear market lows as the 10-year Treasury yield races toward 4%. Here's what to do now.",VRTX
6,2022-09-28,"Headline: MaxCyte signs strategic platform license with Vertex Pharmaceuticals, source:Thefly.com, summary: MaxCyte (MXCT) announces ... MXCT, VRTX, Headline: MaxCyte Signs Platform License with Vertex Pharmaceuticals, source:MarketWatch, summary: By Michael Susin MaxCyte Inc. said Wednesday that it has signed a strategic platform license with Vertex Pharmaceuticals Inc. to continue the use of..., Headline: Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever, source:Yahoo, summary: Let's talk about two leaders in their markets and a well-diversified healthcare company with a track record of success.  Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating returns for investors for quite a while.  Vertex is the global market leader in the treatment of cystic fibrosis (CF)., Headline: The 2 Best Stocks to Invest $5,000 in Right Now, source:Yahoo, summary: Between rumors of a recession, rising interest rates, and inflation, it's tough to find stocks that you're confident will keep growing instead of going to zero.  Vertex Pharmaceuticals (NASDAQ: VRTX) is worth a $2,500 investment because it's the world's largest public business devoted to curing rare diseases, and it's proven to be quite adept at that goal so far., Headline: 3 Biotech Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: Several biotech stocks have outperformed the struggling market this year.  This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN).  Let's consider why these three biotechs are solid buys for the next decade., Headline: Dow Jones Rises Ahead Of Powell Speech; 10-Year Treasury Yield Briefly Tops 4%, source:Yahoo, summary: The Dow Jones Industrial Average rose Wednesday, ahead of Fed chief Powell's speech, struggling to avoid a seventh straight decline., Headline: Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy, source:Yahoo, summary: Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.69% to $292.41 Wednesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Dow Jones Jumps 549 Points As Treasury Yields Tumble, But Now What? Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now., Headline: Vertex Nears Buy, Joins Crispr To Advance A Gene-Editing First, source:Yahoo, summary: As biotech leaders Vertex and Crispr shoot for a gene-editing first, VRTX stock takes aim at a new breakout.",VRTX
7,2022-09-29,"Headline: 3 Stocks to Buy if You're Afraid to Buy Stocks, source:Yahoo, summary: Concerns are mounting that a full-blown recession could be on the way.  Here are three stocks to buy if you're afraid of buying stocks.  The stock market's huge downturn so far this year hasn't impacted Vertex Pharmaceuticals (NASDAQ: VRTX) in the least., Headline: Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks., Headline: Vertex Pharmaceuticals' (NASDAQ:VRTX) five-year earnings growth trails the 14% YoY shareholder returns, source:Yahoo, summary: When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking..., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.13% higher to $292.80 Thursday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $292.80 in the latest trading session, marking a +0.13% move from the prior day., Headline: VRTX vs. SRPT: Which Biotech Stock is Better?, source:TipRanks, summary: It seems that hedge funds have a love/hate relationship with the biotechnology sector, and it&#8217;s easy to see why they are split on the sector. In this piece, w...",VRTX
8,2022-09-30,"Headline: Got $1,000? 2 Safe Stocks to Buy This Month, source:Yahoo, summary: If you're not familiar with Vertex Pharmaceuticals (NASDAQ: VRTX), this healthcare stock is certainly one to put on your radar.  The company develops and manufactures medicines that treat rare diseases.  As of right now, it has four approved products, and all of them treat cystic fibrosis., Headline: Dow Jones Drops On Hot Inflation Data; Tesla Stock Rises Before AI Day, source:Yahoo, summary: The Dow Jones Industrial Average dropped Friday on hot inflation data. Tesla stock fell ahead of the company's AI Day., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.11% to $289.54 Friday, on what proved to be an all-around dismal trading session for the stock market, with...",VRTX
9,2022-10-01,"Headline: Vertex Stock Flashes Buy Signal; Gene-Editing Play Leads 5 Resilient Stocks In Bear Market, source:Yahoo, summary: Vertex Pharmaceuicals flashed a buy signal last week on positive gene-editing news. It's one of several resilient stocks to watch in the bear market., Headline: 3 Growth Stocks Poised to Skyrocket, source:Yahoo, summary: What's better than a growth stock that's performed well in the past?  The answer is easy: A growth stock that should perform well in the future.  Here's why they chose Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX).",VRTX
10,2022-10-03,"Headline: Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio , source:TalkMarkets, summary: Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio., Headline: Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value, source:SeekingAlpha, summary: Following the breakthrough deal with GSK, Spero is in a comfortable position to advance its pipeline. Read more to see why I'm bullish on SPRO stock., Headline: Investing in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago would have delivered you a 87% gain, source:Yahoo, summary: Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the..., Headline: bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line, source:Yahoo, summary: bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line., Headline: Dow Jones Rallies As Tesla Stock Dives On Deliveries Miss, source:Yahoo, summary: The Dow Jones Industrial Average rallied 450 points Monday. Tesla stock skidded after the company missed estimates on vehicle deliveries., Headline: Vertex Among 9 Stocks To Watch In Struggling Market, source:Yahoo, summary: As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength., Headline: Stocks To Watch In Today's Market Include Dow Jones Leader UnitedHealth, source:Yahoo, summary: Dow Jones leader UnitedHealth is one of the top stocks to watch in today's market rally. The current stock market correction continues., Headline: ARKG: Too Hard To Pin Down, Too Volatile For Comfort, source:SeekingAlpha, summary: ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. Click here to read more., Headline: Vertex Pharmaceuticals: A Buy For Growth Potential, source:SeekingAlpha, summary: Vertexâs cystic fibrosis franchise is the main source of value at present. Learn more about VRTX stock and my recommendation., Headline: Dow Jones Surges 765 Points To Start New Stock Market Rally Attempt, What To Do Now, source:Yahoo, summary: Dow Jones futures were little changed ahead of Tuesday's open. A new stock market rally attempt started Monday, as the Dow Jones industrials surged.",VRTX
11,2022-10-04,"Headline: 1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now), source:Yahoo, summary: The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon., Headline: Spiros Segalas Snatches Up Ver - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Guru releases 3rd-quarter portfolio, Headline: Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock, source:Yahoo, summary: No summary, Headline: Dow Jones Surges 600 Points As Treasury Yields Tumble; Apple, Tesla Rally, source:Yahoo, summary: The Dow Jones Industrial Average surged 600 points Tuesday, as the 10-year Treasury yield continues to tumble. Apple and Tesla rallied., Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended., Headline: Stock Market Holds Morning Gains, Oil and Gas Play Breaks Out, source:Yahoo, summary: The stock market rallied for a second day, with fewer job openings than expected driving the upside. This diabetes stock rises on approval in Europe.",VRTX
12,2022-10-05,"Headline: 3 Healthcare Stocks That Could Make You Richer, source:Yahoo, summary: If you're looking to get richer over time (and who isn't?), healthcare stocks are often a good choice.  Vertex Pharmaceuticals (NASDAQ: VRTX) is at a major turning point in an already successful story.  Vertex is the leader in the global cystic fibrosis (CF) treatment market., Headline: Vertex Among 25 Market Leaders On The IBD Breakout Stocks Index, source:Yahoo, summary: As the market shows signs of a rebound, Vertex, Enphase and Shockwave Medical are among 25 stocks to watch., Headline: Dow Jones Sells Off After Jobs Data; Key Economic Data, OPEC Meeting On Tap, source:Yahoo, summary: The Dow Jones Industrial Average sold off 300 points Wednesday after a stronger-than-expected ADP employment report., Headline: Why Vertex Pharmaceuticals' Shares Rose 2.8% in September, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX), a biopharmaceutical company that specializes in gene-editing therapies, saw its shares rise 2.8% in September, according to data provided by S&P Global Market Intelligence.  Vertex easily went against the tide, though.  Vertex, known for its franchise of therapies to treat cystic fibrosis (CF), a rare genetic disorder that affects the lungs, pancreas, liver, kidneys, and intestines, showed that it is about to expand its portfolio of marketed drugs., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $302.02, marking a +0.46% move from the previous day., Headline: Dow Jones Futures Rise: Market Rally At Pivotal Point; Tesla, Enphase Fall, source:Yahoo, summary: The stock market rally showed resilience, as the Dow Jones slashed early losses, but is at a pivotal point. Tesla fell while Enphase plunged.",VRTX
13,2022-10-06,"Headline: 3 Stocks Savvy Investors Are Buying Hand Over Fist, source:Yahoo, summary: While the SPDR S&P Healthcare ETF is down 10% year to date, the SPDR S&P Biotech ETF has plummeted 29%.  Investors should always keep the long-term potential of businesses in mind when investing in the stock market.  Sunosi, purchased from Jazz Pharmaceuticals in May, has been Axsome's blockbuster drug., Headline: VRTX November 25th Options Begin Trading, source:Stock Options Channel, summary: Staff article entitled VRTX November 25th Options Begin Trading, about stock options, from Stock Options Channel., Headline: Dow Jones Futures Fall: Market Rally At Pivotal Point; Tesla, Enphase Skid, source:Yahoo, summary: The stock market rally showed resilience, as the Dow Jones slashed early losses, but is at a pivotal point. Tesla fell while Enphase plunged., Headline: Dow Jones Slides As Jobless Claims Rise; Pivotal Jobs Report On Deck, source:Yahoo, summary: The Dow Jones Industrial Average fell Thursday after weekly jobless claims. The pivotal September payroll report is due out Friday morning., Headline: This Biotech Stock Nears Buy Point As It Expands Into Other Markets, source:Yahoo, summary: Vertex Pharmaceuticals is approaching a buy point as this biotech stock expands into other markets, gains institutional investors.",VRTX
14,2022-10-07,"Headline: 4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire, source:Yahoo, summary: Most investors would like to see their stock portfolio grow significantly, especially if they have quite a few years left until retirement.  Alphabet (NASDAQ: GOOG), Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly and Company (NYSE: LLY), and Meridian Bioscience (NASDAQ: VIVO) all show solid potential to grow your investments significantly.  Alphabet's stock has risen 105% over the past five years., Headline: Pinning Down Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) P/E Is Difficult Right Now, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 24x might make it look like..., Headline: The Best Mutual Funds Invest Huge Sums In These 24 Stocks, source:Yahoo, summary: As the market tries to rebound, the best mutual funds bet big on 24 stocks including Vertex, Lilly and Enphase., Headline: Dow Jones Plunges 500 Points On Jobs Report; AMD Stock Tumbles On Revenue Warning, source:Yahoo, summary: The Dow Jones Industrial Average plunged 500 points Friday on the September jobs report. AMD lost 8% after a third-quarter revenue warning., Headline: IBD Stock Of The Day Vertex Pharma: Why Its 'Sandbox' Approach Is Unusual In Biotech, source:Yahoo, summary: Vertex Pharmaceuticals is the IBD Stock Of The Day as VRTX stock climbs higher on expectations for its next act in gene editing., Headline: 10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital, source:Yahoo, summary: In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital. […], Headline: Is Vertex Pharmaceuticals Incorporated (VRTX) a Good Value Stock?, source:Yahoo, summary: Carillon Tower Advisers, an investment management company, released its “Carillon Scout Mid Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, majority of the equity indexes declined due to interest rate hikes, Russia-Ukraine war, and Federal Reserve’s balance-sheet tapering. Mid-cap and small-cap stocks poorly […], Headline: 2 Cathie Wood Stocks That Are Beating the Market This Year, source:Yahoo, summary: Has famed investor Cathie Wood lost her touch?  Vertex Pharmaceuticals is close to hitting a new all-time high as the drugmaker's business is firing on all cylinders.  During the second quarter, Vertex Pharmaceuticals' top line jumped by 22% year over year to $2.20 billion., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -1.14%: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.23, moving -1.14% from the previous trading session.",VRTX
15,2022-10-10,"Headline: 7 Biotech Stocks Set to Boom in 2023, source:InvestorPlace, summary: This article looks at seven biotech stocks that look like good options to move significantly higher in 2023, Headline: These 7 Biotech Stocks Are Set to Boom in 2023, source:Yahoo, summary: Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa, Headline: Dow Jones Reverses Ahead Of Earnings Season; Tesla Hits Record China Deliveries, source:Yahoo, summary: The Dow Jones Industrial Average reversed lower Monday ahead of earnings season. Tesla stock reported record China deliveries in September., Headline: Here's Why You Should Invest in Vertex (VRTX) Stock Now, source:Yahoo, summary: Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development., Headline: Top Analyst Reports for NVIDIA, Pfizer & Citigroup, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).",VRTX
16,2022-10-11,"Headline: 3 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: If there is, it's wrong too -- at least when applied to the stock market.  As a case in point, here are three top biotech stocks that are defying the bear market.  Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022., Headline: Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency, source:Yahoo, summary: BOSTON, October 11, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the advancement of its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare, genetic disease characterized by a protein folding defect that can lead to liver and lung disease., Headline: Subdued Growth No Barrier To Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Price, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 23.6x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending..., Headline: Dow Jones Falls, Tech Stocks Dive As 10-Year Treasury Yield Nears 4%, source:Yahoo, summary: The Dow Jones Industrial Average fell Tuesday, as the 10-year Treasury yield neared 4% after gains in recent sessions., Headline: Vertex Moves Its Alpha-1 Antitrypsin Deficiency Program Forward, source:Yahoo, summary: Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has advanced its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare genetic disease characterized by a protein folding defect that can lead to liver and lung disease. Vertex announced that the FDA had cleared the Investigational New Drug (IND) Application for VX-634, enabling the company to initiate a first-in-human clinical trial for this small molecule AAT corrector in healthy volunteers. Also see: Vertex Pharma's Flagship, Headline: Dow Jones Futures: S&P 500, Nasdaq Hit Fresh Bear Market Lows; Big Inflation Reports Due, source:Yahoo, summary: The Nasdaq and S&P 500 sank to new bear market lows Tuesday as chip stocks and Tesla slumped. Big inflation reports are ahead.",VRTX
17,2022-10-12,"Headline: Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold, source:Yahoo, summary: Axsome Therapeutics wowed investors when it soared more than 80% this year through August.  Investors cheered Axsome's first steps in the world of product commercialization.  Vertex is best known for its leadership in the world of cystic fibrosis (CF) treatment., Headline: The Best Stocks to Invest $50,000 in Right Now, source:Yahoo, summary: The stock market has left many investors uneasy lately.  With valuations of many once-high-flying stocks tumbling in recent months, as well as concerns about a global recession rising, businesses across a range of industries are facing unique challenges.  If you have $50,000 to put in the stock market right now, here are three powerhouse stocks to consider for at least part of that investment., Headline: Dow Jones Futures Rise, Bond Yields In Flux With Inflation Reports Due, source:Yahoo, summary: Futures pared gains as the 10-year Treasury yield in flux with big inflation reports due. The S&P 500 is at bear market lows., Headline: 2 Breakout Growth Stocks to Buy for the Long Haul, source:Yahoo, summary: These unstoppable stocks could be resilient choices to buy and hold in the next bear market and beyond., Headline: Dow Jones Reverses On Hot Inflation Data; Fed Minutes Up Next; PepsiCo Jumps On Earnings, source:Yahoo, summary: The Dow Jones Industrial Average fell Wednesday on hot inflation data. Minutes from Federal Reserve's policy meeting are due out today., Headline: Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic, source:Yahoo, summary: The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.70% to $290.13 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...",VRTX
18,2022-10-13,"Headline: Dow Jones Futures Rise Ahead Of CPI Inflation Report; Investors Avoid This Mistake, source:Yahoo, summary: Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived., Headline: The Best Stocks to Invest $5,000 in Right Now, source:Yahoo, summary: Here's why I think that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), MercadoLibre (NASDAQ: MELI), and Vertex Pharmaceuticals (NASDAQ: VRTX) are the top picks.  Thanks to its 20-for-1 stock split conducted in July, you can buy a lot more shares of Alphabet with less money than you could've in the past.  For one thing, Alphabet's share price has fallen more than 30% year to date., Headline: 3 Red-Hot Stocks That Could Continue to Beat the Market, source:Yahoo, summary: Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell.  Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon.  Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization., Headline: Dow Jones Futures Rise On U.K. U-Turn Ahead Of CPI Inflation Report, source:Yahoo, summary: Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived., Headline: Dow Jones Dives 500 Points On Hot Inflation Report; 10-Year Treasury Yield Tops 4%; Apple, Tesla Drop, source:Yahoo, summary: The Dow Jones Industrial Average dived Thursday on hot inflation data from the consumer price index. The 10-year Treasury yield topped 4%., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.21% to $296.54 Thursday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Vertex to Announce Third Quarter 2022 Financial Results on October 27, source:Yahoo, summary: BOSTON, October 13, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals Third Quarter 2022 Earnings Call"".",VRTX
19,2022-10-14,"Headline: My Best Stocks to Buy Now and Hold Forever, source:Yahoo, summary: Unsurprisingly, Warren Buffett gave some excellent investing advice several years ago.  Let me begin by acknowledging that Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) faces some challenges.  Alphabet's shares have also fallen more than 30% year to date., Headline: Dow Jones Futures Rise As JPMorgan, UnitedHealth Rally On Earnings; Retail Sales Data Next, source:Yahoo, summary: Dow Jones futures rose in mixed premarket action Friday, ahead of retail sales data. JPMorgan and UnitedHealth rose on Q3 earnings results., Headline: Dow Jones Reverses As JPMorgan, UnitedHealth Rally On Earnings; Retail Sales Miss, source:Yahoo, summary: The Dow Jones Industrial Average reversed lower Friday on hot inflation data. JPMorgan and UnitedHealth rallied on earnings results., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.12% to $293.21 Friday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -1.12%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $293.21, marking a -1.12% move from the previous day.",VRTX
20,2022-10-15,"Headline: Investor Optimism Abounds Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) But Growth Is Lacking, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 23.5x might make it look...",VRTX
21,2022-10-16,"Headline: Vertex Pharmaceuticals price target raised to $293 from $288 at Piper Sandler, source:Thefly.com, summary: Piper Sandler analyst Do ... VRTX",VRTX
22,2022-10-17,"Headline: Dow Jones Surges 600 Points As Bank Of America Jumps On Earnings; Apple Called Top Pick, source:Yahoo, summary: The Dow Jones Industrial Average rallied Monday, as Bank of America jumped on strong earnings results. Apple stock was named a top pick., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.30% to $297.02 Monday, on what proved to be an all-around favorable trading session for the stock market,...",VRTX
23,2022-10-18,"Headline: 2 Top Healthcare Stocks to Buy for the Long Haul, source:Yahoo, summary: Amgen is more established and has a dividend, while Vertex is one of several companies looking for therapies using the CRISPR Cas/9 gene-editing technique, which won the Nobel Prize just two years ago.  Amgen helped pioneer biotechnology and sells its therapies in more than 100 countries., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.06% to $300.17 Tuesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Biogen and 10 Other Healthcare Stocks Thriving in This Bear Market, source:MarketWatch, summary: Of the 56 stocks in the S&P 500 that have seen their share prices climb at least 10% since Jan. 3, 11 are healthcare stocks, a Barron's screen found., Headline: Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: ARK Investâs 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022., Headline: TECL: Lining Up A Supercharged Bet On Fed Reversal Within Months, source:SeekingAlpha, summary: The Direxion TECL ETF is one of the most intriguing investment options. What do I say the timing for betting on TECL is not here yet? Click here to find out.",VRTX
24,2022-10-19,"Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Business Is Yet to Catch Up With Its Share Price, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 24.1x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending..., Headline: 2 Unstoppable Stocks That Are Beating the Bear Market, source:Yahoo, summary: Biotech company Vertex Pharmaceuticals is a top name in cystic fibrosis (CF), and that has been what's driving its sales growth today.  Last month, Vertex said it planned to submit a biologics licensing application for exa-cel to the Food and Drug Administration for a rolling review that will begin as early as November and will be complete early next year.  Shares of Vertex have soared 35% this year, eclipsing the S&P 500., Headline: Dow Jones Falls As Netflix Soars On Earnings; Tesla Earnings Next, source:Yahoo, summary: The Dow Jones Industrial Average fell Wednesday, as Netflix soared on strong earnings results. Tesla earnings are due out after the close., Headline: 2 Under-the-Radar Biotech Stocks to Buy in 2022, source:Yahoo, summary: With that said, let's examine two biotech stocks that could be excellent long-term bets: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).  CRISPR Therapeutics is a clinical-stage biotech.  The company's targets include several forms of cancer and two rare blood-related conditions called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 2.72% to $292.02 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",VRTX
25,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: FOSTER DYKEMA CABOT & CO INC/M - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth, source:Yahoo, summary: Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.64% to $290.16 Thursday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.64%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $290.16, marking a -0.64% move from the previous day.",VRTX
26,2022-10-21,"Headline: TriaGen Wealth Management LLC  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Top 5 3rd Quarter Trades of Pa - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: First Week of VRTX December 16th Options Trading, source:Stock Options Channel, summary: Staff article entitled First Week of VRTX December 16th Options Trading, about stock options, from Stock Options Channel., Headline: These 3 Stocks Are Winning the Bear Market -- Here's How, source:Yahoo, summary: Picking the right markets to compete in makes surviving bear markets much more manageable for these companies., Headline: Vertex Pharmaceuticals Stock Near Buy Zone With Earnings Due, source:Yahoo, summary: Vertex Pharmaceuticals is forming a base and near a possible buy point ahead of its next quarterly earnings report, expected on or around Oct. 27., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 3.39% to $300.00 Friday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Market Rally Roars, 5 Growth Stocks Near Buy Points; Apple, Big Earnings Due, source:Yahoo, summary: The market rally has stepped up on Fed pivot hopes. Snowflake is among 5 high-growth stocks near buy points. Apple headlines a huge week of upcoming earnings.",VRTX
27,2022-10-22,"Headline: S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength, source:Yahoo, summary: S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market., Headline: 3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later, source:Yahoo, summary: Here's why they chose Bristol Myers Squibb (NYSE: BMY), Viatris (NASDAQ: VTRS), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (Bristol Myers Squibb): Drugmaker Bristol Myers Squibb is among the select group of companies that are outperforming the market this year.  The company's shares are up by 13% year to date., Headline: 2 Powerhouse Stocks That Could Go Parabolic, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique competitive edge over the average healthcare stock in that it is the market leader in a multibillion-dollar industry with minimal competition.  Vertex develops and manufactures drugs that treat cystic fibrosis patients.  CFTR modulator therapies are changing the landscape of the fight against cystic fibrosis -- a disease that afflicts 40,000 individuals in the U.S. alone -- and there are only four of these therapies that have as yet been approved and made it to market.",VRTX
28,2022-10-23,"Headline: Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV, source:SeekingAlpha, summary: Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation., Headline: Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows, source:Yahoo, summary: Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking., Headline: RGA Investment Advisors Q3 2022 Investment Commentary, source:SeekingAlpha, summary: For RGA Investment Advisors, the third quarter saw a continuation of the ugly trend from the first half of the year. Click here to read the full fund letter., Headline: Vertex Pharmaceuticals' (NASDAQ:VRTX) investors will be pleased with their favorable 100% return over the last five years, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking..., Headline: Dow Jones Futures: Market Rally Gains Steam; Tesla Cuts Model 3, Y Prices In China, source:Yahoo, summary: Futures signaled further market rally gains. Snowflake leads 5 growth stocks near buy points. Tesla cut Model 3 and Y prices in China.",VRTX
29,2022-10-24,"Headline: Vertex Pharmaceuticals price target raised to $327 from $319 at JPMorgan, source:Thefly.com, summary: JPMorgan analyst Jessica ... VRTX, Headline: Top 5 3rd Quarter Trades of E  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Dow Jones Futures Signal Market Rally To Extend Gains; Tesla Cuts Model 3, Y Prices In China, source:Yahoo, summary: Futures signaled further market rally gains. Snowflake leads 5 growth stocks near buy points. Tesla cut Model 3 and Y prices in China., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 3.50% to $310.50 Monday, on what proved to be an all-around great trading session for the stock market, with..., Headline: AbbVie CF combo progressing, worth keeping eye on, says RBC Capital, source:Thefly.com, summary: RBC Capital analyst Brian... VRTX, ABBV",VRTX
30,2022-10-25,"Headline: Vertex Pharmaceuticals Reaches Analyst Target Price, source:ETF Channel, summary: Staff article entitled Vertex Pharmaceuticals Reaches Analyst Target Price, about ETFs, from ETF Channel., Headline: Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline, source:Yahoo, summary: Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.42% to $309.21 Tuesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates., Headline: Top 5 3rd Quarter Trades of MO - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: David J Yvars Group Goes on Bu - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",VRTX
31,2022-10-26,"Headline: 2 Monster Stocks to Buy Without Any Hesitation, source:Yahoo, summary: Many investors are hesitating before buying stocks.  Let's take a closer look at these players to buy -- without any hesitation.  AbbVie (NYSE: ABBV) sells treatments in a variety of high-growth areas, including immunology and neuroscience., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.64% higher to $311.18 Wednesday, on what proved to be an all-around mixed trading session for the stock..., Headline: Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More, source:Yahoo, summary: Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27., Headline: GLOBAL BRIEFING: Meta quarterly revenue drops; Xi wants US cooperation, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals reports Q3 EPS $4.01, consensus $3.64, source:Thefly.com, summary: Reports Q3 revenue $2.33B... VRTX, Headline: Vertex Pharmaceuticals raises 2022 revenue to $8.8B-$8.9B from $8.6B-$8.9B, source:Thefly.com, summary: Consensus $8.77B.... VRTX",VRTX
32,2022-10-27,"Headline: Notable companies reporting after market close, source:Thefly.com, summary: Notable companies reporti... AAPL, AMZN, TMUS, INTC, GILD, VRTX, EW, DXCM, COF, PINS, ZEN, FSLR, TXRH, Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 81% Above Its Share Price, source:Yahoo, summary: Does the October share price for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) reflect what it's really worth..., Headline: Better Buy: CRISPR Therapeutics vs. Bluebird Bio, source:Yahoo, summary: Gene editing refers to techniques that allow researchers to modify the DNA of various organisms.  Given that it offers the potential to help discover innovative therapies, it isn't surprising that more and more drugmakers are turning to the technology.  Two prominent biotechs that focus on gene editing are CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE)., Headline: Vertex: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Stocks making the biggest moves after hours: Amazon, Apple, Pinterest, Intel and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading. , Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 7.48% to $287.89 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Cramer's lightning round: Stay with Vertex Pharmaceuticals, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed., Headline: Vertex Reports Third Quarter 2022 Financial Results, source:Yahoo, summary: BOSTON, October 27, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022 and increased its full year 2022 revenue guidance., Headline: Vertex Pharmaceuticals Incorporated 2022 Q3 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2022 Q3 earnings call., Headline: Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates, source:Yahoo, summary: Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Vertex Pharmaceuticals Incorporated (VRTX) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Q3 2022 Earnings Conference Call October 27, 2022, 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor..., Headline: Vertex Pharmaceuticals (VRTX) Q3 2022 Earnings Call Transcript, source:Yahoo, summary: Image source: The Motley Fool.  Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2022 Earnings CallOct 27, 2022, 4:30 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day, and welcome to the Vertex Pharmaceuticals third quarter 2022 earnings call.",VRTX
33,2022-10-28,"Headline: Dow Jones Futures: Apple Holds, Amazon Joins Megacap Meltdown; What To Do Now, source:Yahoo, summary: Apple dipped after the iPhone giant topped views. Amazon crashed on guidance, joining the megacap earnings meltdown., Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Vaccitech Plc (VACC), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (<span class='tr-stock-ticker' style='co..., Headline: Needham Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: Needham analyst Joseph Stringer maintained a Hold rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report) today. The company&#8217;s shares closed yesterday..., Headline: Vertex Pharmaceuticals price target raised to $330 from $315 at Cowen, source:Thefly.com, summary: Cowen analyst Philip Nade... VRTX, Headline: Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo, source:TipRanks, summary: Wells Fargo analyst Mohit Bansal maintained a Buy rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report) today and set a price target of $335.00. The compa..., Headline: Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (<span class='tr-stock-ticker' style='colo..., Headline: Morgan Stanley Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report) today and set a price target of $285.00. T..., Headline: Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Vertex Pharmaceuticals (VRTX) and Argenx Se (ARGX), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Teleflex (<span class='tr-stock-ticker' style='color:blue; font-w..., Headline: Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance, source:Yahoo, summary: Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 9.03% to $313.89 Friday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Top 10 Gainers on Friday, source:Yahoo, summary: In this article, we will take a look at the top 10 gainers on Friday. If you want to see some more stocks rallying today, go directly to Top 5 Gainers on Friday. All three key U.S. indices jumped this morning, thanks to better-than-expected earnings of giants like Apple Inc. (NASDAQ:AAPL), Intel Corporation (NASDAQ:INTC) and […], Headline: Vertex Shrugs Off Recent Malaise With A Third-Quarter Beat-And-Raise, source:Yahoo, summary: Vertex beat third-quarter expectations and raised its sales outlook, helping VRTX stock surge on Friday, shrugging off Thursday's pain., Headline: Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday, source:Yahoo, summary: Shares of Vertex Pharmaceuticals (NASDAQ: VRTX), a biopharmaceutical stock that specializes in cystic fibrosis (CF) and gene-editing therapies, saw its shares jump 9.03% on Friday.  The company released its third-quarter earnings report after the market closed on Thursday and the numbers were strong enough to give the stock a boost on Friday.  Vertex reported revenue of $2.33 billion, up 18% year over year, and net income of $931 million and earnings per share (EPS) of $3.59, both up 9% over the same period in 2021.",VRTX
34,2022-10-29,"Headline: This Bear Market Could Be the Best Investing Opportunity in More Than a Decade, source:Yahoo, summary: This bear market could be the best investing opportunity in more than a decade.  For investors, the present (or at least the near future) could be a time to party like it's 2009 instead.  No one knew how long the bear market would last.",VRTX
35,2022-10-30,"Headline: 5 Top Stocks for November, source:Yahoo, summary: Trevor Jennewine (Microsoft): Microsoft saw its share price tumble more than 7% following its earnings report for the first fiscal quarter (ended Sept. 30, 2022).  Worse yet, guidance came in short of Wall Street's expectations, as CFO Amy Hood said weak PC demand would persist into the second quarter, negatively impacting revenue from Windows and Surface devices., Headline: Vertex Pharmaceuticals (VRTX) Gets a Hold from Robert W. Baird, source:TipRanks, summary: Robert W. Baird analyst Brian Skorney maintained a Hold rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report) on October 28 and set a price target of $280..., Headline: Vertex Pharmaceuticals (VRTX) Receives a Hold from SVB Securities, source:TipRanks, summary: In a report released on October 27, David Risinger from SVB Securities maintained a Hold rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report). The compan..., Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: A long-term investment in any of these powerhouse stocks could reap generous returns for many years to come.",VRTX
36,2022-10-31,"Headline: Here's a No-Brainer Stock to Buy Now That's Trouncing the Market, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) shares have skyrocketed more than 35% year to date.  Vertex enjoys a monopoly in treating the underlying genetic cause of cystic fibrosis (CF).  Vertex Chief Operating Officer Stuart Arbuckle said in the Q3 call that the company expects to file for U.S. approval of Kalydeco in treating children ages one month to less than four months before the end of this year., Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly KZIA, ETON, ACOR, VRTX, SURF, Headline: Can Biotech Stocks Continue Rallying In This Bear Market? , source:TalkMarkets, summary: Despite a vicious bear market in 2022 biotech stocks have come back in October recovering with the XBI up 3.72% to $83.76 on Friday., Headline: Top 10 Stock Picks of Eli Casdin’s Casdin Capital, source:Yahoo, summary: In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […], Headline: Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 44% Discount?, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated..., Headline: Vertex Pharmaceuticals Inc. stock falls Monday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.60% to $312.00 Monday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Vertex Pharmaceuticals (VRTX &#8211; Research Report) yesterday and set a price target of $289.00. ...",VRTX
37,2022-11-01,"Headline: Top 5 3rd Quarter Trades of JE - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Highview Capital Management LL - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: ClearBridge All Cap Growth Strategy Q3 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge All Cap Growth Strategy performed in line with its Russell 3000 Growth Index benchmark in the Q3 2022. Click here to read the full fund letter., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.71% higher to $314.20 Tuesday, on what proved to be an all-around poor trading session for the stock market,...",VRTX
38,2022-11-02,"Headline: Is Vertex Pharmaceuticals About to Become a Dividend Stock?, source:Yahoo, summary: The big biotech has a cash stockpile of nearly $10 billion. Here's how Vertex plans to use the money., Headline: What Awaits Lantheus Holdings (LNTH) This Earnings Season?, source:Yahoo, summary: Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.33% to $310.01 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
39,2022-11-03,"Headline: 3 Nasdaq 100 Stocks to Buy Hand Over Fist in November, source:Yahoo, summary: The innovation-driven Nasdaq Composite and Nasdaq 100 -- the Nasdaq 100 is comprised of the 100-largest non-financial Nasdaq-listed companies -- have both lost over a third of their value on a peak-to-trough basis.  What follows are three Nasdaq 100 stocks investors can confidently buy hand over fist in November.  The first Nasdaq 100 stock that's an absolute screaming buy in November is fintech-giant PayPal Holdings (NASDAQ: PYPL)., Headline: Bear Market Investing: Should You Buy Today's Top Performers?, source:Yahoo, summary: Across industries, headwinds such as rising inflation and general economic woes are weighing on companies and stock performance.  Now, the question is: Should you hop on the bandwagon and buy shares of some of the top performers?  Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed more than 40% since the start of the year, and for good reason., Headline: Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference, source:Yahoo, summary: BOSTON, November 03, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented in posters and oral presentations at this year’s North American Cystic Fibrosis Conference (NACFC), including studies demonstrating the clinical benefits and long-term safety of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)., Headline: Investors in drug stocks should ignore dubious valuations based on rigged methodologies, source:MarketWatch, summary: The QALY is a methodology imported from socialized medicine systems that helps to put a fig leaf on their denials of access to breakthrough drugs., Headline: Pfizer: Q3 Earnings Review - Planning For Life After COVID, source:SeekingAlpha, summary: Pfizer released its Q3 2022 earnings on 1st November. PFE had another blockbuster quarter, generating $22.6B revenues & $8.6B net income. Read more here., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.42% higher to $311.30 Thursday, on what proved to be an all-around dismal trading session for the stock...",VRTX
40,2022-11-04,"Headline: Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD), source:Yahoo, summary: BOSTON, November 04, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch ""Power Forward"" (www.PowerForwardTogether.com), an educational initiative aimed at raising awareness of APOL1-mediated kidney disease (AMKD), highlighting the importance of early diagnosis and genetic testing., Headline: Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 38% Undervaluation?, source:Yahoo, summary: How far off is Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) from its intrinsic value? Using the most recent..., Headline: 2 Biotech Stocks That Could Make You Richer, source:Yahoo, summary: Equity markets are deep in the red for the year, and so is the broader biotech industry.  Vertex Pharmaceuticals is living proof that drugmakers do not necessarily need a diversified and deep lineup to be successful.  Here's the catch: Vertex holds a monopoly in this area., Headline: TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down, source:Yahoo, summary: TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact., Headline: Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up, source:Yahoo, summary: Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.80% to $308.82 Friday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Top Biotech Stocks for Q4 2022, source:Yahoo, summary: The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.  This means that investors may wait for years before knowing whether a drug under development will pay off.  The industry includes smaller start-up companies with recent traction as well as large, well-established corporations that aim to develop a range of drugs and technologies.",VRTX
41,2022-11-05,"Headline: Vanguard Health Care Fund Exit - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by James Li and the topic is about: Health care-oriented fund releases quarterly portfolio, Headline: 4 Growth Stocks to Buy and Hold Forever, source:Yahoo, summary: Investing in the stock market isn't for the faint of heart these days, but the decisions you make now about your portfolio could impact your financial future for years to come.  If you have the money to put into your portfolio at this point in time, there are still great businesses to be found, even if some of them have seen shares decline in recent months against the backdrop of broader market volatility.  Today, we're going to take a look at four top growth stocks that you may want to consider adding to your buy list before we hit the end of 2022.",VRTX
42,2022-11-06,"Headline: Got $1,000? 2 No-Brainer Stocks to Buy and Hold for at Least the Next Decade, source:Yahoo, summary: In the current environment, with ongoing macroeconomic and foreign currency headwinds, geopolitical unrest, and fears of a global recession, companies across all sectors are being tested.  Biotech stocks tend to be somewhat volatile, higher-risk investments in the world of healthcare stocks.  As always, though, there are exceptions, and Vertex Pharmaceuticals (NASDAQ: VRTX) is arguably one of the most prominent., Headline: Got $1,000? 2 Smart Stocks to Consider Buying Right Now, source:Yahoo, summary: While no stock is entirely impervious to factors like the economy or market volatility, healthcare stocks can be a wise place to park your cash; they are businesses that face consistent demand and can provide steady, gradual portfolio returns over time.  If you have $1,000 to invest right now, here are two smart stocks to consider.  Vertex Pharmaceuticals (NASDAQ: VRTX) may not be as familiar a name as other healthcare companies, but if you're looking to expand into these types of stocks, it's certainly one to add to your watch list.",VRTX
43,2022-11-07,"Headline: Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.81% to $303.23 Monday, on what proved to be an all-around positive trading session for the stock market, with...",VRTX
44,2022-11-08,"Headline: Kymera: Upcoming Trial Data Will Make Or Break The Company, source:SeekingAlpha, summary: Kymera has some critical trial data coming up this quarter. Other IRAK4 inhibitors have been having trouble. Click here to read a full analysis of KYMR stock., Headline: Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 105%, source:Yahoo, summary: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares..., Headline: Should You Invest in Vertex Pharmaceuticals Incorporated (VRTX)?, source:Yahoo, summary: ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from […], Headline: Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View, source:Yahoo, summary: Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.08% to $306.50 Tuesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Here is Why Growth Investors Should Buy Vertex (VRTX) Now, source:Yahoo, summary: Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",VRTX
45,2022-11-09,"Headline: Vertex to Participate in Upcoming Investor Conferences, source:Yahoo, summary: BOSTON, November 09, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences:, Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.93% higher to $309.34 Wednesday, on what proved to be an all-around rough trading session for the stock...",VRTX
46,2022-11-10,"Headline: 3 Top Healthcare Stocks Defying the Bear Market, source:Yahoo, summary: Many healthcare stocks' earnings reports lately include the phrases ""inflationary pressures,"" ""labor shortages,"" ""supply chain issues,"" and ""short-term macroeconomic conditions"" to describe why earnings are flat or down.  UnitedHealth Group (NYSE: UNH), AbbVie (NYSE: ABBV), and Vertex Pharmaceuticals (NASDAQ: VRTX) are all up 8.5% or more this year despite the headwinds affecting so many companies.  It's easy to see why UnitedHealth Group's shares are up more than 8.5% so far this year., Headline: SECTOR GAMMA AS Buys 1, Sells  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up, source:Yahoo, summary: AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged., Headline: Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales, source:Yahoo, summary: Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.55% higher to $311.03 Thursday, on what proved to be an all-around great trading session for the stock market,...",VRTX
47,2022-11-11,"Headline: Stocks making the biggest moves midday: Walgreens, Coinbase, Duolingo, Ralph Lauren and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is something of a unicorn in the world of stocks right now.  While the S&P 500 has slid by nearly 20% over the past 12 months, Vertex is up by around 60% in that same period.  While it's true that healthcare stocks tend to outperform when the market is down, this is far from the only tailwind driving Vertex's precipitous growth in such a volatile market., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 2.50% to $303.26 Friday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
48,2022-11-12,"Headline: Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade, source:Yahoo, summary: While there are no guarantees when it comes to investing in the stock market, setting defined goals for your portfolio and investing accordingly in companies that align with your risk tolerance and interests can help you build a profitable basket of holdings that stand the test of time.  Vertex Pharmaceuticals (NASDAQ: VRTX) is one company that has fundamentally changed the meaning of a cystic fibrosis diagnosis.  This means that among a range of benefits, these drugs can help cystic fibrosis patients live longer.",VRTX
49,2022-11-13,"Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 63% Above Its Share Price, source:Yahoo, summary: Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Vertex Pharmaceuticals..., Headline: Vertex: High Growth For Years Ahead, source:SeekingAlpha, summary: Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.",VRTX
50,2022-11-14,"Headline: Vertex Pharmaceuticals: Buy at the High?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has a lot going on these days.  The biotech company is developing two candidates that could make it even stronger in the billion-dollar cystic fibrosis (CF) treatment market.  Vertex already is a leader in the market., Headline: Vertex Pharmaceuticals: Is the Recovery Story Intact?, source:Yahoo, summary: Vertex Pharmaceuticals  is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.  Trading volume has been stable but an increasing pattern would be preferred.  The On-Balance-Volume (OBV) line shows a rise over the past year telling me that buyers of VRTX have been more aggressive than sellers., Headline: This Biotech's Bull Signal Has Never Been Wrong, source:Yahoo, summary: The stock could hit fresh highs, if past is prologue, Headline: Tweedy, Browne Fund Q3 2022 Commentary, source:SeekingAlpha, summary: In this volatile environment, the Tweedy, Browne Funds trailed their respective primary benchmark indices for the quarter. Click here to read the full fund letter.",VRTX
51,2022-11-15,"Headline: BRIDGER MANAGEMENT, LLC Buys 1 - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: 5 Top Stocks to Buy Before 2023, source:Yahoo, summary: Amazon (NASDAQ: AMZN) is a leader in two markets set to grow in the double-digits this decade: e-commerce and cloud computing.  As a result, Amazon's reported declines in operating income.  Amazon has the market position and financial resources to weather these times., Headline: Crispr Therapeutics Stock: Bull vs. Bear, source:Yahoo, summary: Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology.  The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S., Europe, and the U.K. this month.  If regulators give Crispr the nod, it may soon reach the major milestone of product commercialization., Headline: AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use, source:Yahoo, summary: The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi., Headline: Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal, source:Yahoo, summary: Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.",VRTX
52,2022-11-16,"Headline: Vertex Pharmaceuticals Incorporated (VRTX) Jefferies London Healthcare Conference (Transcript), source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Jefferies London Healthcare Conference November 16, 2022 4:10 AM ET Company Participants Stu Arbuckle â Executive Vice President and..., Headline: 2 Hot Growth Stocks That Can Continue to Soar in 2023, source:Yahoo, summary: Two of the hottest stocks on the markets this year are Vertex Pharmaceuticals (NASDAQ: VRTX) and Occidental Petroleum (NYSE: OXY).  Vertex is up almost 37% so far in 2022 and Occidental is up an amazing 156%!  Here's why these two hot growth stocks could continue to do well in 2023., Headline: Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Outperformed in the Third Quarter, source:Yahoo, summary: Artisan Partners, an investment management company, released its “Artisan Value Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund underperformed its benchmark index. Its Investor Class fund ARTLX returned -7.04%, Advisor Class fund APDLX posted a return of -7.07%, and Institutional Class fund APHLX […], Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.05% higher to $305.44 Wednesday, on what proved to be an all-around poor trading session for the stock market,...",VRTX
53,2022-11-17,"Headline: 2 Growth Stocks That Could Double in 2023, source:Yahoo, summary: Investing in biotech companies, especially relatively small ones, can be a double-edged sword.  With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE).  Right now, CRISPR Therapeutics is a clinical-stage biotech., Headline: VRTX or TECH: Which Is the Better Value Stock Right Now?, source:Yahoo, summary: VRTX vs. TECH: Which Stock Is the Better Value Option?, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.46% to $309.90 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",VRTX
54,2022-11-18,"Headline: 3 Top Growth Stocks to Buy Sooner Rather Than Later, source:Yahoo, summary: If you want some great investing advice, just listen to The Rolling Stones: You can't always get what you want, but time is on your side.  The biggest knock against MongoDB is that it isn't profitable yet., Headline: An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 37% Undervalued, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated..., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.53% to $314.63 Friday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Dow Jones Futures: 7 Investing Rules For A Tricky Market Rally; Tesla Skids To Bear Market Lows, source:Yahoo, summary: Dow Jones futures: The market rally found support but new buys struggled. Here are seven investing rules to follow. Tesla stock hit fresh bear-market lows.",VRTX
55,2022-11-19,"Headline: Bear Market Blues? 3 of the Best Stocks to Own in 2023, source:Yahoo, summary: Most investors are more than ready for stocks to take off in a new bull market.  Vertex Pharmaceuticals (NASDAQ: VRTX) is heading for its biggest catalyst in a long while.  First, it marks Vertex's move beyond its cystic fibrosis (CF) specialty into another treatment area., Headline: Market Rally Holds Key Levels, But This Has Been Difficult; Tesla Woes Continue, source:Yahoo, summary: Dow Jones futures: The market rally found support but new buys struggled. Here are seven investing rules to follow. Tesla stock hit fresh bear-market lows., Headline: 3 Unstoppable Growth Stocks to Buy and Hold, source:Yahoo, summary: Three simple words can make you a lot of money over the long run: buy and hold.  Here's why they chose Pfizer (NYSE: PFE), Thermo Fisher Scientific (NYSE: TMO), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (Pfizer): Pfizer has grown its top line at an incredible pace over the past two years.",VRTX
56,2022-11-21,"Headline: Why Vertex Pharmaceuticals (VRTX) is a Top Value Stock for the Long-Term, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.50% higher to $316.20 Monday, on what proved to be an all-around rough trading session for the stock market,...",VRTX
57,2022-11-22,"Headline: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 36% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated..., Headline: AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag, source:Yahoo, summary: The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL., Headline: We still think there's more room for biotech to go higher, says Jefferies' Yee, source:CNBC, summary: Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.67% to $321.48 Tuesday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
58,2022-11-23,"Headline: GSK to Withdraw Blenrep From U.S. Market on FDA Request, source:Yahoo, summary: GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.65% to $316.16 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: 7 Stocks on the Perfect 10 List, source:Yahoo, summary: A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of companies. Despite many of these stocks to buy scoring so highly on one particular attribute, the market has heavily discounted most of these companies. Thus, it appears a tug-of-war",VRTX
59,2022-11-24,"Headline: BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing, source:Yahoo, summary: The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.",VRTX
60,2022-11-25,"Headline: Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead, source:Yahoo, summary: Cathie Wood remains optimistic. Her ARK Invest exchange-traded funds (ETFs) have continued to scoop up stocks during the steep downturn this year. But she's apparently not optimistic about all of her ARK holdings.",VRTX
61,2022-11-26,"Headline: Are Robust Financials Driving The Recent Rally In Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ:VRTX) has had a great run on the share market with its stock up by a significant 11...",VRTX
62,2022-11-28,"Headline: Early notable gainers among liquid option names on November 28th, source:Thefly.com, summary: No summary, Headline: 2 Stocks Near 52-Week Highs That Could Climb Higher, source:Yahoo, summary: Rising interest rates and a looming recession that those higher rates could cause are weighing heavily on stock prices across the board.  Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years.  The stock rocketed higher in 2021 after the FDA granted a highly controversial approval to the company's Alzheimer's disease drug, Aduhelm., Headline: Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead, source:TalkMarkets, summary: No summary",VRTX
63,2022-11-29,"Headline: Vertex Pharmaceuticals: Growth Outside Of Cystic Fibrosis Critical For Additional Value Creation, source:SeekingAlpha, summary: Vertex reported strong results in the third quarter, driven by growth in ex-U.S. markets. VRTX is well-positioned for long-term growth. Read more on VRTX here., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.33% higher to $316.33 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...",VRTX
64,2022-11-30,"Headline: Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects, source:Yahoo, summary: Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage., Headline: Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 37% Discount?, source:Yahoo, summary: Does the November share price for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) reflect what it's really worth..., Headline: Top Healthcare Stocks, source:Yahoo, summary: The top healthcare stocks include Azenta Inc. for best value, McKesson Corp. for fastest growth, and Signify Health Inc. for most momentum.",VRTX
65,2022-12-01,"Headline: Looking for a Once-in-a-Decade Buying Opportunity? Buy These 3 Stocks Before 2023, source:Yahoo, summary: The dark cloud of a bear market has a silver lining: It offers investors opportunities to get in on great stocks for a bargain price.  Today's bear market is handing us a few once-in-a-decade buying opportunities on a silver platter.  Vertex shares are heading for a 44% gain so far this year., Headline: Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug, source:Yahoo, summary: Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months., Headline: Vertex Pharmaceuticals Incorporated present at 5th Annual Evercore ISI HealthCONx Conference (Transcript), source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) 5th Annual Evercore ISI HealthCONx Conference November 30, 2022 9:15 a.m., Headline: 3 Growth Stocks That Are Too Cheap to Ignore, source:Yahoo, summary: The stock market hates uncertainty, and the global factors driving the market in 2022 have understandably left many investors feeling frustrated.  While no one can predict when this volatile period will wrap up, the history of the stock market has shown that patient investors who maintain stakes in great businesses can sustain and compound rewarding returns with time.  Currently, the company relies on its portfolio of cystic fibrosis (CF) medicines to drive revenue and profits, and it continues to deliver on both fronts year after year., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.38% to $320.76 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $320.76, moving +1.38% from the previous trading session.",VRTX
66,2022-12-02,"Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: If you're looking to add more stocks to your portfolio right now, here are three top healthcare stocks to consider when formulating your list of long-term buys.  Vertex Pharmaceuticals (NASDAQ: VRTX) has a near monopoly over the multibillion-dollar cystic fibrosis treatment industry with its portfolio of medicines.  In a patient with cystic fibrosis, the CFTR gene becomes mutated, which means this protein is not able to function normally., Headline: If You Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has been a bright spot in this year's bear market.  The past few years have brought Vertex ups and downs.  Vertex stock was trading at about $140 exactly five years ago., Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more., Headline: Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug, source:Yahoo, summary: Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.19% higher to $321.37 Friday, on what proved to be an all-around mixed trading session for the stock market,...",VRTX
67,2022-12-03,"Headline: 12 Top Stocks to Buy in December, source:Yahoo, summary: The number 12 is tightly linked with December. It's the 12th month, of course. There are 12 days of Christmas, according to the traditional carol. Allow me to add one more connection with 12 to the list., Headline: My 2 Top Growth Stocks to Buy for 2023 and Beyond, source:Yahoo, summary: Long-time shareholders of these companies can testify that both have patterns of beating the market., Headline: 3 Stocks to Buy Hand Over Fist in December, source:Yahoo, summary: Here's why they think that AbbVie (NYSE: ABBV), Exelixis (NASDAQ: EXEL), and Vertex Pharmaceuticals (NASDAQ: VRTX) are stocks to buy hand over fist in December.  Prosper Junior Bakiny (AbbVie): The end of the year is always a great time to review your investment portfolio.  The drugmaker is set to lose U.S. patent protection for its biggest cash cow -- autoimmune-disease medicine Humira -- next year.",VRTX
68,2022-12-04,"Headline: Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 124%, source:Yahoo, summary: When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can..., Headline: Is This Biotech Stock a Buy Following a Landmark Approval?, source:Yahoo, summary: Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months.  The company can thank the expected and eventual approval of Tzield for that performance.  In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.",VRTX
69,2022-12-05,"Headline: 2 Generational REIT Buying Opportunities, source:SeekingAlpha, summary: REITs are volatile and this results in a lot of opportunities to profit. Read why REITs are again priced at historically low valuations., Headline: Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?, source:Yahoo, summary: Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues., Headline: GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe, source:Yahoo, summary: GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023., Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.17% to $317.60 Monday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
70,2022-12-06,"Headline: Is It Too Late to Buy Vertex Pharmaceuticals Stock?, source:Yahoo, summary: Take Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that has delivered market-beating returns over the past decade.  The drugmaker is still at it even amid the market downturn and currently sits near its 52-week high.  Vertex has certainly been impressive, but are the company's best days already in the rearview mirror?, Headline: 3 Stocks to Buy Before 2023 That Can Set You Up for Life, source:Yahoo, summary: Given all the market uncertainty this year and the downward trend of the major indices, it's no surprise that some investors are hesitant to buy right now.  Knowing the right time to pull the trigger on a stock purchase (or a sale) is often one of the hardest parts of being an investor.  Three such buy-now opportunities are Vertex Pharmaceuticals (NASDAQ: VRTX), Mattel (NASDAQ: MAT), and Nvidia (NASDAQ: NVDA)., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.82% to $311.81 Tuesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: 2 Sector ETFs Hovering Around a 52-Week High, source:Yahoo, summary: We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.",VRTX
71,2022-12-07,"Headline: 3 Fierce Stocks That Are Screaming Buys in December, source:Yahoo, summary: As 2023 approaches, it marks the end of what can be called a turbulent year for the stock market.  In a volatile market, it is smart to own stocks that have high growth prospects.  Thanks to its rising top and bottom line, Vertex Pharmaceuticals (NASDAQ: VRTX) shares have surged 46% so far this year., Headline: Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression, source:Yahoo, summary: Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST., Headline: Centene (CNC) Invests Nearly $8M to Build Texas Community Center, source:Yahoo, summary: Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.85% to $317.58 Wednesday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.58, marking a +1.85% move from the previous day.",VRTX
72,2022-12-08,"Headline: Vertex Pharmaceuticals, Entrada Therapeutics enter EEV therapeutics pact, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Reaches Analyst Target Price, source:ETF Channel, summary: No summary, Headline: Entrada Therapeutics shares jump on collaboration with Vertex, source:MarketWatch, summary: Shares of Entrada Therapeutics Inc. undefined rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals..., Headline: 2 Unstoppable Growth Stocks to Buy in 2022 and Beyond, source:Yahoo, summary: Two biotech companies are great examples of this: giant Vertex Pharmaceuticals (NASDAQ: VRTX) and up-and-coming player Axsome Therapeutics (NASDAQ: AXSM).  Vertex shares have climbed about 40% so far this year.  Vertex may be about to show that it can expand beyond its specialty of cystic fibrosis (CF) treatment -- and with a potential blockbuster product., Headline: Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1), source:Yahoo, summary: BOSTON, December 08, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development., Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Been Rising: Are Strong Financials Guiding The Market?, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ:VRTX) stock up by 9.9% over the past three months. Given that the market rewards strong..., Headline: Entrada Therapeutics Shares Rise 18% After Vertex Collaboration News, source:MarketWatch, summary: By Stephen Nakrosis Shares of Entrada Therapeutics Inc. were trading higher on the Nasdaq Thursday, following news the company will collaborate with Vertex..., Headline: Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?, source:Yahoo, summary: Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?, Headline: Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy, source:Yahoo, summary: Entrada Therapeutics inked a $250 million deal with Vertex Pharmaceuticals to develop a muscular dystrophy drug, and the biotech stock surged., Headline: Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Entrada Therapeutics Inc (NASDAQ: TRDA) announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development. Under the terms of the agreement, Entrada will receive an upfront payment of $224 million and an equity investment of $26 milli, Headline: Health Care Up on Merger Views -- Health Care Roundup, source:MarketWatch, summary: Health-care companies rose amid anticipation of further merger activity in the sector. The U.S. Food and Drug Administration extended the authorization of..., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.18% to $321.32 Thursday, on what proved to be an all-around positive trading session for the stock market,..., Headline: 3 Reasons Growth Investors Will Love Vertex (VRTX), source:Yahoo, summary: Vertex (VRTX) could produce exceptional returns because of its solid growth attributes., Headline: Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX) and Design Therapeutics (DSGN), source:TipRanks, summary: No summary",VRTX
73,2022-12-09,"Headline: 2 Growth Stocks That Could Help Set You Up for Life, source:Yahoo, summary: The market has taken growth investors for a bumpy ride over the past year.  Vertex Pharmaceuticals (NASDAQ: VRTX) is one of them.  Not only does the company have an incredible history of delivering favorable revenue growth and profits, but its stock has been a high performer for investors even in the volatility of the past year., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 2.83% to $312.22 Friday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Our 7 Top Biotech Stock Picks for 2023, source:Yahoo, summary: If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed. Moving forward, this segment will carry this momentum toward other breakthroughs. Nevertheless, even the top biotech stock picks for 2023 can’t avoid economic realities. With macro",VRTX
74,2022-12-10,"Headline: 3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023, source:Yahoo, summary: With this in mind, we asked three Motley Fool contributors to pick high-flying stocks in 2022 that can keep soaring in 2023.  Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Merck (NYSE: MRK), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Keith Speights (Axsome Therapeutics): With just a few weeks left in the year, shares of Axsome Therapeutics have more than doubled., Headline: Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition, source:Yahoo, summary: BOSTON and ZUG, Switzerland, December 10, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral, encore presentation of clinical data from patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) treated with the investigational therapy exagamglogene autotemcel (exa-cel) in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study. Vertex will also present new health economics and",VRTX
75,2022-12-11,"Headline: 3 Red-Hot Stocks That Could Continue to Beat the Market, source:Yahoo, summary: Axsome Therapeutics (NASDAQ: AXSM) has absolutely sizzled this year.  The biotech stock has more than doubled, with most of the gain coming in just the last couple of months.  It should file for FDA approvals of AXS-07 in treating migraine and AXS-14 in treating fibromyalgia next year as well.",VRTX
76,2022-12-12,"Headline: FDA clears Vertex IND application for VX-522 to treat CF, source:Thefly.com, summary: No summary, Headline: Vertex receives IND clearance for mRNA cystic fibrosis therapy, source:Seeking Alpha, summary: No summary, Headline: Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 24.5x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending..., Headline: Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA, source:Yahoo, summary: BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin, Headline: 3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns, source:Yahoo, summary: Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.63% higher to $314.19 Monday, on what proved to be an all-around great trading session for the stock market,...",VRTX
77,2022-12-13,"Headline: 3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way, source:Yahoo, summary: Citigroup CEO Jane Fraser expects a recession in 2023.  Here are three high-flying stocks to buy and hold if a recession is on the way.  Biotech stocks often soar, regardless of what's going on with the economy., Headline: More Likely to 5X First: Johnson & Johnson vs. Vertex Pharmaceuticals, source:Yahoo, summary: Racking up a five-bagger investment -- when one of your holdings grows by 5x -- is quite the accomplishment, and finding potential five-baggers is a great way to set your portfolio up for success.  On that note, powerful pharmaceutical businesses like Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX) are stable enough and profitable enough to 5x, and they've both done it before.  Johnson & Johnson's market capitalization is around $461 billion, making it one of the largest businesses in the world., Headline: Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy, source:Yahoo, summary: Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 2.26% to $307.09 Tuesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Sickle cell cure will be cost-effective if health disparities  considered -study finds, source:Reuters, summary: Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.",VRTX
78,2022-12-14,"Headline: Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.63% to $312.09 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $312.09 in the latest trading session, marking a +1.63% move from the prior day.",VRTX
79,2022-12-15,"Headline: 3 Growth Stocks With More Potential Than Any Cryptocurrency, source:Yahoo, summary: While it's true that growth stocks don't make investors jump for joy like they used to, companies in this investment category that can win over the long term are still to be found.  Vertex Pharmaceuticals (NASDAQ: VRTX) is a bit of a rarity in the world of healthcare stocks, boasting a business that tends to generate revenue and earnings growth at a clip well beyond that of the average stock in this space.  Case in point: The company has seen its annual revenue and earnings surge by respective amounts of 204% and 789% in the past five years., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.18% to $308.40 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: IBD Stock Of The Day Vertex Eyes A Brighter 2023 On Moderna, Crispr Plans, source:Yahoo, summary: Vertex is the IBD Stock Of The Day. The FDA signed off on its newest study in cystic fibrosis, but VRTX stock is trading sideways., Headline: U.S. Parkinson's disease incidence far higher than earlier estimates -study, source:Reuters, summary: The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -1.18%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.40, marking a -1.18% move from the previous day.",VRTX
80,2022-12-16,"Headline: Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 24.2x might make it look..., Headline: 4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023, source:Yahoo, summary: Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.17% to $304.80 Friday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Which Is the Better Buy: Vertex or Invitae?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%.  Looking at these two biotech stocks from a long-term perspective, is Invitae now the better buy?  Or is Vertex's strong run this year likely to extend into 2023?",VRTX
81,2022-12-17,"Headline: Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows., source:Yahoo, summary: Fannie Mae expects a modest recession to begin in the first quarter of 2023, and 60% of the economists polled by Reuters think the U.S. economy will enter a recession sometime next year. Economists surveyed by Bloomberg think there's a 65% risk of a recession over the next 12 months., Headline: 3 Beaten-Down Stocks That Could Explode Higher in 2023, source:Yahoo, summary: Three Motley Fool contributors were asked to pick beaten-down stocks that they think could explode higher in 2023.  Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Moderna (NASDAQ: MRNA), and Zoetis (NYSE: ZTS).  David Jagielski (CRISPR Therapeutics): CRISPR Therapeutics' shares have underperformed in the current bear market, with the gene-editing stock down almost 40% year to date.",VRTX
82,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF., Headline: My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023, source:Yahoo, summary: Devon Energy (NYSE: DVN) would be in a close second place for me if I only looked at share price gains this year.  Counting dividends, Devon has generated a year-to-date total return of more than 50%, with only a few days remaining in 2022., Headline: Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock, source:Yahoo, summary: The bear market has weighed on stocks across industries this year.  Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX) have both climbed in the double digits -- and for good reason.  Which one of these top stocks represents the better bear market buy right now?, Headline: Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatments.  Vertex's latest CF drug, Trikafta, still has plenty of revenue growth ahead.  Instead, it has to do with Vertex's candidate for blood disorders, exa-cel -- a one-time curative treatment for two blood disorders with limited treatment options today., Headline: Where Will Vertex Pharmaceuticals Be in 10 Years?, source:Yahoo, summary: For a company like Vertex Pharmaceuticals (NASDAQ: VRTX), 10 years isn't a long time. The drug-development process takes between 12 and 14 years, on average, around 8 years of which are devoted to clinical-stage testing and the regulatory-review process., Headline: Vertex Pharmaceuticals downgraded to hold at Jefferies on valuation, stock outperformance, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals downgraded to Hold from Buy at Jefferies, source:Thefly.com, summary: No summary",VRTX
83,2022-12-19,"Headline: Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro, source:TalkMarkets, summary: No summary, Headline: The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant, source:Yahoo, summary: Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog., Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 4.33% to $291.59 Monday, on what proved to be an all-around poor trading session for the stock market, with the..., Headline: Tuesday Talk: Where is Santa?, source:TalkMarkets, summary: No summary",VRTX
84,2022-12-20,"Headline: Unpleasant Surprises Could Be In Store For Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Shares, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-earnings (or ""P/E"") ratio of 22.9x might make it look..., Headline: Entrada (TRDA) Down on Regulatory Update for DMD Candidate, source:Yahoo, summary: Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.56% higher to $293.23 Tuesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Vertex Pharmaceuticals: Expect Growth Beyond Trikafta, source:SeekingAlpha, summary: Vertex revenue grew 18% y/y in Q3 2022. Read why I have started accumulating VRTX stock as a long-term investment.",VRTX
85,2022-12-21,"Headline: Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform, source:SeekingAlpha, summary: Avidity seeks to tackle a fundamental challenge in the RNA space, namely delivery outside the liver via AOC platform technology. See why the stock is a Buy., Headline: XBI: Attractive Value In Diversified Biotech Growth, source:SeekingAlpha, summary: Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI)., Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: If you have $20,000 to invest in the stock market right now, you're likely searching for durable businesses with a strong track record of growth that can generate consistent returns in a wide variety of markets.  Despite increased competition through the years, Johnson & Johnson (NYSE: JNJ) remains a giant in each of the three key markets in which it operates: consumer health, pharmaceuticals, and medical devices.  The company's consumer health business, which it is about to spin off into a stand-alone company called Kenvue, sells some of the world's most well-known daily use brands like Band-Aid, Tylenol, and Listerine., Headline: 3 Growth Stocks That Are Screaming Buys in December, source:Yahoo, summary: If you have the cash to invest right now and are looking to add some powerhouse growth stocks to your portfolio before year's end, here are three notable contenders to consider.  Vertex Pharmaceuticals (NASDAQ: VRTX) isn't a household name like some healthcare stocks, but this biopharmaceutical company has grown into a giant in the rare disease drug market over the more than three decades since its founding.  In fact, its cystic fibrosis products generated $7.6 billion in revenue for all of 2021, in a market that was valued at around $9 billion as of 2020., Headline: 3 Growth Stocks That Are Too Cheap to Ignore, source:Yahoo, summary: Despite the short-term impact that $10 billion worth of write-downs had on Teladoc Health's (NYSE: TDOC) balance sheet in the first half of 2022, the company remains an undefeated leader in the global telehealth market.  While more companies are expanding into the telehealth space, few are doing so at Teladoc's scale.  In the most recent quarter, Teladoc's revenue surged 17% from the year-ago period to $611 million., Headline: Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond, source:Yahoo, summary: For many investors, now would be an opportune time to take advantage of great stocks trading at a discount., Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.91% to $290.55 Wednesday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $290.55 in the latest trading session, marking a -0.91% move from the prior day., Headline: Thursday Sector Leaders: Healthcare, Utilities, source:Market News Video, summary: No summary",VRTX
86,2022-12-22,"Headline: 4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire, source:Yahoo, summary: Most investors won't build life-changing wealth from the stock market overnight, but when you're investing in wonderful stocks for many years at a time, you don't need to hit a one-time jackpot to build and sustain meaningful returns.  Here are four different stocks, each on a unique growth trajectory, that have the potential to multiply a $100,000 investment by at least 5 times in the years ahead.  E-commerce spend will account for 31% of all retail transactions in the U.S. alone by 2026, compared to its current share of 23%, according to Morgan Stanley., Headline: 2 No-Brainer Biotech Stocks to Buy Right Now, source:Yahoo, summary: Vertex Therapeutics (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN) have swum against the tide all year, with their shares rising as the S&P 500 has struggled.  While Vertex's pipeline is about to extend well beyond cystic fibrosis (CF), Amgen's combination of emerging drugs, plus the accretive nature of its deal to buy Horizon Therapeutics, could reward investors in the long run., Headline: Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?, source:Yahoo, summary: Crispr expects to make history in 2023 with a first-ever request in gene-editing technology by the same name, which could stoke shares., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.16% to $293.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with...",VRTX
87,2022-12-23,"Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.44% to $289.69 Friday, on what proved to be an all-around favorable trading session for the stock market, with...",VRTX
88,2022-12-24,"Headline: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 38% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Vertex Pharmaceuticals...",VRTX
89,2022-12-26,"Headline: Here Are the Best Stocks To Own as 2022 Draws to a Close, source:Yahoo, summary: Amazon (NASDAQ: AMZN) is heading for a 49% loss this year, and it's trading at its lowest in relation to sales since 2015.  If you look at Amazon's earnings reports this year, you may wonder why I'm so optimistic.  After all, the company has reported declines in operating income quarter after quarter.",VRTX
90,2022-12-27,"Headline: Is Vertex Pharmaceuticals a Buy?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has beaten the bear market by far this year: The stock is heading for a 30% gain.  Vertex is the global leader in the cystic fibrosis (CF) treatment market.  Vertex sells four CF drugs., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.82% to $287.32 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $287.32 in the latest trading session, marking a -0.82% move from the prior day.",VRTX
91,2022-12-28,"Headline: Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues, source:SeekingAlpha, summary: Vertex Pharmaceuticals is doing very well with respect to sales of its CF franchise. Click here to read why VRTX is a great speculative biotech play., Headline: Subdued Growth No Barrier To Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Price, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 22.5x Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) may be sending..., Headline: 2 Top Stocks to Invest $2,000 in Before the End of 2022, source:Yahoo, summary: Despite what the broad share price decline across sectors might indicate, there are plenty of wonderful companies that are still delivering strong performance in this macro environment.  While the broader market has continued to take investors for a wild ride over the past year, Vertex Pharmaceuticals (NASDAQ: VRTX) has kept delivering strong shareholder returns.  While it's true that healthcare companies tend to outperform the broader market during bearish periods, Vertex's remarkable performance is nothing new, with the stock having delivered a total return of nearly 600% over the past decade., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.54% to $285.76 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",VRTX
92,2022-12-29,"Headline: 2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond, source:Yahoo, summary: For instance, biotech giants Vertex Pharmaceuticals (NASDAQ: VRTX) and Incyte (NASDAQ: INCY) -- both of which feature in Wood's Ark Genomic Revolution ETF -- have outperformed the market over the past year.  Let's consider why both of these Cathie Wood stocks can still deliver solid returns.  It'd be hard to find a biotech giant that has performed better than Vertex Pharmaceuticals this year., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.16% to $289.08 Thursday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: 5 Stocks That Outperformed the S&P 500 in 2022, source:GuruFocus, summary: No summary",VRTX
93,2022-12-30,"Headline: Opco reveals three biotech stocks that will outperform in 2023, source:Thefly.com, summary: No summary, Headline: VRTX Makes Notable Cross Below Critical Moving Average, source:Market News Video, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slumped 0.10% to $288.78 Friday, on what proved to be an all-around rough trading session for the stock market, with...",VRTX
94,2023-01-01,"Headline: Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), source:Yahoo, summary: When close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") below 14x, you may...",VRTX
95,2023-01-03,"Headline: 3 Stocks to Buy for 2023 That Are Practically Money Machines, source:Yahoo, summary: With this in mind, here are three stocks to buy for 2023 that are practically money machines.  Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) should report 2022 revenue in the ballpark of $280 billion, with its Google Search product leading the way.  With those kinds of huge numbers, it's not surprising that Alphabet has amassed a ginormous cash stockpile., Headline: 3 Top Healthcare Stocks Defying the Bear Market, source:Yahoo, summary: Let's take a closer look at these three healthcare stocks defying the current bear market.  Shares for TransMedics Group rose 222% in 2022.  The price jump was due in part to the company's financial performance and partly to its extended moat as the only organ transplant system approved by the Food and Drug Administration (FDA) to transport multiple organs., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. dropped 0.96% to $286.02 Tuesday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $286.02, moving -0.96% from the previous trading session.",VRTX
96,2023-01-04,"Headline: CRISPR Therapeutics: 2023 Could Be The Right Year, source:SeekingAlpha, summary: CRISPR Therapeutics AG is a gene editing company based on CRISPR/Cas9 technology. Read more to see why my rating is a buy on CRSP stock., Headline: 10 Top Stocks That Can Make You Richer in 2023, source:Yahoo, summary: When the closing bell tolled, the benchmark S&P 500 ended down by 19%, with the iconic Dow Jones Industrial Average and tech-heavy Nasdaq Composite also entering bear market territory during the course of the year.  The first top-notch stock that can help you build wealth in the new year is payment processor Mastercard (NYSE: MA).  To begin with, Mastercard's management team has kept the company focused on payment processing while avoiding the lending arena., Headline: Where to Invest $100,000 in 2023, source:Yahoo, summary: Dividend stocks are a good bet because they guarantee you recurrent income.  This indicates dividend growth is important to that particular company.  You'll want your dividend stock to hold earnings growth potential, too., Headline: 3 Must-Have Stocks to Buy in 2023, source:Yahoo, summary: The company's Google Search dominates the search-engine market.  There's no compelling reason to believe that Alphabet won't remain on top.  Sure, the advertising business is struggling a bit right now., Headline: Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, source:Yahoo, summary: BOSTON, January 04, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT., Headline: ARKG: Despite A Huge Price Loss In 2022, Not The Right Time To Accumulate, source:SeekingAlpha, summary: ARKG ETF invests in small-cap and mid-cap companies engaged in genomic revolution. Find out whether it's time to take a position in the fund., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.28% higher to $286.83 Wednesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",VRTX
97,2023-01-05,"Headline: February 24th Options Now Available For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 81%, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses..., Headline: Biotech stocks: Vertex looks bullish on ‘rapidly-growing CF business,’ analyst says, source:Yahoo, summary: Bank of America Global Research Sr. Pharma Analyst Geoff Meacham joins Yahoo Finance Live to discuss China's COVID-19 chaos, the pharma space, biotech stocks, and the outlook for biopharma., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: No summary",VRTX
98,2023-01-06,"Headline: Barron’s Trader Stock Picks Had a Better Year Than the Market. What Worked—and What Didn’t., source:MarketWatch, summary: The call we’re most proud of was one made before 2022 began, when we warned the year would start off badly. We stayed bearish, and we’re glad we did., Headline: 3 Biotech Companies to Watch in 2023, source:Yahoo, summary: Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. With growing demand for gene therapies, immune oncology, and precision medicine, biotech companies have a unique opportunity to impact the world of healthcare. Undoubtedly, these stocks offer a valuable option for investors seeking in innovative solutions to benefit a glob",VRTX
99,2023-01-07,"Headline: These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy., source:Yahoo, summary: Axsome Therapeutics (NASDAQ: AXSM) soared more than 100%.  Vertex submitted a potential blockbuster in a new treatment area to regulators.  Let's check out why Axsome and Vertex are still stocks to buy., Headline: Looking for Growth in 2023? Where to Invest $5,000, source:Yahoo, summary: This year, some of the stocks most heavily hit by the market downturn could start to make a comeback.  And they're trading at 28 times forward earnings estimates, which looks cheap considering Etsy's earnings performance in tough times.",VRTX
100,2023-01-08,"Headline: 2 Healthcare Stocks That Could Make You Richer, source:Yahoo, summary: While the healthcare industry may not seem at first glance like the most exciting place to invest your cash, it has proven to be one of the most resilient sectors for investing.  Healthcare companies tend to supply the products and services that consumers need no matter what is happening with the market or the economy.  If you are looking to add cash to more fantastic healthcare stocks in the month of January, here are two no-brainer buys that can enrich your portfolio over the long term.",VRTX
101,2023-01-09,"Headline: Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish, source:Seeking Alpha, summary: No summary, Headline: Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex`s CF Royalties, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?, source:Yahoo, summary: It is hard to get excited after looking at Vertex Pharmaceuticals' (NASDAQ:VRTX) recent performance, when its stock has..., Headline: Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference - (Transcript), source:Seeking Alpha, summary: No summary, Headline: 41st Annual J.P. Morgan Healthcare Conference, source:Seeking Alpha, summary: No summary, Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: While the day-to-day machinations of the financial markets have left many investors feeling discouraged lately, stocks can still be a fantastic way to build and sustain wealth over a period of many years.  Vertex Pharmaceuticals (NASDAQ: VRTX) is at the forefront of cystic fibrosis (CF) treatment, a space on track to eclipse $17 billion by the end of the decade.  Therapeutic drugs designed to target the root cause of CF and enhance a patient's quality of life, known as CFTR modulators, remain key to managing the disease for thousands of people globally., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: No summary",VRTX
102,2023-01-10,"Headline: Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade, source:Yahoo, summary: Turning an initial $300,000 investment into seven figures in a decade may seem like a lofty aspiration, but it would require an annualized return of just around 13% to make that happen.  Considering that the S&P 500 has delivered total returns of 220% over the past decade, which works out to 12.3% on an annualized basis, this begins to look like a much more attainable goal., Headline: 2 Growth Stocks That Could Help Set You Up for Life, source:Yahoo, summary: Growth-oriented stocks have faced serious headwinds lately, and the volatility may continue well into 2023.  If you have spare cash to put to work to build your portfolio right now, here are two fantastic growth stocks in the healthcare space that you may want to consider adding to your buy list before the end of January.  Vertex Pharmaceuticals (NASDAQ: VRTX) has largely eluded the trends driving the broader market over the last year., Headline: Healthcare Stocks, a Star in 2022, Are Going Nowhere in 2023, source:MarketWatch, summary: Public commentary from management just hasn't been enough to provide a boost., partly because dividends are low relative to the shares' prices., Headline: Moderna (MRNA) Reports 2023 Business View & Pipeline Updates, source:Yahoo, summary: Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $288.75, marking a +1.95% move from the previous day.",VRTX
103,2023-01-11,"Headline: Vertex Pharmaceuticals expands collaboration with Arbor Biotechnologies, source:Thefly.com, summary: No summary, Headline: 2 Supercharged Stocks to Buy Right Now That Could Soar in 2023, source:Yahoo, summary: Major indices such as S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average fell by around 19%, 34%, and 9%, respectively, in the past year.  Despite the broad sell-off, a few stocks, such as Pinduoduo (NASDAQ: PDD) and Vertex Pharmaceuticals (NASDAQ: VRTX), managed to excel even in the difficult macroeconomic environment thanks to a solid growth story and robust financials.  China-based e-commerce player Pinduoduo built an online marketplace to bring cheap and high-quality products (electronics, fashion, household items) and agricultural produce to price-conscious consumers., Headline: 3 Top Healthcare Stocks to Buy for January, source:Yahoo, summary: My Motley Fool colleague Sean Williams even predicts that it will be the year's top-performing sector.  Here are three top healthcare stocks to buy for January.  Vertex also is moving forward with early-stage clinical testing of VX-522., Headline: Prime Medicine `Crispr 3.0` Vs. Crispr Therapeutics, source:Seeking Alpha, summary: No summary, Headline: Vertex, Arbor Biotechnologies extend agreement on precision gene editing technology, source:Seeking Alpha, summary: No summary, Headline: Ranking The 10 Largest Biotechs By Pipeline, source:SeekingAlpha, summary: The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list., Headline: 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond, source:Yahoo, summary: The stocks for healthcare companies IQVIA Holdings (NYSE: IQV) and Vertex Pharmaceuticals (NASDAQ: VRTX), for example, have been on the upswing recently thanks to reports of increased revenues, rising earnings, and management outlooks that point to more growth on the way.  IQVIA's shares were down more than 18% over the past year, but they're up more than 18% over the past three months.  The company is starting to see volumes get back to normal now that the worst effects of the pandemic are fading., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.21% to $292.25 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Vertex Pharmaceuticals Stock Sees Rising Relative Strength, source:Yahoo, summary: A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?, Headline: Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics, source:SeekingAlpha, summary: Despite being founded 10 years ago, CRISPR Therapeutics could very well lose out to 3-year-old Prime Medicine. Read more to see the comparison.",VRTX
104,2023-01-12,"Headline: IBB: A History Of Outperformance During Recessions, source:SeekingAlpha, summary: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now., Headline: VRTX March 3rd Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: 4 Growth Stocks to Buy and Hold Forever, source:Yahoo, summary: Warren Buffett would tell you the answer is ""forever.""  TikTok is a serious challenger to YouTube's dominance in the video app market.  OpenAI's ChatGPT AI tool could threaten Alphabet's most important business -- Google Search., Headline: Vera: Disappointing Data From Phase 2 ORIGIN Trial, Initiating Coverage With A Sell Rating, source:SeekingAlpha, summary: Veraâs phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. Read about the VERA's outlook here., Headline: 1 Top Growth Stock Set to Crush the Market Again in 2023, source:Yahoo, summary: Last year, biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) did not disappoint its shareholders.  The good news for investors is that the company has developments that could lead to a similarly strong showing in 2023.  Over the past decade, the only medicines that Vertex commercialized have targeted cystic fibrosis (CF), a rare genetic condition that damages patients' lungs and causes digestive problems., Headline: 2 Top Healthcare Stocks to Buy for the Long Haul, source:Yahoo, summary: The healthcare industry may not carry the same glitz and glamour for investors as other sectors.  The rare disease drug market is a fast-growing but historically underserved space on track to see its valuation grow to about $340 billion by the year 2030.  A key player in this industry is Vertex Pharmaceuticals (NASDAQ: VRTX), a company that has made a name for itself and built a robust history of profitability around its portfolio of medicines that treat the rare genetic disease cystic fibrosis., Headline: Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX), Intuitive Surgical (NASDAQ: ISRG), and cannabis company Green Thumb Industries (OTC: GTBIF) are three stocks that offer potential long-term rewards.  Boston-based Vertex Pharmaceuticals is a biotechnology company whose cystic fibrosis (CF) drugs have proven to be a huge success.  Trikafta is currently Vertex's best-selling CF treatment., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.37% to $296.25 Thursday, on what proved to be an all-around favorable trading session for the stock market, with...",VRTX
105,2023-01-13,"Headline: If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity, source:Yahoo, summary: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story..., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.58% to $300.94 Friday, on what proved to be an all-around positive trading session for the stock market, with...",VRTX
106,2023-01-14,"Headline: Is It Too Late to Buy Vertex Pharmaceuticals Stock?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) did something most other biotech companies didn't last year: It beat the bear market.  Vertex was on its way to proving it could be successful in areas beyond CF.  The company had reported positive data for its blood-disorders candidate and then began regulatory submissions., Headline: 3 Dirt Cheap Stocks to Buy in January, source:Yahoo, summary: While the stock market has performed abysmally over the past 12 months, there are plenty of stocks available at steep discounts.  Three Motley Fool contributors were asked to identify dirt cheap stocks to buy in January.  Here's why they chose Pfizer (NYSE: PFE), Teva Pharmaceutical Industries (NYSE: TEVA), and Vertex Pharmaceuticals (NASDAQ: VRTX).",VRTX
107,2023-01-16,"Headline: 2 Stocks Down More Than 25% to Buy Right Now, source:Yahoo, summary: Two healthcare stocks in particular have caught the attention of Motley Fool contributors Adria Cimino and Keith Speights.  Keith Speights (Intuitive Surgical): I have bad news, good news, and great news with respect to Intuitive Surgical (NASDAQ: ISRG).  Intuitive Surgical was also negatively affected by COVID-related lockdowns in China., Headline: 3 Biopharma Stocks That Could Help Make You a Fortune, source:Yahoo, summary: As any biotech investor will tell you freely, investing in biopharma is rife with risks.  Clinical trials can miss the mark, and successful medicines on the market can get outcompeted by newer entrants.  To do that, they tend to have a mix of reliable sales alongside a bunch of ambitious projects to provide upside.",VRTX
108,2023-01-17,"Headline: Vertex Pharmaceuticals upgraded to Outperform at SVB Securities, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND), source:TipRanks, summary: No summary, Headline: TEALWOOD ASSET MANAGEMENT INC Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: SVB Securities upgrades Vertex to Outperform, raises price target to $374, source:Thefly.com, summary: No summary, Headline: Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7, source:Yahoo, summary: BOSTON, January 17, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call""., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 3.67% to $311.98 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Market Rally Pauses, Tesla Keeps Rebounding; United Airlines, Moderna, Microsoft In Focus, source:Yahoo, summary: The market rally had a quiet day, with Tesla leading. United Airlines and Moderna rose overnight on news. Microsoft job cuts loom., Headline: 7 Biotech Stocks That Will Make You Rich in 10 Years, source:InvestorPlace, summary: No summary, Headline: Dow Jones Futures Rise On Bank Of Japan Surprise; Tesla Jumps, source:Yahoo, summary: Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom., Headline: Dow Jones Futures: Bank Of Japan Surprise; Tesla Jumps, source:Yahoo, summary: Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom.",VRTX
109,2023-01-18,"Headline: Vertex Pharmaceuticals initiated with a Hold at Canaccord, source:Thefly.com, summary: No summary, Headline: David J Yvars Group`s Top 5 Buys of the 4th Quarter, source:GuruFocus, summary: No summary, Headline: 5 Reasons to Buy Vertex Pharmaceuticals Now, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) defied 2022's bear market thanks to its tangible business progress.  Over the course of the year, the biotech company and its partner Crispr Therapeutics brought their treatment candidate for blood disorders toward the commercialization finish line.  Vertex has started off this year with gains too, and its winning streak may be far from over., Headline: Vertex Pharmaceuticals (VRTX) is a Top-Ranked Growth Stock: Should You Buy?, source:Yahoo, summary: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage., Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.68% to $309.86 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the..., Headline: How IBD Stock Of The Day Vertex Is Stacking Up Billions In Potential Sales, source:Yahoo, summary: Vertex is Wednesday's IBD Stock Of The Day. As the biotech eyes several blockbuster opportunities, VRTX stock is finding renewed support., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.68%: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed at $309.86 in the latest trading session, marking a -0.68% move from the prior day., Headline: Vertex Pharmaceuticals Stock Meets 80-Plus Relative Strength Rating Benchmark, source:Yahoo, summary: Vertex Pharmaceuticals stock now meets that criteria, with a jump from 75 to 84 Wednesday.  As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.  Is Vertex Pharmaceuticals Stock A Buy?",VRTX
110,2023-01-19,"Headline: Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler, source:Thefly.com, summary: No summary, Headline: 3 Unstoppable Stocks to Keep Buying in 2023, source:Yahoo, summary: Investors bought certain stocks hand over fist.  In most cases, these particular companies offered investors a solid reason to be optimistic about their future.  Up-and-coming biotech Axsome Therapeutics (NASDAQ: AXSM) commercialized its first two products., Headline: Dow Jones Falls 225 Points After Jobless Claims; Netflix Earnings Due, source:Yahoo, summary: The Dow Jones Industrial Average fell 225 points Thursday after first-time jobless claims. Netflix earnings are due out after the market close., Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. dropped 0.62% to $307.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: S&P 500, Nasdaq Break Key Levels, But Watch These 5 Stocks; Netflix Subscriber Growth Strong, source:Yahoo, summary: The S&P 500 and Nasdaq fell below their 50-day lines. Medpace and Exxon lead resilient stocks. Netflix jumped late as subscriber growth easily beat views., Headline: Dow Jones Futures Rise, Netflix Jumps On Subscribers After Market Rally Breaks Key Levels, source:Yahoo, summary: The market rally suffered more damage as the S&P 500 fell below its 50-day line. Netflix subscriber growth easily beat.",VRTX
111,2023-01-20,"Headline: Top 5 4th Quarter Trades of Brendel Financial Advisors LLC, source:GuruFocus, summary: No summary, Headline: Dow Jones Futures: Netflix Jumps On Subscribers, Google Slashing 12,000 Jobs After Market Rally Breaks Key Levels, source:Yahoo, summary: The market rally suffered more damage as the S&P 500 fell below its 50-day line. Netflix subscriber growth easily beat. Google will cut 12,000 jobs., Headline: 2 Healthcare Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: While the stock market volatility continues, day in and day out, not all companies have witnessed declines in their results.  In fact, many wonderful businesses are continuing to thrive in the current environment -- and that includes healthcare stocks.  If you're looking to add no-brainer healthcare stocks to your portfolio right now, here are two top names you'll want to consider when formulating your list of buys., Headline: Dow Jones Falls Ahead Of Housing Data; Netflix Surges On Subscriber Growth, source:Yahoo, summary: The Dow Jones Industrial Average fell Friday ahead of housing data. Netflix stock surged after the company's stronger-than-expected subscriber growth., Headline: The Best Stocks to Invest $5,000 In Right Now, source:Yahoo, summary: The stock market has already marked its fair share of high highs and low lows in 2023, and we're not even a full month in.  Vertex Pharmaceuticals (NASDAQ: VRTX) isn't one of those healthcare stocks with a massive portfolio of drugs that has tapped out its heyday of superior growth.  At present, Vertex has just four approved drugs in its portfolio, and all of them treat the genetic disease cystic fibrosis.",VRTX
112,2023-01-21,"Headline: 3 Smart Stocks to Buy if a Recession Is on the Way, source:Yahoo, summary: Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices.  Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients., Headline: BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential, source:Yahoo, summary: BP and Chinese search leader Baidu lead this weekend's watch list of 5 stocks near buy points with strong growth opportunities., Headline: 10 Best Healthcare Stocks For Recession, source:Yahoo, summary: In this article, we will take a look at the 10 best healthcare stocks for recession. You can skip this part and go to 5 Best Healthcare Stocks For Recession. The healthcare sector in 2022 outperformed the market despite several headwinds and a negative macroeconomic backdrop. Data shows that the Health Care Select Sector SPDR exchange-traded […]",VRTX
113,2023-01-22,"Headline: Global drug spending to reach $1.9T by 2027 ��� IQVIA, source:Seeking Alpha, summary: No summary",VRTX
114,2023-01-23,"Headline: First Week of March 17th Options Trading For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: Healthcare Outlook 2023, source:SeekingAlpha, summary: Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here., Headline: Healthcare Sector Is Lagging As We Enter 2022 Earnings Season, source:TalkMarkets, summary: No summary, Headline: Dow Jones Rises As Dollar Fades; Economic Data, Earnings Reports Due; AMD Surges On Upgrade, source:Yahoo, summary: The Dow Jones rose Monday ahead of a busy week of key economic data and earnings reports, with Tesla earnings due out Wednesday., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.64% higher to $311.81 Monday, on what proved to be an all-around favorable trading session for the stock..., Headline: Stocks To Buy And Watch: Dow Jones Banking Giant JPMorgan, 3 Others In Or Near Buy Zones, source:Yahoo, summary: Among the top stocks to buy and watch, Dow Jones banking giant JPMorgan is below its recent buy point, while Axon is breaking out today.",VRTX
115,2023-01-24,"Headline: Morgan Stanley Remains a Hold on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Dow Jones Falls 200 Points With 8 Key Earnings Movers; Microsoft Earnings Due, source:Yahoo, summary: The Dow Jones Industrial Average fell 180 points Tuesday as J&J and Verizon reported earnings. Microsoft earnings are due out after the stock market close., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.56% higher to $313.57 Tuesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day., Headline: 7 Cream-of-the-Crop Stocks to Buy Today, source:InvestorPlace, summary: No summary, Headline: 3 Gene Editing Stocks to Buy Now OR You`ll Be Kicking Yourself Later, source:InvestorPlace, summary: No summary",VRTX
116,2023-01-25,"Headline: Top 5 4th Quarter Trades of Lindbrook Capital, LLC, source:GuruFocus, summary: No summary, Headline: Dow Jones Falls 325 Points As Boeing, Microsoft Drop On Earnings; Tesla Skids Ahead Of Earnings, source:Yahoo, summary: The Dow Jones dropped 300 points Wednesday, as Boeing and Microsoft fell on earnings. Tesla earnings are due after the close., Headline: 3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later, source:Yahoo, summary: To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",VRTX
117,2023-01-26,"Headline: Dow Jones Reverses Lower After GDP, Jobless Claims; Tesla Surges On Earnings, Musk Comments, source:Yahoo, summary: The Dow Jones reversed lower after GDP and first-time jobless claims. Tesla stock surged on earnings and CEO Elon Musk's upbeat comments., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: No summary",VRTX
118,2023-01-27,"Headline: VRTX Crosses Above Average Analyst Target, source:ETF Channel, summary: No summary, Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: If you want solid healthcare stocks that will be worth buying and holding for the next 10 years, you need to set the bar pretty high.  But thanks to its portfolio and late-stage pipeline therapies, its next few years should feature strong growth., Headline: bluebird bio: More Share Dilution Likely, source:SeekingAlpha, summary: In our opinion, bluebird bio faces significant challenges that could decrease future investor returns. Read more to see BLUE's headwinds and why I think more share dilution is likely., Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: Companies in the healthcare industry in particular are often known for producing steady performance even in a tough macro period as they aren't exposed to the same economic cyclicality that other industries are.  Vertex Pharmaceuticals (NASDAQ: VRTX) is a healthcare company that specializes in medicines and therapies targeting rare diseases.  Right now, the company's approved medicines are all for the rare genetic disease cystic fibrosis, and it controls the lion's share of this multibillion-dollar market with its four products that treat the ailment., Headline: Dow Jones Reverses After Inflation Data; Intel Plunges 10% On Earnings, source:Yahoo, summary: The Dow Jones Industrial Average reversed higher Friday after key inflation data. Intel stock plunged over 10% on an earnings miss.",VRTX
119,2023-01-29,"Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",VRTX
120,2023-01-30,"Headline: Dow Jones Falls 100 Points With Fed Meeting In Sight; Tesla Stock Upgraded To Buy After 33% Surge, source:Yahoo, summary: The Dow Jones fell 100 points Monday, with the Federal Reserve's policy meeting set for this week. Tesla stock was upgraded to buy., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $319.98, marking a -0.46% move from the previous day., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary",VRTX
121,2023-01-31,"Headline: Highview Capital Management LLC/DE/ Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P., source:GuruFocus, summary: No summary, Headline: 3 Things About CRISPR Therapeutics That Smart Investors Know, source:Yahoo, summary: It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach.  In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon.  CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX)., Headline: Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release, source:Yahoo, summary: Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: This Clue Helps Spot The Best Stocks To Watch, Including These 11, source:Yahoo, summary: The best stocks to watch often hail from the top-ranked industries. Here's a look 11 stocks, including VRTX ad ULTA, that fit that bill., Headline: MOODY LYNN & LIEBERSON, LLC Buys 4, Sells 1 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of FOSTER DYKEMA CABOT & CO INC/MA, source:GuruFocus, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
122,2023-02-01,"Headline: A New Bull Market Could Arrive in February: 3 Stocks to Buy Now, source:Yahoo, summary: What will it take for a new bull market to begin?  The commonly accepted definition of a bull market is when stock prices rise 20% or more above their previous low.  A new bull market realistically could be on the way in February., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.27, marking a -1.8% move from the previous day., Headline: Parnassus Comments on Vertex, source:GuruFocus, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
123,2023-02-02,"Headline: 3 No-Brainer Stocks to Buy in February, source:Yahoo, summary: Wouldn't it be nice if investors had an ""easy button"" like the one that was featured in Staples commercials years ago?  Unfortunately, the ""easy button"" doesn't exist.  Actually, Amazon's stock has already begun a rebound, up more than 20% year to date after plunging nearly 50% in 2022., Headline: 2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade, source:Yahoo, summary: The healthcare industry has proven to be a remarkably resilient place to put capital to work in a wide range of environments.  From life-saving medicines and therapies to vaccines, these are just a few examples of the essential products that healthcare companies make that render them particularly defensive investments in a bearish environment.  AbbVie (NYSE: ABBV) is a pharmaceutical giant., Headline: Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release, source:Yahoo, summary: Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
124,2023-02-03,"Headline: 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond, source:Yahoo, summary: Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities.  Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM).  Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy., Headline: Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.",VRTX
125,2023-02-05,"Headline: When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?, source:TalkMarkets, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: No summary",VRTX
126,2023-02-06,"Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL, source:Yahoo, summary: Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7., Headline: Vertex Appears a Bit Under the Weather Ahead of Earnings, source:Yahoo, summary: Vertex Pharmaceuticals  is scheduled to report their latest quarterly top- and bottom-lines on Tuesday after the close of trading.  Prices pulled back to test the rising 200-day moving average line and a close below the early January low will turn the trend lower and could precipitate further declines.  The trading volume has been steady instead of increasing and the On-Balance-Volume (OBV) line shows a steady rise into late January., Headline: In virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay Area, source:Yahoo, summary: The Cystic Fibrosis Foundation is spinning some of the half-billion dollars it received as part of a royalty deal in 2016 into Bay Area companies looking at ways to tackle persistent infections and perhaps even mutation-fixing cures., Headline: GLOBAL BRIEFING: Australia lifts interest rates by 25 basis points, source:Alliance News, summary: No summary, Headline: Vertex options imply 3.7% move in share price post-earnings, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals reports Q4 EPS $3.76, consensus $3.51, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals guides FY23 revenue $9.55B-$9.70B, consensus $9.6B, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals board authorizes $3.0B buyback, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Non-GAAP EPS of $3.76 beats by $0.25, revenue of $2.3B in-line, source:Seeking Alpha, summary: No summary, Headline: Vertex indicates slowdown in growth; announces share buybacks, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary",VRTX
127,2023-02-07,"Headline: Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports, source:Thefly.com, summary: No summary, Headline: 3 Nasdaq 100 Stocks to Buy Hand Over Fist in February, source:Yahoo, summary: After growth stocks were Wall Street's savior in 2021, they were primarily responsible for dragging the major indexes into a bear market last year.  The growth-dependent Nasdaq Composite and Nasdaq 100 -- an index comprised of the 100 largest nonfinancial companies listed on the Nasdaq exchange -- each plunged 33% in 2022.  Thankfully, when there's pain on Wall Street, you can always find opportunity., Headline: 3 Top Stocks to Buy If There Is a Market Pullback, source:Yahoo, summary: It's even possible that we could soon see the beginning of a new bull market.  Investors could have the equivalent of this happen with the stock market.  If the stock market indeed retreats, one of the most likely culprits is that investors fear a recession is coming., Headline: Notable companies reporting after market close, source:Thefly.com, summary: No summary, Headline: Vertex under fire as activists demand generics for best-selling drug, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Battles Back With A Boost To 81 RS Rating, source:Yahoo, summary: Vertex Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 81., Headline: Vertex Pharmaceuticals Sets $3B Share Repurchase Program, source:MarketWatch, summary: By Kathryn Hardison Vertex Pharmaceuticals Inc.'s board of directors has approved a new share repurchase program for up to $3 billion of common stock. The..., Headline: Vertex: Q4 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Vertex Pharmaceuticals sees improved annual earnings and revenue, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals Incorporated 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2022 Q4 earnings call., Headline: The 7 Best Biotech Stocks to Buy for February 2023, source:Yahoo, summary: While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from, Headline: Vertex Reports Fourth Quarter and Full Year Financial 2022 Results, source:Yahoo, summary: BOSTON, February 07, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2022 and provided full year 2023 financial guidance., Headline: Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ETCompany ParticipantsSusie Lisa â Senior Vice President-Investor..., Headline: Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views, source:Yahoo, summary: Vertex Pharmaceuticals offered an upbeat look for 2023 sales after reporting an earnings beat and in-line sales., Headline: Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates, source:Yahoo, summary: Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Dow Jones Futures: Market Rallies On Powell, Microsoft AI Arms Race; Fortinet, Enphase Jump On Earnings, source:Yahoo, summary: The stock market rallied Tuesday on Fed chief Jerome Powell and a Microsoft AI arms race. Fortinet and Enphase were big winners late., Headline: GLOBAL BRIEFING: Stocks called higher after Fed chair remarks, source:Alliance News, summary: No summary, Headline: Vertex has built a CF empire. Next up: cell and gene therapy., source:Yahoo, summary: The pharmaceutical giant's next play is a CRISPR-based gene therapy that could launch as soon as this year., Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $342 from $313 at Barclays, source:Thefly.com, summary: No summary",VRTX
128,2023-02-08,"Headline: Vertex Pharmaceuticals price target raised to $325 from $300 at H.C. Wainwright, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals (VRTX) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: My name is Susie Lisa, and as the senior vice president of investor relations for Vertex, it is my pleasure to welcome you to our fourth quarter and full year 2022 financial results conference call.  On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex' CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer., Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Rocket Pharmaceuticals (RCKT), source:TipRanks, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Illumina (ILMN) and Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Siegfried Holding AG (OtherSGFEF) and Demant (OtherWILLF), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target lowered to $365 from $374 at SVB Securities, source:Thefly.com, summary: No summary, Headline: Sivik Global Healthcare LLC Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Piper Sandler Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Vertex Pharmaceuticals (VRTX) and Inspire Medical Systems (INSP), source:TipRanks, summary: No summary, Headline: Here's What Key Metrics Tell Us About Vertex (VRTX) Q4 Earnings, source:Yahoo, summary: Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers., Headline: Vertex Pharmaceuticals (VRTX) Gets a Buy from BMO Capital, source:TipRanks, summary: No summary, Headline: Dow Jones Futures Fall, AI Arms Race Intensifies; Fortinet, Enphase, Uber Jump On Earnings, source:Yahoo, summary: A Microsoft-Google AI arms race is keeps expanding. Fortinet, Uber and Enphase were big winners early Wednesday., Headline: Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging, source:Yahoo, summary: Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023., Headline: Vertex Pharmaceuticals: Pioneering Scientific Advances To Tackle Serious Diseases, source:SeekingAlpha, summary: Vertex focuses on creating transformative medicines for serious diseases, with a special emphasis on specialty markets. See why VRTX stock is a Buy., Headline: 2 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: The bear market crushed many top healthcare stocks -- from young high-growth players to long-established companies generating billions of dollars in earnings.  Vertex is the worldwide leader in the cystic fibrosis (CF) treatment market.  In fact, last year product revenue climbed 18% to more than $8.9 billion., Headline: Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat, source:Yahoo, summary: Vertex Pharmaceuticals' fourth-quarter sales divided analysts Wednesday as VRTX stock toppled on a lack of near-term catalysts., Headline: Meta Platforms Announces $40 Billion Share Buyback - Buyback Wednesdays, source:SeekingAlpha, summary: nan, Headline: Vertex��Pharmaceuticals: As Strong As Ever In Cystic Fibrosis, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",VRTX
129,2023-02-09,"Headline: Entrada Therapeutics closes agreement with Vertex, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV), source:TipRanks, summary: No summary, Headline: Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen., source:Yahoo, summary: CRISPR and partner Vertex Pharmaceuticals have applied for authorization of exa-cel, a candidate to treat blood disorders.  If all goes well, Wall Street's average forecast for a 70% jump in CRISPR shares within the coming 12 months could happen.  CRISPR and Vertex use this technology in exa-cel to tackle the blood disorders beta thalassemia and sickle cell disease., Headline: Vertex Pharmaceuticals Full Year 2022 Earnings: In Line With Expectations, source:Yahoo, summary: Vertex Pharmaceuticals ( NASDAQ:VRTX ) Full Year 2022 Results Key Financial Results Revenue: US$8.93b (up 18% from FY..., Headline: Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?, source:Yahoo, summary: With a new bull market potentially near, investors might be forced to soon make such hard decisions.  If we were talking about which of these biotech stocks is the better pick for a bear market, it would be an easy decision.  All we have to do is look at how Vertex and CRISPR Therapeutics stocks performed in the bear market last year., Headline: VRTX Crosses Below Key Moving Average Level, source:Market News Video, summary: No summary, Headline: CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings., Headline: Vertex Pharmaceuticals: As Strong As Ever In Cystic Fibrosis, source:SeekingAlpha, summary: Despite a snapped streak of 20+ quarters of revenue beats, Vertex Pharmaceuticals is a decent buy. Click here to see our take on VRTX stock., Headline: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Call Transcript February 7, 2023 Operator: Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter and Full Year 2022 Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. […], Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",VRTX
130,2023-02-10,"Headline: Is Vertex Pharmaceuticals Stock a Buy Right Now?, source:Yahoo, summary: Investors looking for stocks that can produce impressive gains regardless of the general market's direction should turn their attention to the biopharmaceutical industry.  Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) gained a stunning 33.5% in 2023 while the Nasdaq Composite index that it's a part of sank 33.1% lower.  Of course, one very good year doesn't necessarily mean Vertex Pharmaceuticals can keep climbing in the years to come., Headline: 2 Top Stocks to Buy Without Hesitation in 2023, source:Yahoo, summary: Johnson & Johnson (NYSE: JNJ) is one of the world's largest healthcare companies, soon to be split into two separate entities.  The company is in the process of spinning off its consumer health business into a new company called Kenvue, while its medical device and pharmaceutical businesses will remain under the umbrella of the Johnson & Johnson name.  CEO Joaquin Duato noted in the company's recent 2022 earnings call that ""we filed our form S-1 with the SEC, giving us the option to pursue an IPO as a potential step in the separation."", Headline: 3 Stocks That Could Soar Whether There's a New Bull Market or Not, source:Yahoo, summary: Here are three stocks that could soar whether there's a new bull market or not.  Axsome Therapeutics (NASDAQ: AXSM) stock more than doubled last year while the S&P 500 plunged.  The reality is that Axsome's performance this year won't hinge in the least on what the overall stock market does., Headline: 25 Biggest Massachusetts Companies and Stocks, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest Massachusetts companies and stocks. To skip our detailed analysis, you can go directly to see the 5 biggest Massachusetts companies and stocks. If all U.S. states were countries, Massachusetts would be 32nd largest economy in the world based on a 2021 GDP […]",VRTX
131,2023-02-11,"Headline: This Growth Stock Crushed the Market Last Year. 5 Words from the CEO Suggest There's More to Come., source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) stock climbed more than 31% last year even as the overall market touched bear territory.  Now, investors may wonder if the good news is priced into Vertex shares -- and if gains are over.  First, though, a quick summary of Vertex's story so far: The company is the global leader in CF treatment., Headline: 2 Biotech Stocks That Could Help Set You Up for Life, source:Yahoo, summary: Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are each up about 20% over the past year.  The biotech companies have shown increased revenue and earnings per share (EPS) over the past three years and have burgeoning pipelines that should continue to drive growth., Headline: 3 Surefire Growth Stocks You Can Buy Right Now, source:Yahoo, summary: With this in mind, we asked three Motley Fool contributors to identify surefire growth stocks you can buy right now.  Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Keith Speights (Axsome Therapeutics): It usually takes only one big product to be a game changer for a small biotech stock.",VRTX
132,2023-02-12,"Headline: The Best Stocks To Invest $5,000 in Right Now, source:Yahoo, summary: When Bill Miller says a stock is a great pick, it pays to listen.  Specifically, Miller called Amazon ""one of the easiest names in the market right now.""  This optimism about Amazon isn't just because the stock remains more than 40% below its previous high (although that is the case)., Headline: ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood, source:InvestorPlace, summary: No summary, Headline: Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary, Headline: Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary",VRTX
133,2023-02-13,"Headline: 2 Top Stocks to Buy in February and Hold Forever, source:Yahoo, summary: The stock market can be a fantastic way to build and sustain strong financial returns, but only if you stay in the market for many years.  While there are plenty of healthcare companies that sell surgical robotics systems, none have come close to snagging the market share of Intuitive Surgical., Headline: 3 Unstoppable Growth Stocks to Buy for 2023 and Beyond, source:Yahoo, summary: Here are three unstoppable growth stocks to buy for 2023 and beyond.  Sure, Disney's (NYSE: DIS) stock performance last year made it look very stoppable.  Bob Iger, who previously served as Disney's CEO and was called to duty again in November 2022, knows what he's doing., Headline: 2 Top Healthcare Stocks to Buy for the Long Haul, source:Yahoo, summary: The healthcare industry is booming, and this presents no shortage of opportunities to invest in promising businesses., Headline: 3 Growth Stocks With More Potential Than Any Cryptocurrency, source:Yahoo, summary: If you have money to put into the stock market right now, there are plenty of companies just begging to be bought with tremendous growth potential to tap into in the years ahead.  Vertex Pharmaceuticals (NASDAQ: VRTX) is coming off of another robust year of growth in 2022.  The company delivered approximately $9 billion on the top line in the 12-month period, paired with earnings of $3.3 billion and operating income of $4.3 billion., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.60% higher to $299.18 Monday, on what proved to be an all-around favorable trading session for the stock...",VRTX
134,2023-02-14,"Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.36% higher to $300.25 Tuesday, on what proved to be an all-around rough trading session for the stock market,...",VRTX
135,2023-02-15,"Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slumped 0.50% to $298.75 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",VRTX
136,2023-02-16,"Headline: 2 Monster Stocks to Buy Hand Over Fist in 2023, source:Yahoo, summary: A pandemic favorite and a healthcare growth stock each have something to add to the long-term investor's portfolio., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 2.25% to $292.04 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...",VRTX
137,2023-02-17,"Headline: First Week of VRTX October 20th Options Trading, source:Stock Options Channel, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.55% higher to $293.66 Friday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Beat the Dow Jones With CRISPR Therapeutics Stock, source:Yahoo, summary: Back in 2020, CRISPR Therapeutics (NASDAQ: CRSP) left the Dow Jones Industrial Average (DJIA) in the dust.  The stock soared more than 150%, while the DJIA delivered a modest 7% increase.  Investors were excited about biotech companies -- and CRISPR's gene-editing technology caught their attention.",VRTX
138,2023-02-18,"Headline: 3 Top Stocks to Buy and Hold for the Next Decade and Beyond, source:Yahoo, summary: Can Amazon successfully expand into new major markets?  If Amazon CEO Andy Jassy is right, over the next 10 to 15 years nearly 95% of global IT spending could be in the cloud.  Sure, it's possible that the company could be toppled.",VRTX
139,2023-02-19,"Headline: 2 No-Brainer Growth Stocks to Buy Right Now, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has amassed a profitable and high-revenue growth business around a relatively small portfolio of drugs.  While the addressable market for Vertex's existing portfolio of cystic fibrosis drugs is massive -- management estimates that as many as 20,000 people globally could benefit from the company's products but are not yet taking them -- and additional indications for these drugs are expanding its patient population, the company is looking to new sources of growth.  It currently has an impressive pipeline of products spanning disease areas ranging from rare blood disorders to type 1 diabetes to acute pain., Headline: Got $1,500? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond, source:Yahoo, summary: The stock market has challenged the fortitude of even the most seasoned investors over the past year, with extreme volatility driving shares of some of the largest and most popular companies down.  Regardless of what stocks do in the coming weeks or months, superior businesses primed for growth can come out on top in the long run.  Vertex Pharmaceuticals (NASDAQ: VRTX) has actually beaten the market over the trailing 12 months, delivering a share price increase of around 30% compared to the S&P 500's negative return that currently sits right around 7%.",VRTX
140,2023-02-21,"Headline: BRIDGER MANAGEMENT, LLC Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: The healthcare industry has long proven itself to be a resilient place for investors to park their cash.  Vertex Pharmaceuticals (NASDAQ: VRTX) has continued to report explosive financial growth from its core portfolio of products, all while expanding its pipeline into new disease areas ripe for disruption.  It's delivered a total return of 24% over the past year, compared to the S&P 500's negative return of 7% in that same period., Headline: 2 Bruised Growth Stocks to Buy While They're Cheap, source:Yahoo, summary: Every time the market gets a stock wrong, you have an opportunity to profit by buying and holding it, and that's especially true for growth stocks that are likely to flourish again in due time.  With that in mind, let's examine two temporarily down-on-their-luck growth stocks that are positioned to rally after they execute on their core strategies a bit longer.  Ginkgo Bioworks (NYSE: DNA) saw its shares fall by 69% over the last 12 months, but that could be just the opening that value-hunting investors need to start a position., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.40% to $292.48 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7, source:Yahoo, summary: BOSTON, February 21, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET., Headline: Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX)., Headline: AbbVie sued in Netherlands for breaching human rights over Humira pricing, source:Seeking Alpha, summary: No summary",VRTX
141,2023-02-22,"Headline: Crispr Therapeutics price target lowered to $123 from $153 at Chardan, source:Thefly.com, summary: No summary, Headline: CRISPR surges 13% most in over two years after Q4 earnings, source:Seeking Alpha, summary: No summary, Headline: CRISPR surges 14% most in over two years after Q4 earnings, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills, source:Yahoo, summary: JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog., Headline: Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done, source:MarketWatch, summary: The company said it expects to complete a filing for FDA approval for the treatment by March, highlighting its lead in a competitive field., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.64% higher to $294.36 Wednesday, on what proved to be an all-around poor trading session for the stock market,..., Headline: CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss, source:Yahoo, summary: CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.",VRTX
142,2023-02-23,"Headline: Oppenheimer Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y, source:Yahoo, summary: Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023., Headline: Industry Leaders Building Breakouts And Buy Zones Right Now, source:Yahoo, summary: The best stocks to watch often hail from the top-ranked industries. Here's a look 15 stocks, including CROX and ABNB, that fit that bill., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.61% to $292.57 Thursday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
143,2023-02-24,"Headline: Vertex Pharmaceuticals management to meet with Truist, source:Thefly.com, summary: No summary, Headline: Will Weakness in Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Prove Temporary Given Strong Fundamentals?, source:Yahoo, summary: With its stock down 7.2% over the past month, it is easy to disregard Vertex Pharmaceuticals (NASDAQ:VRTX). But if you..., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.78% to $287.37 Friday, on what proved to be an all-around rough trading session for the stock market, with the...",VRTX
144,2023-02-25,"Headline: Regeneron: Innovation And Disruption Done Right, source:SeekingAlpha, summary: Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now., Headline: Nasdaq Bear Market: 5 Superb Growth Stocks You'll Regret Not Buying on the Dip, source:Yahoo, summary: A 33% plunge in the Nasdaq Composite is the perfect excuse for opportunistic investors to pounce on innovation-driven businesses., Headline: 3 Top Stocks to Invest $3,000 in Right Now, source:Yahoo, summary: Will a new bull market begin soon? Maybe, but maybe not. But some enticing opportunities await investors regardless of what happens. Some stocks have prospects that are simply too attractive to ignore., Headline: 3 Stocks to Buy Right Now That Are Cash Cows, source:Yahoo, summary: With this in mind, three Motley Fool contributors were asked to pick stocks to buy right now that are cash cows.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (AbbVie): There are many ways in which a company can be deemed a ""cash cow.""",VRTX
145,2023-02-26,"Headline: Baron Health Care Fund Q4 2022 Quarterly Letter, source:Seeking Alpha, summary: No summary",VRTX
146,2023-02-27,"Headline: Beyond Crispr`s Exa-Cel Program: A Scalable Pipeline, source:Seeking Alpha, summary: No summary, Headline: Beyond Crispr's Exa-Cel Program: A Scalable Pipeline, source:SeekingAlpha, summary: CRISPR Therapeutics is a gene-editing startup that uses CRISPR/Cas9 technology to develop therapies. Click here to read my full analysis of CRSP stock., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.01% higher to $287.40 Monday, on what proved to be an all-around great trading session for the stock market,..., Headline: The 20 worst U.S. stocks in February: the biggest loser dropped 35%, source:MarketWatch, summary: No summary",VRTX
147,2023-02-28,"Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.01% to $290.29 Tuesday, on what proved to be an all-around rough trading session for the stock market, with...",VRTX
148,2023-03-01,"Headline: ImmunoGen announces license agreement with Vertex Pharmaceuticals, source:Thefly.com, summary: No summary, Headline: Vertex in pact with ImmunoGen to expand gene editing reach, source:Seeking Alpha, summary: No summary, Headline: ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents, source:Business Wire, summary: No summary, Headline: Immunogen confident in early Elahere launch, says Guggenheim, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.32% higher to $291.23 Wednesday, on what proved to be an all-around mixed trading session for the stock..., Headline: ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing, source:Yahoo, summary: ImmunoGen Inc (NASDAQ: IMGN) announced a global, multi-target license and option agreement that granted Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rights for ImmunoGen's ADC technology to discover targeted conditioning agents for use with gene editing. After each target's research period, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target. ImmunoGen will retain f",VRTX
149,2023-03-02,"Headline: April 14th Options Now Available For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 32%?, source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$430 Vertex..., Headline: 3 Incredible Growth Stocks to Buy if the Market Dips, source:Yahoo, summary: U.S. stock markets are in a precarious place.  Bargain hunters bid up a wide swath of growth equities during the first month of the year, but these same equities, on balance, found it hard to retain these monthly gains over the course of February.  The core issue at play is the uncertainty surrounding the future of inflation, U.S. interest rates, and the global economy., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.16% to $290.76 Thursday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
150,2023-03-03,"Headline: 3 Nasdaq 100 Stocks to Buy Hand Over Fist in March, source:Yahoo, summary: The growth-focused Nasdaq Composite and Nasdaq 100 -- an index comprised of the 100 largest nonfinancial companies listed on the Nasdaq exchange -- were hit the hardest.  More specifically, every bear market decline throughout history in the major indexes (which can also include the Nasdaq 100) has eventually been put into the rearview mirror by a bull market.  With the Nasdaq 100 well off of its all-time high, bargains abound., Headline: 2 Growth Stocks to Invest $1,000 in Right Now, source:Yahoo, summary: While the bear market might have convinced some investors that growth stocks are permanently out of fashion, you don't need to look very far to find a few companies that are bucking the trend by powering forward despite gloomy conditions.  Vertex Pharmaceuticals (NASDAQ: VRTX) is a rare disease drug developer that's worth an investment of $1,000 because it's in the process of making big moves that'll almost certainly transform (and grow) the company.  With a top line of $8.9 billion in 2022 -- all of which was derived from its sales of drugs treating cystic fibrosis (CF), a rare hereditary pulmonary disease -- Vertex is now diversifying its sources of revenue., Headline: AXON, MBLY, AVGO Lead Top-Rated Stocks In Top 20 Industries, source:Yahoo, summary: AXON, MBLY, LSCC, CROX and AVGO lead 23 top-rated stocks to watch leading moves in the top-ranked industries., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.09% to $290.51 Friday, on what proved to be an all-around positive trading session for the stock market, with...",VRTX
151,2023-03-04,"Headline: Prediction: These 3 S&P 500 Stocks Will at Least Double in 7 Years, source:Yahoo, summary: This punchline comes to mind when I look at the S&P 500.  Which stocks in the S&P 500 will work the most for investors throughout this decade?  When asked about Amazon, the first thoughts of many individuals would probably be about the company's online shopping platform or its Prime Video streaming service., Headline: 3 Game-Changing Stocks to Buy in March, source:Yahoo, summary: Three Motley Fool contributors were asked to select stocks to buy in March that truly are game changers.  Here's why they picked Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Keith Speights (Beam Therapeutics): Base editing is an approach to editing genes invented in 2016 by a team led by David Liu., Headline: 3 Things About CRISPR Therapeutics That Smart Investors Know, source:Yahoo, summary: Shares of CRISPR Therapeutics (NASDAQ: CRSP) are down nearly 17% over the past year but up over 16% so far in 2023.  The clinical-stage biotech company is named for the CRISPR/Cas9 gene-editing method that won the Nobel Prize for chemistry in 2020, and the buzz for the company seems to be growing.  The company is looking to CRISPR/Cas9 gene editing to find therapies for a multitude of maladies.",VRTX
152,2023-03-06,"Headline: 3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing, source:Yahoo, summary: The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery. These companies bring new avenues in medicine and biotech that a smart investor can advantage. CRISPR/Cas allows scientists to work on curing previously incurable genetic di, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.38% higher to $291.62 Monday, on what proved to be an all-around favorable trading session for the stock..., Headline: 7 Cathie Wood Stocks for Your March Buy List, source:InvestorPlace, summary: No summary",VRTX
153,2023-03-07,"Headline: MaxCyte revenue grows in 2022, expects further revenue climb in 2023, source:Alliance News, summary: No summary, Headline: Vortex Energy Corp. Announces Letter Agreement for Acquisition of Blue Ocean Salt Corp., source:GlobeNewswire, summary: No summary, Headline: Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 67%, source:Yahoo, summary: Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the..., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.73% to $286.58 Tuesday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference Transcript, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) 43rd Annual Cowen Healthcare Conference March 7, 2023 2:50 PM ETCompany ParticipantsReshma Kewalramani â President and Chief...",VRTX
154,2023-03-08,"Headline: 2 No-Brainer Growth Stocks to Buy Right Now, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has a solid track record of steady revenue growth and profitability thanks to its portfolio of top-selling cystic fibrosis medicines.  Its flagship product, Trikafta, is approved to treat more than 90% of the cystic fibrosis patient population in the U.S., and the continued expansion of indications for its portfolio of medicines over the years extended the availability of these products to younger and younger groups of patients.  Vertex Pharmaceuticals also bears the distinction of being the only company with cystic fibrosis medicines on the market that target the underlying cause of the disease., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.49% to $285.18 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",VRTX
155,2023-03-09,"Headline: Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes, source:Thefly.com, summary: No summary, Headline: Vertex gets FDA nod to start trial of cell therapy VX-264 for type 1 diabetes, source:Seeking Alpha, summary: No summary, Headline: 4 Growth Stocks to Buy and Hold Forever, source:Yahoo, summary: How long does Warren Buffett like to own a stock?  Here are four growth stocks to buy and hold forever.  Amazon (NASDAQ: AMZN) can legitimately claim to rank as one of the most disruptive companies ever., Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes, source:Yahoo, summary: BOSTON, March 09, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex-developed, immunoprotective device with the potential to treat type 1 diabetes (T1D). The VX-264 program does not require the use of immunosuppression, which may broaden the population of pe, Headline: Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold, source:Yahoo, summary: Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up more than 19% over the past 12 months during a period in which many other gene-editing biotech stocks tumbled.  The company is profitable thanks to its cystic fibrosis therapies, and its key CRISPR-editing therapy, exa-cel, is waiting for approval from the Food and Drug Administration (FDA) to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).  It might be too late to get in on the Vertex run-up, but there's another CRISPR-editing company that could be an even better long-term buy, one that Vertex is already collaborating with on exa-cel: CRISPR Therapeutics (NASDAQ: CRSP)., Headline: 2 Explosive Stocks That Could Go Parabolic, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has built a name for itself in the rare disease drug market with its global footprint in the cystic fibrosis treatment space.  It's estimated that there are 88,000 people in North America, Europe, and Australia alone that have the genetic disease.  Vertex is the only company on the market with approved CFTR modulators -- drugs that work to correct the underlying genetic malfunction causing cystic fibrosis., Headline: 2 Top Stocks to Buy in March and Hold Forever, source:Yahoo, summary: If you're looking for more great stocks to add to your portfolio this month, you don't have to look far to find quality businesses with compelling growth stories.  Provided you have the capital on hand to invest right now that you can put into your portfolio and leave alone for the next few years, even the current choppy waters of the market are still presenting investors with wonderful opportunities to buy great companies.  Here are two names to consider adding to your portfolio in the near future and holding for years., Headline: Vertex (VRTX) Down 2.8% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",VRTX
156,2023-03-10,"Headline: GLOBAL BROKER RATINGS: BoA raises Vertex Pharma; Barclays cuts Segro, source:Alliance News, summary: No summary, Headline: If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today, source:Yahoo, summary: Growth stocks took off during 2020 amid the early stages of the pandemic.  One of the stocks that benefited from that bullishness was CRISPR Therapeutics (NASDAQ: CRSP), a Cathie Wood favorite.  By January 2021, amid the meme stock hype, shares of CRISPR reached highs of more than $200, and the stock was looking like a fantastic buy., Headline: This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy, source:Yahoo, summary: Over the past decade, biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has made a fortune thanks to its monopoly in treatments for cystic fibrosis (CF).  Despite its success in CF that continues today, Vertex has sought to diversify its lineup of medicines -- and the company seems very close to accomplishing this goal.  Vertex Pharmaceuticals has been developing exa-cel, a therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in collaboration with CRISPR Therapeutics., Headline: Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.13% higher to $287.24 Friday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $287.24, marking a +0.13% move from the previous day.",VRTX
157,2023-03-11,"Headline: Is Now The Time To Put Vertex Pharmaceuticals (NASDAQ:VRTX) On Your Watchlist?, source:Yahoo, summary: Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...",VRTX
158,2023-03-12,"Headline: 3 Supercharged Stocks With More Potential Than Any Cryptocurrency, source:Yahoo, summary: Airbnb (NASDAQ: ABNB) continues to benefit from the travel recovery, but its recent financial reports indicate a growth story that is broadly eclipsing that of the typical travel stock.  With a platform that caters to vacationers, business travelers, and those blending both in the digital age, Airbnb can benefit from the post-pandemic travel recovery as well as long-term trends.  On the flip side, with a difficult economy causing worries about income security, more and more people are looking at Airbnb as a way to earn extra money as hosts.",VRTX
159,2023-03-13,"Headline: Prediction: These 3 Stocks Will Be in the Dow by 2030, source:Yahoo, summary: Being added to the Dow Jones Industrial Average would just be another feather in the cap for these successful stocks., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.17% to $293.46 Monday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade, source:Yahoo, summary: Vertex Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating",VRTX
160,2023-03-14,"Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.61% higher to $295.25 Tuesday, on what proved to be an all-around positive trading session for the stock...",VRTX
161,2023-03-15,"Headline: The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector, source:InvestorPlace, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.33% to $294.27 Wednesday, on what proved to be an all-around rough trading session for the stock market, with...",VRTX
162,2023-03-16,"Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147), source:Yahoo, summary: BOSTON, March 16, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants, a severe, rapidly progressive form of chronic kidney disease also known as APOL1-mediated kidney disease (AMKD). AMKD is caused by, Headline: Vertex: On The Verge Of Becoming A Very Serious Proposition For Buyers, source:SeekingAlpha, summary: Vertex is a Cystic Fibrosis powerhouse that earned revenues of $8.9bn in 2022 and was highly profitable. See why I think VRTX stock looks like a buy., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.16% to $300.64 Thursday, on what proved to be an all-around favorable trading session for the stock market,...",VRTX
163,2023-03-17,"Headline: Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Semiconductor Stocks Ignite Breakouts And Buy Zones, source:Yahoo, summary: The best stocks to watch often hail from the top-ranked industries. Here's a look 23 such stocks, including AMAT, AVGO and MBLY., Headline: 3 Pharma Stocks That Could Benefit from Global Healthcare Trends, source:Yahoo, summary: When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it’s much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing. The following three drug stocks certainly fit that criterion. One has a very promising treatment for cancer, which is a leading cause of death in both the U.S. an, Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 1.62% to $295.77 Friday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.77, moving -1.62% from the previous trading session.",VRTX
164,2023-03-18,"Headline: 3 Beaten-Down Stocks That Could Soar This Year, source:Yahoo, summary: Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Exelixis (NASDAQ: EXEL), and Intellia Therapeutics (NASDAQ: NTLA).  Prosper Junior Bakiny (CRISPR Therapeutics): Unprofitable clinical-stage biotech companies got hammered last year.  Gene-editing specialist CRISPR Therapeutics fits that description to a T, so it got dragged down along with the broader market.",VRTX
165,2023-03-19,"Headline: Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat, source:Yahoo, summary: If you're worried about how the banking sector turmoil will impact your investments, let me help ease your mind.  As a result, investors who own renewable energy stocks shouldn't have anything to worry about.  You can invest in Brookfield Renewable in a couple of ways.",VRTX
166,2023-03-20,"Headline: Vortex Energy Corp. Announces Appointment of Paul Sparkes as Chief Executive Officer & Director, source:GlobeNewswire, summary: No summary, Headline: 3 Surefire Stocks That Can Thrive During a Recession, source:Yahoo, summary: These time-tested businesses have the sustainable cash flow and catalysts needed to outperform when the U.S. economy isn't at its best., Headline: Vertex Pharmaceuticals For Strong CF Franchise Growth Plus Exciting Pipeline, source:SeekingAlpha, summary: Vertex Pharmaceuticals is noted for its dominance in the cystic fibrosis therapy space. Click here to see why VRTX stock is a Buy., Headline: 3 Monster Stocks to Buy Without Any Hesitation, source:Yahoo, summary: These stocks are monsters now. They'll probably be much bigger monsters over the next decade and beyond., Headline: Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet, source:Yahoo, summary: According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?, Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.08% to $298.95 Monday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Vertex Pharmaceuticals initiated with an Outperform at Bernstein, source:Thefly.com, summary: No summary",VRTX
167,2023-03-21,"Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: Critics of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) believe that the company is lagging behind OpenAI and Microsoft in the artificial intelligence (AI) race.  It could be a huge mistake to underestimate Alphabet's AI expertise or Google Search's resilience., Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Here's Why You Should Add CRISPR Stock to Your Portfolio, source:Yahoo, summary: CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.24% to $302.66 Tuesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Bernstein Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Outperform Recommendation, source:Fintel, summary: nan",VRTX
168,2023-03-22,"Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.58% to $297.87 Wednesday, on what proved to be an all-around rough trading session for the stock market, with...",VRTX
169,2023-03-23,"Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary, Headline: Got $3,000? 3 Growth Stocks to Double Up on Right Now, source:Yahoo, summary: If you've got $3,000, here are three growth stocks to double up on right now.  Amazon (NASDAQ: AMZN) has gotten off to a great start this year, with shares jumping around 16%.  There are two main reasons behind Amazon's weak stock performance., Headline: This Is My Highest-Conviction Stock to Own in 2023 and Beyond, source:Yahoo, summary: While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town.  Vertex markets the only medicines that target the underlying causes of CF.  In 2022, the company's revenue of $8.93 billion jumped by 18% year over year., Headline: This Cathie Wood Stock Could Nearly Double, According to Wall Street, source:Yahoo, summary: One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP).  This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood.  Wood isn't the only one on Wall Street who likes CRISPR., Headline: Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Semiconductor Plays Dominate This Screen Of 21 Stocks To Watch, source:Yahoo, summary: The best stocks to watch often hail from the top-ranked industries. Here's a look at 21 such stocks, including AMAT, AVGO and MBLY.",VRTX
170,2023-03-24,"Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 3.16% to $314.39 Friday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Lightning Round: Occidental is Warren Buffett's favorite, it's not my favorite, source:CNBC, summary: Mad Money host Jim Cramer weighs in on all manner of stocks, including Barrick Gold, Occidental, Lumentum Holdings, Nordic American Tanker, Petrobras, Vertex Pharmaceuticals, Dana Inc. and Catalyst Pharmaceuticals.",VRTX
171,2023-03-25,"Headline: The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket, source:InvestorPlace, summary: No summary, Headline: Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend, source:Yahoo, summary: The past 15 months haven't been easy for growth stock investors.  The Nasdaq Composite index has fallen a disappointing 25% since the beginning of 2022, making this an unusually long bear market.  You don't need an economics degree to see that every bear market in history has been wiped away by subsequent recoveries.",VRTX
172,2023-03-26,"Headline: Want $1 Million in Retirement? Buy and Hold These 5 Stocks, source:Yahoo, summary: There's no guarantee that you'll be a millionaire retiree. But these stocks could improve your odds.",VRTX
173,2023-03-27,"Headline: Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact, source:Thefly.com, summary: No summary, Headline: Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes, source:Yahoo, summary: BOSTON & ZUG, Switzerland, March 27, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D)., Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Has Fared Decently: Is the Market Following Strong Financials?, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 9.4% over the past three months. Since the market usually pay for..., Headline: Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.88% to $308.47 Monday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: IBD 50 Stocks To Watch: Vertex Pharmaceuticals Nears Buy Point; Institutions Scoop Up Shares, source:Yahoo, summary: Vertex Pharmaceuticals is forming a base and back above its 50-day moving average. VRTX stock ranks third out of 792 biotechs., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.",VRTX
174,2023-03-28,"Headline: nan, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver Best Returns?, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Returns?, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?, source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.55% to $313.25 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
175,2023-03-29,"Headline: Vertex Pharmaceuticals price target raised to $350 from $340 at Argus, source:Thefly.com, summary: No summary, Headline: The 3 Best Growth Stocks to Buy in the Biotech Sector, source:InvestorPlace, summary: No summary, Headline: Bluebird Bio reaction to lovo-cel BLA delay `overdone,` says Raymond James, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.32% higher to $314.24 Wednesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market.  Vertex and AbbVie also happen to offer a lot of growth potential.  Vertex has a new potential blockbuster drug on the horizon.",VRTX
176,2023-03-30,"Headline: 2 No-Brainer Growth Stocks to Buy and Hold for Years, source:Yahoo, summary: A long-term investment in these highly profitable businesses could pay off in manifold returns over the next 5 to 10 years., Headline: 2 No-Brainer Stocks to Buy Before the Next Bull Market, source:Yahoo, summary: While no one can predict when the next prolonged bull move will appear, the stock market has proven time and again its ability to rebound from even the most dire periods of volatility.  Vertex Pharmaceuticals (NASDAQ: VRTX) has continued to deliver gains against the backdrop of the broader volatile market over the last year, but this isn't only a testament to the typical resilience of the healthcare industry in times of economic turmoil.  The company continues to rake in revenue, profits, and cash from its portfolio of cystic fibrosis medicines -- currently the only drugs on the market that target the underlying root causes of the genetic ailment., Headline: 2 Top Stocks to Buy With $1,000 Right Now, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) may not be a household name like some healthcare companies, but this is a business that investors may be hard-pressed to overlook, bull or bear market.  Vertex has a long history of profitability and revenue growth, and amassed earnings of $3.3 billion in 2022 alone.  The life expectancy for cystic fibrosis patients has improved dramatically over the past few decades., Headline: What Bear Market? These 2 Winning Stocks Are Still Worth Buying., source:Yahoo, summary: The stock market is in a precarious place.  The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022.  The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples., Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slumped 0.66% to $312.16 Thursday, on what proved to be an all-around positive trading session for the stock market,...",VRTX
177,2023-03-31,"Headline: Buy Crispr Therapeutics On Approval Odds, source:SeekingAlpha, summary: Crispr Therapeutics is nearing the launch of CTX001, which likely has high approval odds. Click here to find out why CRSP stock is a Buy., Headline: Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market, source:Yahoo, summary: The market has kept investors on a rollercoaster ride over the past year, and the choppy waters may continue for some time to come.  No one can predict when smooth waters may be here to stay, particularly given the ongoing economic volatility that's affecting the current investing environment.  Here are two such stocks to consider buying in the near future, regardless of whether another full-fledged bear market appears in 2023., Headline: This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has made a fortune developing medicines for cystic fibrosis (CF), a rare disease that causes damage to the lungs.  The company is awaiting approval for exa-cel -- a therapy for the blood disorder sickle cell disease -- which it developed in combination with CRISPR Therapeutics.  Recently, these two longtime partners announced a new deal to target another disease, type 1 diabetes (T1D)., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.93% higher to $315.07 Friday, on what proved to be an all-around favorable trading session for the stock...",VRTX
178,2023-04-01,"Headline: Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders.  First, let's talk a little bit about CRISPR's technology.  In T1D, the body destroys islet cells that normally would control blood sugar levels.",VRTX
179,2023-04-02,"Headline: 5 Top Stocks for April, source:Yahoo, summary: Daniel Foelber (Rivian Automotive): Rivian hasn't even spent 18 months on the public markets, and already the stock has made a name for itself for all the wrong reasons.  Its meteoric ascent in November 2021 pole-vaulted its market cap to over $150 billion.  Today, Rivian has a market cap of $11.7 billion., Headline: A Nasdaq Bull Market Could Begin in April: 3 Top Stocks to Buy Now, source:Yahoo, summary: Dec. 28 was the date the Nasdaq Composite Index reached a bottom after declining throughout much of the previous 12 months.  To kick off a new bull market, the index will need to rise by at least 20% above that low.  At the end of March, the Nasdaq needed to climb less than 1% to reach that threshold., Headline: Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 29% Discount?, source:Yahoo, summary: Key Insights The projected fair value for Vertex Pharmaceuticals is US$443 based on 2 Stage Free Cash Flow to Equity...",VRTX
180,2023-04-03,"Headline: Vertex Pharmaceuticals, Crispr Therapeutics complete rolling BLAs to FDA, source:Thefly.com, summary: No summary, Headline: Vertex, CRISPR finish rolling submission of application for sickle cell candidate, source:Seeking Alpha, summary: No summary, Headline: Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, source:Yahoo, summary: BOSTON & ZUG, Switzerland, April 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The BLAs include requests for Priority Review, which if granted, would shorten the FDA’, Headline: Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags, source:TalkMarkets, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.40% higher to $316.33 Monday, on what proved to be an all-around favorable trading session for the stock..., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $316.33, marking a +0.4% move from the previous day.",VRTX
181,2023-04-04,"Headline: Vortex Energy Completes Acquisition of Blue Ocean Salt Corp., source:GlobeNewswire, summary: No summary, Headline: Maxim Group Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Stock Sees Composite Rating Edge Up To 96, source:Yahoo, summary: On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.60% to $314.42 Tuesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel, source:Yahoo, summary: CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia., Headline: Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs.  In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time.  The biotech giant and partner CRISPR Therapeutics (NASDAQ: CRSP) aim to bring exa-cel, a gene editing treatment for blood disorders, to market.",VRTX
182,2023-04-05,"Headline: Vertex Pharmaceuticals Takes Over #108 Spot From Tapestry, source:ETF Channel, summary: No summary, Headline: Video: S&P 500 Analyst Moves: VRTX, source:Market News Video, summary: No summary, Headline: 2 Under-the-Radar Biotech Stocks to Buy in 2023, source:Yahoo, summary: The biotech industry tends to be highly volatile, because of the hit-and-miss nature of the products they are developing.  Moderna is a recent example, having grown from a $4 billion company to a $59 billion company thanks in large part to the pandemic and the successful rollout of its coronavirus vaccine.  As investors look for the next biotech hitmaker, they might want to take a closer look at two under-the-radar biotech firms that have some outstanding products up their sleeves., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 2.39% to $321.94 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...",VRTX
183,2023-04-06,"Headline: 2 Top Stocks to Buy Before the Next Nasdaq Bull Market, source:Yahoo, summary: Value investing pioneer Benjamin Graham's words ring true in every market environment, but especially in the highly volatile one that investors have been contending with over the past year.  Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up nearly 19% over the trailing 12 months, which is no small feat given the S&P 500's broader 11% decline during that same period.  The strength of Vertex Pharmaceuticals' underlying business has also been a catalyst., Headline: The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals, source:Yahoo, summary: bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog., Headline: Where to Invest $2,500 Right Now, source:Yahoo, summary: Even another bear market doesn't need to deter investors with the appropriate buy-and-hold horizon., Headline: 2 Smartest Growth Stocks to Buy Without Hesitation Right Now, source:Yahoo, summary: Growth stocks have faced continued headwinds from a tough economic landscape and volatile investor sentiment over the past year.  Vertex Pharmaceuticals (NASDAQ: VRTX) has built a thriving and profitable growth story on the power of four products, all of which treat the rare genetic disease cystic fibrosis.  Cystic fibrosis afflicts more than 160,000 people worldwide, and in the past, a diagnosis was something close to a death sentence., Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.09% to $321.66 Thursday, on what proved to be an all-around positive trading session for the stock market, with...",VRTX
184,2023-04-07,"Headline: Vertex Pharmaceuticals (VRTX) Gets a Hold from RBC Capital, source:TipRanks, summary: No summary, Headline: A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right Now, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has gone from strength to strength in a market that has been plagued by volatility.  With the only drugs on the market that treat the underlying cause of cystic fibrosis -- one of them which covers more than 90% of all cystic fibrosis patients in the U.S. alone -- it's safe to say that the demand for Vertex Pharmaceuticals' products is consistent and ongoing.  Vertex Pharmaceuticals has much more than its profitable cystic fibrosis portfolio up its sleeve, however, with a robust pipeline that aims to disrupt many other areas of the rare disease drug market., Headline: Vertex Pharmaceuticals: A Promising Portfolio After A Year Of Growth, source:SeekingAlpha, summary: Vertex completed submission of their gene therapy for treatment of two hematological treatments. See why we recommend a buy on VRTX stock., Headline: 2 Once-in-a-Decade Buying Opportunities in a Growth Stock Bear Market, source:Yahoo, summary: As Warren Buffett once said, ""If a business does well, the stock eventually follows.""  If you have the capital and risk tolerance for putting money into growth stocks, there is certainly no shortage of companies that present compelling opportunities for the long term.  Here are two such names to consider buying right now, one that the market has discounted over the last year and one which has actually beaten the S&P 500 in that period., Headline: 5 S&P 500 Stocks Showing Strength As Recession Fears Rise, source:Yahoo, summary: S&P 500 medical stocks Cardinal Health, Vertex Pharmaceuticals, Merck, Intuitive Surgical and Insulet are in focus this week. Medical stocks are coming into favor again — with companies involved in biotech, pharmaceuticals, medical products and more bouncing back.",VRTX
185,2023-04-08,"Headline: Nasdaq Bear Market: 5 Astonishing Growth Stocks You'll Regret Not Buying on the Dip, source:Yahoo, summary: A 33% plunge in the Nasdaq Composite is the perfect excuse for opportunistic investors to pounce on discounted growth stocks., Headline: CRISPR Stock: Bull vs. Bear, source:Yahoo, summary: Is now the moment to get in on this gene editing specialist?  Motley Fool contributors Adria Cimino and Keith Speights discuss the bull and bear cases.  Adria Cimino: CRISPR has reached the most exciting moment in its story as a company so far., Headline: 3 No-Brainer Stocks to Buy in a New Bull Market, source:Yahoo, summary: Three Motley Fool contributors have identified their picks for no-brainer stocks to buy in a new bull market.  Here's why they chose Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Novo Nordisk): In a bull market, investors pay less attention to earnings multiples and are often more willing to pay a big premium for growth stocks., Headline: 5 S&P 500 Stocks Near Buy Pionts As Recession Fears Rise, source:Yahoo, summary: S&P 500 medical stocks Cardinal Health, Vertex Pharmaceuticals, Merck, Intuitive Surgical and Insulet are in focus this week. Medical stocks are coming into favor again — with companies involved in biotech, pharmaceuticals, medical products and more bouncing back.",VRTX
186,2023-04-09,"Headline: 2 Winning Stocks That Could Turn $10,000 into $50,000 by 2030, source:Yahoo, summary: The stock market has a habit of rewarding investors that stay with it through the ups and downs.  Now, the performance of your portfolio in a wide range of market environments will be very specific to the stocks you buy, the length of time that you hold them, the diversification of your holdings, and the types of industries and companies you gravitate toward, to name a few key factors.  Vertex Pharmaceuticals (NASDAQ: VRTX) has built a profitable and market-leading franchise of cystic fibrosis medicines that, to this day, are the only drugs approved to treat the underlying cause of this insidious genetic disease., Headline: Where Will CRISPR Therapeutics Be in 5 Years?, source:Yahoo, summary: One company that hopes to be at the center of that transition is CRISPR Therapeutics (NASDAQ: CRSP).  The company has a promising treatment that could make a meaningful impact on many lives, while at the same time solidifying itself as a top healthcare stock to watch out for.  Below, I'll look at where CRISPR Therapeutics may be five years from now, and whether investors should consider buying shares of the company today., Headline: Sana Biotechnology CMO Sunil Agarwal to leave, Gary Meininger to succeed, source:Thefly.com, summary: No summary",VRTX
187,2023-04-10,"Headline: Vertex announces Health Canada marketing authorization for ORKAMBI in children, source:Thefly.com, summary: No summary, Headline: My 5 Top Stocks to Buy in April, source:Yahoo, summary: Investing in stocks ranks as one of the best ways to make money over the long term. That's obvious when you look at the past. And while history doesn't repeat itself, the factors that caused stocks to perform well over the last century will likely prevail over the next 100 years as well., Headline: Vertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic Fibrosis, source:MarketWatch, summary: By Robb M. Stewart Vertex Pharmaceuticals Inc. said Monday it received marketing authorization from Canada's medical regulator for the expanded use of its..., Headline: Vertex to Announce First Quarter 2023 Financial Results on May 1, source:Yahoo, summary: BOSTON, April 10, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the ""Vertex Pharmaceuticals First Quarter 2023 Earnings Call."", Headline: Vertex Announces Health Canada Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years, source:Yahoo, summary: Vertex Pharmaceuticals (Canada) Incorporated (Nasdaq: VRTX) today announced that Health Canada, as a partner of the Access Consortium, has granted Marketing Authorization for the expanded use of PrORKAMBI® (lumacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 1 to <2 years who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.49% higher to $323.24 Monday, on what proved to be an all-around favorable trading session for the stock..., Headline: Dow Jones Leader Visa Headlines These 4 Stocks In Or Near Buy Zones In Today's Stock Market, source:Yahoo, summary: Dow Jones payments giant Visa and four other top stocks are in or near buy zones in today's stock market., Headline: Dow Jones Futures: Key Inflation Data, Big Bank Earnings Due; Apple, Pioneer, Tesla In Focus, source:Yahoo, summary: Dow Jones futures: Key inflation data and big bank earnings are key stock market catalysts this week. Apple and Tesla are in focus.",VRTX
188,2023-04-11,"Headline: Dow Jones Rises As Bitcoin Jumps Above $30,000; 7 Top Stocks To Buy And Watch, source:Yahoo, summary: The Dow Jones rose Tuesday, as the price of Bitcoin surged, topping $30,000 for the first time since June 2022., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.49% higher to $324.83 Tuesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023, source:SeekingAlpha, summary: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.",VRTX
189,2023-04-12,"Headline: Wall Street Analysts Are Neutral on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Could This Move Make Vertex's Next Blockbuster Even Bigger?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) recently reported great news.  It completed the submission of exa-cel, its treatment candidate for blood disorders, to the U.S. Food and Drug Administration (FDA).  Vertex has already prepared the infrastructure to launch the treatment -- and it could become the company's next blockbuster., Headline: Dow Jones Rallies 150 Points On Cool CPI Inflation Data; Fed Minutes Later, source:Yahoo, summary: The Dow Jones Industrial Average rallied 150 points Wednesday morning on cool inflation data, with the release of the Consumer Price Index., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.47% higher to $326.37 Wednesday, on what proved to be an all-around dismal trading session for the stock..., Headline: Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $326.37, marking a +0.47% move from the previous day., Headline: UPDATE 1-Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group, source:Yahoo, summary: Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential U.S. drug pricing group said on Wednesday.  The two companies are hoping to get approval for the world's first therapy based on Nobel prize-winning CRISPR technology, for two types of blood disorders - sickle cell disease (SCD) and transfusion-dependent beta thalassemia., Headline: Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group, source:Reuters, summary: Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential U.S. drug pricing group said on Wednesday., Headline: Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?, source:InvestorPlace, summary: No summary",VRTX
190,2023-04-13,"Headline: These Up-and-Coming Stocks Are Screaming Buys Right Now, source:Yahoo, summary: Many of these companies are trading at interesting levels and promise growth down the road.  Here, you'll find companies that have recently launched first products -- and those on the way to reaching the commercial stage.  One of the things I like most about Axsome Therapeutics (NASDAQ: AXSM) is that all of the company's five pipeline candidates are phase 2 or more advanced., Headline: CRISPR jumps 15% as Cantor issues bullish view citing exa-cel approval, source:Seeking Alpha, summary: No summary, Headline: Dow Jones Reverses Lower After Jobless Claims, Inflation Data; Delta Slides On Earnings, source:Yahoo, summary: The Dow Jones turned lower Thursday after first-time jobless claims and more key inflation data. Delta Air Lines sold off on weak earnings., Headline: 2 Nasdaq Growth Stocks That Are Screaming Buys in April, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) -- are particularly appealing.  Vertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.  If you're not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies., Headline: Why Shares of CRISPR Therapeutics Jumped Thursday, source:Yahoo, summary: An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.14% to $333.35 Thursday, on what proved to be an all-around positive trading session for the stock market,..., Headline: $2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis, source:Yahoo, summary: Prices for incoming sickle cell disease gene therapies from Vertex Pharmaceuticals Inc (NASDAQ: VRTX)/CRISPR Therapeutics AG (NASDAQ: CRSP), dubbed exagamglogene autotemcel (exa-cel), and Bluebird bio Inc’s (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) at $2 million could be cost-effective under some scenarios. Although “these gene therapies have an incremental cost-effectiveness that is above commonly cited thresholds from the health care system perspective.” The analysis comes from a U.",VRTX
191,2023-04-14,"Headline: Vertex Pharmaceuticals Reaches Analyst Target Price, source:ETF Channel, summary: No summary, Headline: CRISPR And Vertex: ICER Sheds Light On The Future Of Sickle Cell Treatment, source:SeekingAlpha, summary: nan, Headline: Vertex Pharmaceuticals' (NASDAQ:VRTX) 16% CAGR outpaced the company's earnings growth over the same five-year period, source:Yahoo, summary: The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put..., Headline: Is CRISPR Therapeutics Stock a Buy Now?, source:Yahoo, summary: Gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) has significantly lagged the market over the past year, but there are reasons to be optimistic regarding the company's future.  The biotech seems to be nearing approval of exa-cel, a potential treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) that it developed with Vertex Pharmaceuticals (NASDAQ: VRTX).  CRISPR Therapeutics is currently a clinical-stage biotech, so it will be a big deal if it can cross the finish line with exa-cel., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.05% higher to $333.52 Friday, on what proved to be an all-around poor trading session for the stock market,...",VRTX
192,2023-04-16,"Headline: Better Growth Stock: Axsome vs. CRISPR Therapeutics, source:Yahoo, summary: CRISPR recently requested regulatory approval for a product candidate with blockbuster potential.  Axsome bought the sleep disorder drug Sunosi from Jazz Pharmaceuticals and started selling it last spring.  Of course, failure can happen at any point in development -- but risk does decline as a candidate makes it through the earliest safety and efficacy tests.",VRTX
193,2023-04-17,"Headline: Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary, Headline: Prediction: These Will Be 3 of the Biggest Monster Stocks of the Decade, source:Yahoo, summary: MercadoLibre (NASDAQ: MELI) combines all three in one fell swoop.  MercadoLibre's logistics business Mercado Envios piggybacks off of the success of its e-commerce segment.  It's not surprising that MercadoLibre continues to enjoy exceptional momentum on this front., Headline: Which Stocks Pass Warren Buffett's $10,000 Test?, source:Yahoo, summary: If you didn't watch Warren Buffett's interview on CNBC last week, it would be worth your while to look at some of the highlights online.  One of the most interesting things he said, in my view, was on the topic of Apple (NASDAQ: AAPL).  ...if you're an Apple user and somebody offers you $10,000 but the only proviso is you'll never be able -- to they'll take away your iPhone and you'll never be able to buy another, you're not gonna take it., Headline: Dow Jones Rises Amid Economic Data; State Street Crashes 18% On Earnings Miss, source:Yahoo, summary: The Dow Jones rose Monday, with Q1 earnings season set to heat up this week. State Street crashed 18% on an earnings miss., Headline: Why Shares of Editas Medicine Rose Monday, source:Yahoo, summary: Shares of clinical-stage biotech Editas Medicine (NASDAQ: EDIT) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks.  Editas stock also benefited from the news last week that the company was appointing a new chairman of the board and a new independent director.  Several gene-editing companies saw their shares rise when it was reported that the Institute for Clinical and Economic Review (ICER), an independent group, said that exa-cel -- a one-dose treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) being developed by CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) -- would be cost-effective, at under $1.9 million per dose, compared to the long-term costs most SCD patients face., Headline: Buy Zones And Breakouts: MBLY, AVGO, CROX And Oracle Among 24 Stocks To Watch, source:Yahoo, summary: The best stocks to watch often hail from the top-ranked industries. Here are 24 such stocks, including CROX, AVGO and MBLY., Headline: Why CRISPR Therapeutics Stock Is Marching Higher Today, source:Yahoo, summary: What happened Shares of CRISPR Therapeutics (NASDAQ: CRSP) are enjoying another strong session Monday. Specifically, the gene-editing company's stock was up by a healthy 7.26% on exceptionally heavy volume as of 2:02 p., Headline: Dow Jones Futures: Netflix, Tesla Earnings On Deck; What To Do Now In Today's Stock Market, source:Yahoo, summary: Dow Jones futures were lower late. Netflix earnings are due and Tesla earnings are on deck, as first-quarter earnings season heats up.",VRTX
194,2023-04-18,"Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary, Headline: Analysts` Top Healthcare Picks: Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: The Top Healthcare Stocks to Buy With $100, source:Yahoo, summary: You don't have to start out with thousands of dollars to grow your wealth in the stock market.  Let's talk about two biotech companies that are just beginning their growth story -- and a big pharmaceutical company that's about to embark on a whole new wave of growth.  CRISPR Therapeutics (NASDAQ: CRSP) is a specialist in the exciting area of gene editing., Headline: The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now, source:Yahoo, summary: Staff economists told the FOMC that it's likely that the U.S. will enter into a ""mild recession starting later this year"" because of the banking crisis.  With the FOMC thinking that a recession is more likely, what should investors do?  At first glance, you might not think Dollar General (NYSE: DG) would be such a great stock to buy right now., Headline: 3 High-Growth Biotech Stocks Poised for Success in 2023, source:Yahoo, summary: Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity. Biotech (short for biotechnology) companies research how to use living organisms to make drugs. However, like pharmaceutical companies, biotech companies present substantial risks for investors. Many small biotech companies are not yet profitable and may even be pre-revenue. InvestorPlace - Stock Market News, Stock Advi, Headline: Got $5,000? Buy and Hold These Fast-Growing Stocks for Years, source:Yahoo, summary: Stocks of rapidly growing businesses normally trade at a premium and can be great long-term buys.  If you have $5,000 that you can afford to invest right now, two stocks you should consider putting at least some of that money into are Vertex Pharmaceuticals (NASDAQ: VRTX) and Shopify (NYSE: SHOP).  An investment in Vertex could go a long way given the company's solid growth prospects., Headline: Dow Jones Falls As Goldman Sachs Slides On Earnings; Nvidia Jumps On Buy Rating, source:Yahoo, summary: The Dow Jones fell modestly Tuesday, as Goldman Sachs dived on weak sales results. Nvidia stock jumped on an analyst buy rating., Headline: Why Vertex (VRTX) Could Beat Earnings Estimates Again, source:Yahoo, summary: Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $325.15, moving -0.79% from the previous trading session.",VRTX
195,2023-04-19,"Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: No summary, Headline: Climbing A Wall Of Worry, source:SeekingAlpha, summary: nan, Headline: Dow Jones Falls: Netflix Slides On Q1 Results, Tesla Skids On Pre-Earnings Price Cuts, source:Yahoo, summary: The Dow Jones fell Wednesday morning, as Netflix dropped on weak subscriber growth. Tesla skidded on more price cuts ahead of earnings., Headline: Supreme Court Extends Decision on Abortion Pills to Friday, source:Yahoo, summary: The court’s decision has broad implications for reproductive rights, for the power of the judicial system, and for the pharmaceutical industry.",VRTX
196,2023-04-20,"Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: BMEZ: Attractive Discount On This Riskier Healthcare Fund, source:SeekingAlpha, summary: nan, Headline: Final Trades: Gilead, Vertex, Wynn & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does Next, source:Yahoo, summary: For investors with the cash to put to work during all the market's mood swings, it's always a great time to buy more wonderful companies.  Vertex Pharmaceuticals (NASDAQ: VRTX) has created a business with a track record of profitability and market leadership that is a stand-alone example in the highly competitive healthcare industry.  Vertex is known for its leadership in the cystic fibrosis (CF) treatment space as it is the only company with drugs on the market that treat the underlying cause of this genetic disease., Headline: Better Big Biotech Buy: Biogen vs. Vertex, source:Yahoo, summary: Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX).  Biogen is known for its blockbuster multiple sclerosis drugs, including top seller Tecfidera.  Biogen's immunology drug, Rituxan, has also seen sales slip due to biosimilars in the market., Headline: Top 10 CRISPR Stocks To Buy, source:Yahoo, summary: In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and […]",VRTX
197,2023-04-21,"Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?, source:Yahoo, summary: On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline., Headline: Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW)., Headline: ClearBridge Global Growth Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan, Headline: ClearBridge Aggressive Growth Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan, Headline: ClearBridge Multi Cap Growth Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan",VRTX
198,2023-04-22,"Headline: 3 Stocks With Huge Catalysts on the Way, source:Yahoo, summary: Clinical updates and regulatory decisions can happen throughout the year.  Three Motley Fool contributors identified these stocks with huge catalysts on the way: Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Eli Lilly (NYSE: LLY).  Keith Speights (Axsome Therapeutics): Axsome Therapeutics' first potential catalyst is only a few weeks away.",VRTX
199,2023-04-23,"Headline: FDA PDUFA Date for Vertex Pharmaceuticals Trikafta is April 28, 2023, source:Thefly.com, summary: No summary",VRTX
200,2023-04-24,"Headline: Second Quarter Outlook For Biotech Stocks, source:SeekingAlpha, summary: nan, Headline: Bluebird bio seeks FDA priority review for sickle cell disease therapy lovo-cel, source:Seeking Alpha, summary: No summary, Headline: Vortex Energy Announces the Addition of Shawn Ryan as Technical Advisor, source:GlobeNewswire, summary: No summary, Headline: The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI, source:Yahoo, summary: Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI are included in this Analyst Blog., Headline: Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline, source:Yahoo, summary: Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.53% higher to $332.84 Monday, on what proved to be an all-around positive trading session for the stock..., Headline: 3 Healthcare Stocks That Could Help Make You a Fortune, source:Yahoo, summary: When you think of healthcare stocks, you may think of steady growth and security.  Let's check out three healthcare companies that fit the bill.  In fact, if all goes well, Vertex may launch a new CF treatment in the not-too-distant future., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $332.84, moving +0.53% from the previous trading session.",VRTX
201,2023-04-25,"Headline: Stablix, Vertex collaborate for targeted protein stabilization therapeutics, source:Thefly.com, summary: No summary, Headline: Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9, source:Yahoo, summary: BOSTON, April 25, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET., Headline: 3 Cash-Rich Biotech Stocks to Bet on for the Long Haul, source:Yahoo, summary: The Federal Reserve’s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it’s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich, Headline: Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know, source:Yahoo, summary: Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: 3 Biotech Stocks To Watch Today, source:StockMarket, summary: Biotech stocks for your late-April 2023 watchlist., Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.27% to $331.93 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: IBD 50 Stocks To Watch: Vertex Pharmaceuticals In Buy Zone As Firm Gets On A Roll, source:Yahoo, summary: Vertex enters into a partnership to develop novel small molecules. Shares have gained 15% this year., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.27%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $331.93, marking a -0.27% move from the previous day., Headline: Vertex wins FDA label expansion for cystic fibrosis therapy Trikafta, source:Seeking Alpha, summary: No summary",VRTX
202,2023-04-26,"Headline: Vertex announces U.S. FDA approval for expanded use of Trikafta, source:Thefly.com, summary: No summary, Headline: Vertex: FDA OKs Trikafta for Some Children Ages 2 Through 5 With Cystic Fibrosis With Certain Mutations, source:MarketWatch, summary: By Colin Kellaher Vertex Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration approved the expanded use of its Trikafta..., Headline: Why CRISPR Therapeutics Just Became an Even Better Buy, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) is a growth stock with a lot of long-term potential.  Its gene-editing business could be about to take off if exa-cel obtains approval from the Food and Drug Administration (FDA).  What makes gene-editing therapies potential game changers in the healthcare industry is that they have the potential to revolutionize treatment options for diseases., Headline: IN BRIEF: Vertex receives US FDA approval for expanded use of Trikafta, source:Alliance News, summary: No summary, Headline: Health Care Down on Earnings Fears -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell sharply amid fears that earnings growth would slow as concerns about Covid 19 subside. Kaiser Permanente, a pioneering integrated..., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 2.60% to $323.30 Wednesday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations, source:Yahoo, summary: BOSTON, April 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to TRIKAFTA® based on in vitro data. TRIKAFTA® w",VRTX
203,2023-04-27,"Headline: Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road., Headline: Vortex Energy Announces the Addition of Strategic Advisors & Options Issuance, source:GlobeNewswire, summary: No summary, Headline: Vertex gains as AbbVie ends cystic fibrosis development program, source:Seeking Alpha, summary: No summary, Headline: Is It Too Late to Buy CRISPR Stock?, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) has been a volatile stock over the past couple of years.  Lately, the gene-editing company's shares have been trading for under $51 a share, but I believe they could go much higher, considering the company's long-term potential.  CRISPR is one of just a handful of clinical-stage biotech companies (like Editas Medicine, Intellia Therapeutics, Beam Therapeutics and Verve Therapeutics) that use CRISPR editing to find new therapies., Headline: 2 Growth Stocks That Could Double in 5 Years, source:Yahoo, summary: As a group, growth stocks had a year to forget in 2022.  Let's consider why both healthcare stocks could double in the next five years -- and for those keeping score at home, that amounts to a compound annual growth rate of almost 15%.  Vertex Pharmaceuticals is a biotech company best known for its lineup of medicines that treat the underlying causes of cystic fibrosis (CF), a rare genetic disease., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 4.97% to $339.37 Thursday, on what proved to be an all-around favorable trading session for the stock market, with..., Headline: Biggest Gains in Employee Engagement in the Management Top 250, source:Yahoo, summary: The Management Top 250 ranking, developed by the Drucker Institute, measures corporate effectiveness by examining performance in five categories: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength.  Dell’s score for employee engagement and development jumped 24.3 points, to 64.3., Headline: FDA PDUFA Date for Vertex Pharmaceuticals Trikafta is April 28, 2023, source:Thefly.com, summary: No summary",VRTX
204,2023-04-28,"Headline: Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?, source:Yahoo, summary: Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road., Headline: bluebird bio a new overweight at JP Morgan on sickle cell therapy, source:Seeking Alpha, summary: No summary, Headline: NEW YORK MARKET CLOSE: US stocks end upbeat week on the front foot, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.40% higher to $340.73 Friday, on what proved to be an all-around positive trading session for the stock..., Headline: What To Expect After The Failed AbbVie Drug Sales, source:SeekingAlpha, summary: AbbVie's revenue amounted to $12,225 million in the first three months of 2023, 9.7% less than the previous year. Find out my recent analysis of ABBV stock.",VRTX
205,2023-04-29,"Headline: 3 Unstoppable Stocks to Buy Right Now, source:Yahoo, summary: Three Motley Fool contributors have thoughts on which unstoppable stocks are great picks to buy right now.  Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (AbbVie): This year will undoubtedly be a tough one for AbbVie.",VRTX
206,2023-04-30,"Headline: Notable earnings after Monday`s close, source:Seeking Alpha, summary: No summary, Headline: 2 Stocks That Could Turn $200,000 Into $1 Million by the Time You Retire, source:Yahoo, summary: The stock market has proven its ability to build wealth time and time again.  If you have the capital to invest in the stock market, and a long-term buy-and-hold horizon, there is no shortage of incredible companies begging to be bought right now.  Upstart (NASDAQ: UPST) built a business around an idea designed to revolutionize the lending space., Headline: GLOBAL BRIEFING: Japan's manufacturing sector contracts at slower pace, source:Alliance News, summary: No summary, Headline: Vertex options imply 3.8% move in share price post-earnings, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals backs FY23 revenue view of $9.55B-$9.7B, consensus $9.71B, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Non-GAAP EPS of $3.05 beats by $0.05, revenue of $2.37B beats by $30M, source:Seeking Alpha, summary: No summary",VRTX
207,2023-05-01,"Headline: Vertex Q1 beats thanks to strong Trikafta year-over-year sales increase, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: After-Hours Movers, source:Thefly.com, summary: No summary, Headline: The Best Stocks to Invest $5,000 in Right Now, source:Yahoo, summary: At least, that's what the Federal Reserve and many economists think.  If an economic downturn is indeed on the way, investing in recession-proof stocks and industries is a smart strategy.  The company's name gives away its business., Headline: Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector, source:TalkMarkets, summary: No summary, Headline: ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging, source:Yahoo, summary: ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023. Post the news, shares moved up 25%., Headline: Vertex: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Vertex Pharmaceuticals 1Q Net Down On Higher Costs, source:MarketWatch, summary: By Paul Ziobro Vertex Pharmaceuticals on Monday said first-quarter profit fell as higher expenses tied to drug development and international launches offset..., Headline: Vertex Pharmaceuticals Incorporated 2023 Q1 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2023 Q1 earnings call., Headline: IN BRIEF: Vertex quarterly income falls; affirms full-year outlook, source:Alliance News, summary: No summary, Headline: Stocks making the biggest moves after hours: Arista Networks, MGM Resorts, Stryker and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading. , Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.25% to $345.00 Monday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: Vertex Reports First Quarter 2023 Financial Results, source:Yahoo, summary: BOSTON, May 01, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2023 and reiterated full year 2023 financial guidance., Headline: Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives, source:Yahoo, summary: Vertex retained its full-year outlook Monday despite beating quarterly expectations, and VRTX stock toppled in late trades., Headline: Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates, source:Yahoo, summary: Vertex (VRTX) delivered earnings and revenue surprises of 3.39% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Vertex Pharmaceuticals Incorporated (VRTX) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ETCompany ParticipantsSusie Lisa - CFA, Senior Vice President, Investor..., Headline: GLOBAL BRIEFING: HSBC Q1 pretax profit surges to nearly USD13 billion, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals (VRTX) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: My name is Susie Lisa, and as the senior vice president of investor relations, it is my pleasure to welcome you to our first-quarter 2023 financial results conference call.  On tonight's call making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer.",VRTX
208,2023-05-02,"Headline: Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $380 from $326 at H.C. Wainwright, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $410 from $350 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Urogen Pharma (URGN), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $325 from $280 at Baird, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $385 from $339 at Guggenheim, source:Thefly.com, summary: No summary, Headline: BMO Capital Gives a Buy Rating to Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $340 from $300 at Stifel, source:Thefly.com, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX), Vertex Pharmaceuticals (VRTX) and Travere Therapeutics (TVTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $350 from $330 at TD Cowen, source:Thefly.com, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Oppenheimer Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals is Down After Earnings but the Real Catalyst is Still Emerging, source:Fintel, summary: nan, Headline: Vortex Engages Independent Trading Group as Market Maker, source:GlobeNewswire, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $456 from $341 at Truist, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $315 from $299 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Patients Lose Access to Free Medicines Amid Spat Between Drugmakers, Health Plans, source:Yahoo, summary: The programs have been costing drugmakers billions of dollars a year and have been increasing as health plans seeking to control their own spending have tried to take advantage of the assistance., Headline: Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie, source:Yahoo, summary: While the overall market plummeted last year, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) skyrocketed 31%.  Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV).  AbbVie had been evaluating a triple-drug combo targeting cystic fibrosis (CF) in phase 2 testing., Headline: Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Vertex Pharmaceuticals (VRTX) and Axonics Modulation Technologies (AXNX), source:TipRanks, summary: No summary, Headline: Morgan Stanley Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: 2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030, source:Yahoo, summary: The stock market has been an incredibly volatile place to invest over the last year, and it's highly possible that the choppy market waters could persist in the near future.  Vertex Pharmaceuticals (NASDAQ: VRTX) is on a mission to disrupt the multi-billion-dollar rare disease drug market, having built a rock-solid foundation of revenue growth and profits from its existing portfolio of cystic fibrosis (CF) drugs.  While the company counts just four drugs in its current portfolio of approved products, all of which treat CF, these are the only products that have been commercialized to date that treat the genetic ailment's root cause., Headline: Guggenheim Maintains Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Stifel Maintains Vertex Pharmaceuticals (VRTX) Hold Recommendation, source:Fintel, summary: nan, Headline: Baird Maintains Vertex Pharmaceuticals (VRTX) Neutral Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Maintains Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan, Headline: Oppenheimer Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: Barclays Maintains Vertex Pharmaceuticals (VRTX) Overweight Recommendation, source:Fintel, summary: nan, Headline: 2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 Years, source:Yahoo, summary: While no investor can predict with precision what the market will do in the coming weeks or months, the market has shown its ability to rebound from even the worst periods of volatility time and time again.  If you have a minimum buy-and-hold horizon of three to five years for any stocks you own, and the capital to put into the market, even the ongoing volatility that investors are currently witnessing doesn't mean you need to sit idly on the sidelines.  Here are two supercharged growth stocks to consider hitting the buy button on this week and holding for at least a decade., Headline: Final Trades: Transocean, P&G, Vertex, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y, source:Yahoo, summary: Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023., Headline: Q1 2023 Vertex Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q1 2023 Vertex Pharmaceuticals Inc Earnings Call, Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.30% higher to $346.03 Tuesday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment.  The company is known for its combination therapies targeting a defective protein that causes the disease's devastating symptoms.  AbbVie (NYSE: ABBV) had shepherded its own combination-therapy candidate -- also targeting the defective protein -- into phase 2 studies., Headline: Vertex Extends Its Breakout On Better-Than-Expected Profit; Retains Outlook, source:Yahoo, summary: Vertex Pharmaceuticals retained its full-year outlook and beat quarterly views, pushing VRTX stock higher early Tuesday.",VRTX
209,2023-05-03,"Headline: Vertex announces FDA approval for KALYDECO to treat eligible infants with CF, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $363 from $344 at Bernstein, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $400 from $325 at Maxim, source:Thefly.com, summary: No summary, Headline: 7 Reasons to Buy Vertex Pharmaceuticals Stock Now, source:Yahoo, summary: Vertex's shares subsequently added even more to the nice gains already achieved so far this year.  Vertex is the only company in the world with approved therapies that treat the underlying cause of cystic fibrosis (CF).  Its nearest competition is only in phase 2 testing., Headline: Bernstein Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: Estimating The Fair Value Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), source:Yahoo, summary: Key Insights The projected fair value for Vertex Pharmaceuticals is US$422 based on 2 Stage Free Cash Flow to Equity..., Headline: Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock, source:Yahoo, summary: Had you bought Vertex Pharmaceuticals (NASDAQ: VRTX) shares 10 years ago, you'd be sitting pretty right now.  The drugmaker soundly outperformed the market over that period thanks to its success in developing medicines that target cystic fibrosis.  The first of Vertex's products to treat that rare genetic disease was approved in 2012., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.10% higher to $346.36 Wednesday, on what proved to be an all-around grim trading session for the stock market,..., Headline: Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older, source:Yahoo, summary: BOSTON, May 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages 1 month to less than four months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO® based on clinical and/or in vitro assay data. KALYDECO® is already approved in the U.S. and EU for the treatment, Headline: Interesting VRTX Put And Call Options For June 23rd, source:Stock Options Channel, summary: No summary, Headline: Vertex assumed Overweight at Piper Sandler despite recent rally, source:Seeking Alpha, summary: No summary, Headline: My Methods To Finding The Best Stock Portfolio, source:SeekingAlpha, summary: This is my journey on the road to finding the best portfolio and my early attempts to find the best stocks in which to invest. Click here to see my recommendations., Headline: Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (VRTX) and IVERIC bio (ISEE), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals assumed with an Overweight at Piper Sandler, source:Thefly.com, summary: No summary",VRTX
210,2023-05-04,"Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: 2 Potentially Explosive Stocks to Buy in May, source:Yahoo, summary: Stag Industrial (NYSE: STAG) and Vertex Pharmaceuticals (NASDAQ: VRTX) are off to a good start this year, and some industry tailwinds look to really boost shares in the coming years.  Vertex, already a leader in cystic fibrosis treatment, is on the tip of a gene-editing revolution.  Stag is a real estate investment trust (REIT) that specializes in renting out single-tenant industrial properties with triple-net leases., Headline: Maxim Group Maintains Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan, Headline: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2023 Earnings Call Transcript May 1, 2023 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $3.05, expectations were $3. Operator: Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2023 Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity […], Headline: Vertex Pharmaceuticals Continues Its Impressive Rally: How to Play It, source:Yahoo, summary: On Monday Vertex Pharmaceuticals  reported an earnings and revenue beat and share prices advanced.  In the daily bar chart of VRTX, below, I can see that the shares have staged an impressive rally from early March., Headline: Baron Health Care Fund Q1 2023 Shareholder Letter, source:SeekingAlpha, summary: Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.07% higher to $346.59 Thursday, on what proved to be an all-around rough trading session for the stock market,..., Headline: Top Stock Reports for McDonald's, Deere & Marsh & McLennan, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Deere & Company (DE) and Marsh & McLennan Companies, Inc. (MMC).",VRTX
211,2023-05-05,"Headline: SVB Securities Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Stocks To Watch: Nvidia Partner Drives Liquid-Cooled AI Platform, source:Yahoo, summary: Just one of 21 top-rated stocks to watch on this screen, SMCI stock continues to climb alongside AI partner Nvidia., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.43% higher to $348.09 Friday, on what proved to be an all-around favorable trading session for the stock...",VRTX
212,2023-05-06,"Headline: This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock, source:Yahoo, summary: Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.",VRTX
213,2023-05-07,"Headline: InvestingPro exclusive: 5 biotech beasts to get your hands on, source:Yahoo, summary: Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00., Headline: Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ:VRTX) has had a great run on the share market with its stock up by a significant 14...",VRTX
214,2023-05-08,"Headline: Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward, source:SeekingAlpha, summary: Krystal Biotech, Inc. has a PDUFA date of May 19, 2023, set for the FDA to review B-VEC for potential U.S. marketing approval. Click for my full KRYS review., Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.15% to $344.09 Monday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: CRISPR adds 13% to reach seven-month high after Q1 update, source:Seeking Alpha, summary: No summary",VRTX
215,2023-05-09,"Headline: Vortex Engages RESPEC to Advance its Robinsons River Salt Project in Newfoundland & Labrador, CANADA, source:GlobeNewswire, summary: No summary, Headline: CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat, source:Yahoo, summary: CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates., Headline: Why CRISPR Therapeutics Stock Is on Fire Today, source:Yahoo, summary: Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.",VRTX
216,2023-05-10,"Headline: 2 Cathie Wood Stocks That Can Get You Through Any Recession, source:Yahoo, summary: Economists at the U.S. Federal Reserve recently uttered the dreaded ""R"" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.51% to $350.04 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",VRTX
217,2023-05-11,"Headline: See Which Of The Latest 13F Filers Holds Vertex Pharmaceuticals, source:Preferred Stock Channel, summary: No summary, Headline: This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is already a rock star in the world of cystic fibrosis (CF) treatment.  The company's drugs have been life-changing for children and adults living with the disease.  It's also helped the company build up more than $11 billion in cash to support development of new CF drugs and candidates in other areas., Headline: Here's Why We Think Vertex Pharmaceuticals (NASDAQ:VRTX) Might Deserve Your Attention Today, source:Yahoo, summary: The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even..., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.10% higher to $350.40 Thursday, on what proved to be an all-around grim trading session for the stock market,..., Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: It's always a great idea to buy stocks and hold them for the long term. That means at least five years. This offers you the opportunity to benefit from any dividend payments and/or growth in earnings., Headline: Why These 3 Nasdaq Stocks Were Glowing Green This Week, source:Yahoo, summary: Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week.  The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence.  Among the best performers within the growth stock landscape this week were biopharmaceuticals.",VRTX
218,2023-05-12,"Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.85% to $347.41 Friday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Entrada Therapeutics Stock Deserves Higher Resonance After Q1 2023 Report, source:SeekingAlpha, summary: Entrada is a biotechnology developer of endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. Read why TRDA stock is a buy.",VRTX
219,2023-05-13,"Headline: 3 Growth Stocks to Buy and Hold, source:Yahoo, summary: The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling.  In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks.  Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX)., Headline: Is CRISPR Therapeutics Stock a Buy Now?, source:Yahoo, summary: A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share.  As of Tuesday afternoon, the biotech stock was at $64.  While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet., Headline: Vertex Pharmaceuticals Incorporated (VRTX) Presents at BofA Securities 2023 Health Care Conference (Transcript), source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) BofA Securities 2023 Health Care Conference May 9, 2023 12:20 PM ETCompany ParticipantsCharlie Wagner - EVP and CFODavid Altshuler -...",VRTX
220,2023-05-15,"Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.36% higher to $348.65 Monday, on what proved to be an all-around positive trading session for the stock...",VRTX
221,2023-05-16,"Headline: Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders have earned a 17% CAGR over the last five years, source:Yahoo, summary: When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose..., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.00% to $345.15 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals Offers Value Despite Recent Gains, source:Yahoo, summary: The biotech company benefits from a dominant position in the market for cystic fibrosis treatments",VRTX
222,2023-05-17,"Headline: Vertex Pharmaceuticals Rally Likely Not Over, source:SeekingAlpha, summary: Vertex Pharmaceuticals' blockbuster TRIKAFTA is early in its product cycle. Q1 growth was very strong. Find out why VRTX stock is a Buy., Headline: The Ones That Didn't Get Away — 10 Stocks Serve Up Buy Zones, source:Yahoo, summary: While SMCI, Monster and others have already taken off, Wendy's and Core & Main lead among stocks to watch that are setting up., Headline: 2 Stocks You'll Be Glad You Bought at These Prices, source:Yahoo, summary: Last year, the stock market went into a downward spiral, and growth stocks as a group were dragged down more than most.  This year, the stock market appears to be recovering.  Before their likely rebounds make them too expensive, here are two growth stocks to consider investing in now., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.14% to $341.20 Wednesday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Top 5 1st Quarter Trades of INTERNATIONAL BIOTECHNOLOGY TRUST PLC, source:GuruFocus, summary: No summary",VRTX
223,2023-05-18,"Headline: Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Outperformed in Q1, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […], Headline: Crispr Therapeutics: Potential Beyond Current BLA Filing Of Exa-Cel, source:SeekingAlpha, summary: Patients are currently being enrolled by CRISPR Therapeutics AG in a potentially pivotal single-arm phase 2 study. Click here for more on CRSP stock prospects., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.51% to $339.46 Thursday, on what proved to be an all-around favorable trading session for the stock market, with...",VRTX
224,2023-05-19,"Headline: Vortex Energy Congratulates World Energy GH2 for Receiving International Investment, source:GlobeNewswire, summary: No summary, Headline: 3 Biotech Stocks That Are Revolutionizing Healthcare in 2023, source:Yahoo, summary: The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system. But finding the best biotech stocks to buy is not always simple. Many biotech companies work on drugs for years. And these biotech stocks will swing wildly on the news. Positive results from a clinical trial can send stocks soaring. Conversely, disappointing results c, Headline: 2 Healthcare Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth.  Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT).  Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.66% higher to $341.70 Friday, on what proved to be an all-around dismal trading session for the stock market,...",VRTX
225,2023-05-20,"Headline: 2 Stocks Near 52-Week Highs That Still Look Like Bargains, source:Yahoo, summary: Shares of Facebook's and Instagram's parent company, Meta Platforms (NASDAQ: META), tanked last year in response to top-line revenue that contracted for the first time since the company went public in 2012.  In the fourth quarter of 2022, the company's operating margin shrank to 20%, which did not compare well to the 40% operating margin the company reported in 2021.  To right the ship, Meta CEO Mark Zuckerberg announced sweeping layoffs earlier this year and declared 2023 would be a much-needed year of efficiency.",VRTX
226,2023-05-22,"Headline: 2 Hot Stocks to Buy and Hold Until You Retire, source:Yahoo, summary: Long-term investors recognize the benefits of a buy-and-hold strategy.  The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds.  While 2022 was hard on most stocks, this year seems to be going pretty well for these two growth stocks., Headline: Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.51% to $339.97 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...",VRTX
227,2023-05-23,"Headline: Tweedy, Browne Fund Q1 2023 Commentary, source:SeekingAlpha, summary: Portfolio activity slowed somewhat during the quarter as equity prices advanced. Click here to read the full fund letter., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 1.90% to $333.51 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
228,2023-05-24,"Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: No summary, Headline: Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated data readout from a phase 3 program could be released by the 1st half of 2024. Find out why VRTX stock is a Strong Buy.",VRTX
229,2023-05-25,"Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary, Headline: Vertex Pharmaceuticals initiated with a Hold at WestPark Capital, source:Thefly.com, summary: No summary, Headline: Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare.  CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease.  Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home., Headline: July 7th Options Now Available For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: 2 Top Trends to Invest $5,000 in Right Now, source:Yahoo, summary: Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years.  Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments.  CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.",VRTX
230,2023-05-26,"Headline: Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary, Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: 2 Biotech Stocks That Could Help Set You Up for Life, source:Yahoo, summary: A few successful drugs are all that are required for a biotech company to shine.  Vertex Pharmaceuticals (NASDAQ: VRTX) is well-known for its star product, Trikafta, a cystic fibrosis (CF) medicine.  In the most recent first quarter, Trikafta contributed nearly $2.1 billion of the $2.3 billion in total product revenue.",VRTX
231,2023-05-27,"Headline: The Best Stocks to Invest $20,000 in Right Now, source:Yahoo, summary: Warren Buffett thinks that near-term economic and market forecasts are ""worse than useless.""  My hunch is that the U.S. economy is headed for a mild recession.  Like most investors who aren't billionaires with the surname Buffett, I don't like to see the stocks I buy go down., Headline: 3 No-Brainer Stocks to Buy for Under $100 Right Now, source:Yahoo, summary: Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE).  David Jagielski (CRISPR Therapeutics):  Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off.  The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.",VRTX
232,2023-05-28,"Headline: Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever, source:Yahoo, summary: The good news is that if you've got the money and the time, it's not all that hard to find great investment options.  If the company hits the high end of that range and its share price grows to reflect that internal growth, an initial investment of $10,000 would increase in value to over $163,000 in two decades.  The company's infrastructure assets include natural gas pipelines, electricity transmission lines, smart meters, rail operations, toll roads, telecom towers, data centers, and semiconductor manufacturing foundries., Headline: Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot More, source:Yahoo, summary: Wall Street thinks this stock will rise 12% over the next 12 months.  Let's first address why some on Wall Street don't have greater expectations for Vertex.  One of the biggest factors is the biotech stock's previous success.",VRTX
233,2023-05-29,"Headline: CRISPR Therapeutics an outperform at William Blair on diversified pipeline, source:Seeking Alpha, summary: No summary",VRTX
234,2023-05-30,"Headline: Vertex Pharmaceuticals initiated with an Outperform at William Blair, source:Thefly.com, summary: No summary, Headline: William Blair starts Vertex with Outperform, $382 fair value estimate, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ) and COMPASS Pathways (CMPS), source:TipRanks, summary: No summary, Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Vertex initiated at outperform at William Blair on cystic fibrosis growth, source:Seeking Alpha, summary: No summary, Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, source:Yahoo, summary: BOSTON, May 30, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat on Tuesday, June 13, 2023 at 2:40 p.m. PT., Headline: Expert Ratings for Vertex Pharmaceuticals, source:Benzinga, summary: No summary, Headline: William Blair Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Outperform Recommendation, source:Fintel, summary: nan, Headline: Cantor Fitzgerald Reiterates Vertex Pharmaceuticals (VRTX) Overweight Recommendation, source:Fintel, summary: nan, Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.42% to $325.30 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Tech Roars Back As MSFT, ASML, AMAT, ORCL Lead Industry Charge, source:Yahoo, summary: Find top tech stocks to watch like MSFT, ORCL, ADBE, ASML, AVGO and more with this screen highlighting top-ranked industry groups.",VRTX
235,2023-05-31,"Headline: Wednesday’s Top Analyst Upgrades and Downgrades: Abbott Labs, Boston Scientific, ChargePoint, Coinbase, Dollar General, Equitrans, Ford, Hasbro, Johnson & Johnson, Kenvue, Medtronic and More, source:247WallSt, summary: No summary, Headline: CRISPR Therapeutics: A Galaxy's Worth of Deep Value, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX).  The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia.  What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics., Headline: Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer, source:Yahoo, summary: These businesses have considerable growth runways ahead., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. dropped 0.53% to $323.57 Wednesday, on what proved to be an all-around rough trading session for the stock market, with...",VRTX
236,2023-06-01,"Headline: Vortex Energy Completes Seismic Interpretation, source:GlobeNewswire, summary: No summary, Headline: Barclays ups bluebird rating to overweight, citing sickle cell opportunity, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.02% higher to $323.62 Thursday, on what proved to be an all-around favorable trading session for the stock...",VRTX
237,2023-06-02,"Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 3.14% to $333.78 Friday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
238,2023-06-03,"Headline: Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade, source:Yahoo, summary: Let's consider three stocks that could: Vertex Pharmaceuticals (NASDAQ: VRTX), DexCom (NASDAQ: DXCM), and Amazon (NASDAQ: AMZN).  Vertex Pharmaceuticals is doing great things.  One of the drugmakers that was closest to entering this market with competing products recently threw in the towel., Headline: Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?, source:Yahoo, summary: A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX).  Vertex's forward multiple comes in at more than four times the upper bounds of this range.  Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.",VRTX
239,2023-06-05,"Headline: Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 23% Discount?, source:Yahoo, summary: Key Insights Vertex Pharmaceuticals' estimated fair value is US$431 based on 2 Stage Free Cash Flow to Equity Current..., Headline: Wu administration launches initiative to hire 1,000 Bostonian life sciences workers by 2025, source:Yahoo, summary: Speaking from the BIO International Convention at the Boston Convention and Exhibition Center (BCEC) Monday morning, Mayor Michelle Wu announced the Boston Life Sciences Workforce Initiative, which is aimed at getting 1,000 Bostonians into life sciences jobs by 2025., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.19% higher to $334.42 Monday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
240,2023-06-06,"Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
241,2023-06-07,"Headline: Stocks with top pricing power across all sectors, source:Seeking Alpha, summary: No summary, Headline: A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than Later, source:Yahoo, summary: These stocks are already performing well but could kick into higher gear in a new S&P 500 bull market., Headline: Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.",VRTX
242,2023-06-08,"Headline: FDA accepts BLAs for Vertex Pharmaceuticals' investigational treatment exa-cel, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $323 from $315 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Vortex Energy Identifies At Least Two Salt Structures Suitable for Hydrogen Storage, source:GlobeNewswire, summary: No summary, Headline: Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?, source:Yahoo, summary: Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX).  Let's turn to a smaller biotech that Vertex knows very well: CRISPR Therapeutics (NASDAQ: CRSP).  The two companies are partners in a blood disorders program and recently submitted their treatment candidate for regulatory approval., Headline: 5 Top Stocks to Buy in June, source:Yahoo, summary: It's OK to be more cautious at times and more aggressive at others, but buying stocks regularly helps correct for natural market volatility.  With that in mind, PayPal Holdings (NASDAQ: PYPL), Target (NYSE: TGT), Vertex Pharmaceuticals (NASDAQ: VRTX), Walt Disney (NYSE: DIS), and Chevron (NYSE: CVX) are worth buying in June.  Trevor Jennewine (PayPal Holdings): It's no secret that digital payments are becoming more prevalent, but investors may not realize that digital wallets are driving that trend., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 2.44% to $332.58 Thursday, on what proved to be an all-around positive trading session for the stock market,..., Headline: RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, source:Yahoo, summary: BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescri, Headline: Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application, source:Benzinga, summary: No summary, Headline: IN BRIEF: Vertex says US accepts treatment applications for exa-cel, source:Alliance News, summary: No summary",VRTX
243,2023-06-09,"Headline: Vertex, Crispr announce both exagamglogene autotemcel trials met endpoints, source:Thefly.com, summary: No summary, Headline: Crispr Therapeutics price target raised to $74 from $70 at JMP Securities, source:Thefly.com, summary: No summary, Headline: CRISPR, Vertex gain as FDA starts review for gene edited therapy, source:Seeking Alpha, summary: No summary, Headline: Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress, source:Yahoo, summary: BOSTON & ZUG, Switzerland, June 09, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress., Headline: Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?, source:InvestorPlace, summary: No summary, Headline: Vertex Pharmaceuticals presents data on CFTR modulators at ECFS Conference, source:Thefly.com, summary: No summary, Headline: Is Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by a considerable 16% over the past three months. Given that the..., Headline: 2 Top Biotech Stocks to Buy in June, source:Yahoo, summary: Biotech stocks have taken investors on an unpredictable ride so far in 2023.  Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX).  While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%., Headline: Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference, source:Yahoo, summary: BOSTON, June 09, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria. Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early, Headline: Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months, source:Yahoo, summary: The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.46% higher to $334.11 Friday, on what proved to be an all-around positive trading session for the stock..., Headline: Vertex/CRISPR Partnered Cell Therapy Shows Encouraging Response In Sickle Cell Disease, Thalassemia Patients, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent beta-thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. Of the 48 patients with TDT who had received exa-cel at the time of the analysis, 24/27 (88.9%) achieved the primary endpoint of transfusion independence for at least 12 consecut, Headline: FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel, source:Yahoo, summary: The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $334.11, moving +0.46% from the previous trading session.",VRTX
244,2023-06-10,"Headline: 3 No-Brainer Stocks to Buy in June, source:Yahoo, summary: The stock market has risen so far in June and could go even higher.  Three Motley Fool contributors think some stocks are no-brainers to buy this month.  Prosper Junior Bakiny (Axsome Therapeutics): Sporting a market cap of just $3.3 billion, Axsome Therapeutics is a relatively small and unknown drugmaker.",VRTX
245,2023-06-11,"Headline: Editas upgraded to overweight at Raymond James on sickle cell candidate, source:Seeking Alpha, summary: No summary, Headline: Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground, source:TalkMarkets, summary: No summary",VRTX
246,2023-06-12,"Headline: 5 Stocks to Buy With Explosive 500% Potential, source:InvestorPlace, summary: No summary, Headline: 2 Biotech Stocks That Could Help Make You a Fortune, source:Yahoo, summary: Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.94% to $340.60 Monday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: HC Wainwright & Co. Reiterates Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan",VRTX
247,2023-06-13,"Headline: This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product.  At the same time, the U.S. Food and Drug Administration (FDA) did something that may enter the record books.  The FDA's acceptance of the CRISPR Therapeutics and Vertex files marks a first., Headline: 15 Most Profitable Drugs In The World, source:Yahoo, summary: In this article, we will be taking a look at the 15 most profitable drugs in the world. If you wish to see the top ones, feel free to skip our detailed analysis of the pharma industry and head straight to the 5 Most Profitable Drugs In The World. The pharmaceutical industry has long been […], Headline: Should You Be Adding Vertex Pharmaceuticals (NASDAQ:VRTX) To Your Watchlist Today?, source:Yahoo, summary: The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even..., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.44% higher to $342.10 Tuesday, on what proved to be an all-around great trading session for the stock market,..., Headline: Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 5:40 PM ETCompany ParticipantsReshma Kewalramani -...",VRTX
248,2023-06-14,"Headline: Vortex Energy Appoints the Honourable George J. Furey as an Advisor and Grants Options, source:GlobeNewswire, summary: No summary, Headline: Where Will CRISPR Therapeutics Be in 10 Years?, source:Yahoo, summary: Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.  The company is on the cusp of having its first therapy approved by the Food and Drug Administration (FDA)., Headline: 10 DNA Stocks Billionaires Are Loading Up On, source:Yahoo, summary: In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On. Genomics is the study of a complete set of DNA within an organism. The global genomics market was worth $28.39 billion […], Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.33% to $340.96 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",VRTX
249,2023-06-15,"Headline: 2 Magnificent Growth Stocks to Buy Before the Next Bull Market, source:Yahoo, summary: Instead, by investing in a wide range of quality companies in all types of market environments, you can construct a winning portfolio that helps you move closer to your financial goals.  The stock market has been rising at a rapid clip lately.  While it may be too soon to say if the next prolonged bull market is here, when the next one does appear, investors who stayed with quality stocks can be poised for impressive returns., Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Technological advances are changing life as we know it.  The world is different now than it was 20 years ago in multiple ways thanks to Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL).  Google has become a verb., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 2.38% to $349.08 Thursday, on what proved to be an all-around great trading session for the stock market, with...",VRTX
250,2023-06-16,"Headline: Gene Editing Is Working. Wall Street Is Taking Notice., source:Yahoo, summary: Shares of Crispr Therapeutics are up 45% this year, compared with the Nasdaq Composite's 31% rise., Headline: Vertex Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.34% to $347.89 Friday, on what proved to be an all-around poor trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.34%: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $347.89, moving -0.34% from the previous trading session., Headline: How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities, source:TalkMarkets, summary: No summary",VRTX
251,2023-06-17,"Headline: 2 Market-Beating Stocks With Major Catalysts on the Way, source:Yahoo, summary: For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start.  Two drugmakers that have done particularly well for themselves are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex Pharmaceuticals has a rich portfolio of cystic fibrosis (CF) drugs that generates growing revenue.",VRTX
252,2023-06-18,"Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",VRTX
253,2023-06-19,"Headline: PBE: Healthcare Dashboard For June, source:SeekingAlpha, summary: Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.",VRTX
254,2023-06-20,"Headline: PepGen: FDA Setbacks Offset By Canadian Wins, Clinical Data, source:SeekingAlpha, summary: PepGen (PEPG) faced a setback with FDA's clinical hold notice on its PGN-EDODM1 compound. With mixed prospects in medium-term, hence I reiterate hold. See more here., Headline: 2 Unstoppable Growth Stocks That Could Turn $20,000 into $100,000 by 2030, source:Yahoo, summary: These one-of-a-kind businesses have an edge over the competition that could steadily push their stock prices in the right direction through the end of the decade and beyond., Headline: 3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever, source:Yahoo, summary: Even the most conservative investor hopes to find that one stock that can make them millions. That’s why they look at the biotech sector. One “home run” drug or therapeutic to enter the market can send a stock soaring along with an investor’s portfolio. The problem is that many of these long-term biotech stock investments never pan out. On the other hand, many potentially high return biotech stocks are excellent buy and hold candidates. Some of these companies, particularly the small-cap stocks, Headline: Crispr Therapeutics' Exa-Cel In The Lead For Sickle Cell Disease, source:SeekingAlpha, summary: FDA bestowed Priority Review for CRISPR's gene therapy that keeps its candidate ahead of rival for potential first-to-market. See why I'm bullish on CRSP stock., Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.49% to $342.69 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
255,2023-06-21,"Headline: bluebird bio gains on FDA priority review for new gene therapy, source:Seeking Alpha, summary: No summary, Headline: Is CRISPR Therapeutics Stock a Buy Now?, source:Yahoo, summary: An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP).  The U.S. Food and Drug Administration (FDA) will decide on whether to approve exa-cel for sickle cell disease in December.  It offered the company and partner Vertex Pharmaceuticals priority review for that indication., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.17% higher to $343.28 Wednesday, on what proved to be an all-around grim trading session for the stock market,..., Headline: Alleged Industrial Espionage Makes an Interesting Story, source:Yahoo, summary: If companies can do anything to keep secrets from leaking out.  Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.  To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center., Headline: Analyst Ratings for Vertex Pharmaceuticals, source:Benzinga, summary: No summary",VRTX
256,2023-06-22,"Headline: Analysts Offer Insights on Healthcare Companies: Patterson Companies (PDCO), PTC Therapeutics (PTCT) and Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and Pfizer (PFE), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.42% to $348.16 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $348.16, moving +1.42% from the previous trading session.",VRTX
257,2023-06-23,"Headline: Vortex Energy Unveils 3D Geology Model of the Robinsons River Salt Dome Property, source:GlobeNewswire, summary: No summary, Headline: Vertex Pharmaceuticals reports 'positive' Phase 1/2 VX-880 results, source:Thefly.com, summary: No summary, Headline: Cantor Fitzgerald Remains a Buy on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.33% to $347.00 Friday, on what proved to be an all-around poor trading session for the stock market, with the..., Headline: Vortex Energy Announces Extension of Marketing Campaign, source:GlobeNewswire, summary: No summary, Headline: Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions, source:Yahoo, summary: BOSTON, June 23, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented data on all patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of re",VRTX
258,2023-06-26,"Headline: Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead, source:TalkMarkets, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Esperion (ESPR), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Dexcom (DXCM) and Genmab (GMAB), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals and Lonza to build facility for T1D cell therapies, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals (VRTX) Initiated with a Buy at BMO Capital, source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $379 from $375 at Evercore ISI, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals' VX-880 showed treatment benefit, says BMO Capital, source:Thefly.com, summary: No summary, Headline: Vertex in deal with Lonza for facility to produce cell-based diabetes therapies, source:Seeking Alpha, summary: No summary, Headline: First Week of August 18th Options Trading For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: Vertex Pharmaceuticals Shares Attract Big Money, source:Yahoo, summary: Vertex Pharmaceuticals, Inc. (VRTX) shares are up an impressive 20% in 2023., Headline: Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies, source:Yahoo, summary: BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials., Headline: Weight-loss drugs in development aim to replace injections with pills, source:MarketWatch, summary: Promising results for weight-loss treatments that could compete with Ozempic and Wegovy, along with new screening recommendations for fatty-liver disease,..., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.13% higher to $347.45 Monday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Evercore ISI Group Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Reiterates Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan",VRTX
259,2023-06-27,"Headline: Maxim Group Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.09% to $347.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with..., Headline: Tesla, Microsoft Among 34 Stocks To Watch As Market Takes A Breath, source:Yahoo, summary: Including Tesla, Microsoft and Broadcom, this screen highlights the top-rated stocks to watch in the top-ranked industry groups.",VRTX
260,2023-06-28,"Headline: BMO Capital Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $360 from $350 at TD Cowen, source:Thefly.com, summary: No summary, Headline: SVB Securities Gives a Buy Rating to Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.05% to $350.78 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Sigilon Therapeutics downgraded to Neutral from Buy at BTIG, source:Thefly.com, summary: No summary",VRTX
261,2023-06-29,"Headline: Vertex Pharmaceuticals Takes Over #106 Spot From AES, source:ETF Channel, summary: No summary, Headline: Video: S&P 500 Analyst Moves: VRTX, source:Market News Video, summary: No summary, Headline: 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond, source:Yahoo, summary: There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.  Vertex Pharmaceuticals (NASDAQ: VRTX) and Novo Nordisk (NYSE: NVO) fit the definition of a growth stock.  Vertex, known for its range of cystic fibrosis (CF) therapies, has increased revenue by 193% over the past five years -- and the company's growth trend could just be getting started., Headline: Vortex Energy Unaware of any Material Change, source:GlobeNewswire, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slumped 0.74% to $348.18 Thursday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $348.18, moving -0.74% from the previous trading session.",VRTX
262,2023-06-30,"Headline: Buying These 3 Stocks Could Be the Smartest Investing Move You'll Ever Make, source:Yahoo, summary: Some decisions have consequences that last a lifetime. Ideally, those consequences will be good ones. Granted, such decisions are relatively few and far between. That's usually the case with investing., Headline: Morgan Stanley Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex to Announce Second Quarter 2023 Financial Results on August 1, source:Yahoo, summary: BOSTON, June 30, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the ""Vertex Pharmaceuticals Second Quarter 2023 Earnings Call."", Headline: Morgan Stanley Reiterates Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.07% to $351.91 Friday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst, source:Seeking Alpha, summary: No summary",VRTX
263,2023-07-03,"Headline: Vertex Pharmaceuticals price target raised to $340 from $305 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Stock: Bear vs. Bull, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product.  Investors previously worried about Vertex's ability to expand beyond CF, so a nod here could be big.  Vertex shares have climbed more than 20% so far this year., Headline: Peering Into Vertex Pharmaceuticals's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Vertex: Resilient Growth And Promising Pipeline, source:SeekingAlpha, summary: Vertex Pharmaceuticals continues to outperform in the biotechnology industry. Click here for my take on VRTX stock and its prospects., Headline: Morgan Stanley Reiterates Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation, source:Fintel, summary: nan",VRTX
264,2023-07-04,"Headline: Vertex: Promising Prospects Amid Stretched Valuation, source:SeekingAlpha, summary: Vertex's product revenue increased due to the robust uptake of its cystic fibrosis treatments. VRTX stock is rated as a buy. Read the article to learn more.",VRTX
265,2023-07-05,"Headline: Vertex Pharmaceuticals granted approval for label extension of Orkambi, source:Thefly.com, summary: No summary, Headline: European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old, source:Yahoo, summary: LONDON, July 05, 2023--Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to <2 years old who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common form of the disease., Headline: 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025, source:InvestorPlace, summary: No summary, Headline: CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why, source:Yahoo, summary: Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment., Headline: MP Materials, Wolfspeed rise; Amneal, Knight-Swift fall, Wednesday, 7/5/2023, source:Associated Press, The, summary: No summary, Headline: IN BRIEF: Vertex wins EC approval for cystic fibrosis therapy Orkambi, source:Alliance News, summary: No summary, Headline: Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK, source:SeekingAlpha, summary: Spero can receive up to $525 million in development and sales milestone payments and royalties on net product sales from GSK. Read why SPRO stock is a Strong Buy., Headline: Nkarta Names Alyssa Levin as Chief Financial and Business Officer, source:MarketWatch, summary: By Stephen Nakrosis Nkarta on Wednesday said Alyssa Levin was named as its new chief financial and business officer. Levin joins the biopharmaceutical..., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.22% higher to $348.32 Wednesday, on what proved to be an all-around poor trading session for the stock market,..., Headline: The 3 Best Biotech Stocks to Buy In July, source:Yahoo, summary: Although it’s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B, Headline: 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025, source:Yahoo, summary: Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years. And investors who buy and hold these stocks are typically rewarded with handsome total returns. Even penny stocks can become triple-digit return biotech stocks. However, that payoff can take a long time. Just getting a drug through the clinical trial stage can take several years. And some candidat",VRTX
266,2023-07-06,"Headline: 2 Supercharged Growth Stocks to Invest In Before the Next Bull Market, source:Yahoo, summary: Upstart (NASDAQ: UPST) continues to pursue its mission to change the way the lending industry operates.  This multi-trillion-dollar space long relied on outdated means of assessing consumer creditworthiness, often using little more than the FICO score to determine whether to approve or deny people for loans.  This system left many potentially creditworthy people unable to access credit, despite having never defaulted on a credit product in their life., Headline: 2 Growth Stocks That Might Be Too Cheap to Ignore, source:Yahoo, summary: Biotech giant Vertex Pharmaceuticals has had an impressive stock market performance over the past year.  In the first quarter, Vertex revenue jumped by 13% year over year to $2.37 billion.  Second, Vertex completed regulatory submissions to health agencies in the U.S. and Europe for what will almost certainly be its next blockbuster, exa-cel., Headline: Final Trades: Delta, Vertex, Cooper & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication, source:Yahoo, summary: Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation., Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.73% to $345.76 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves -0.73%: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $345.76, moving -0.73% from the previous trading session.",VRTX
267,2023-07-07,"Headline: Delta Air Lines, Vertex Pharmaceuticals, And A Major US Bank Nearing A Breakout Level: CNBC's 'Final Trades', source:Benzinga, summary: No summary, Headline: Video: Nasdaq 100 Movers: VRTX, DDOG, source:Market News Video, summary: No summary, Headline: An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 23% Undervalued, source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$450 Vertex..., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 2.19% to $338.18 Friday, on what proved to be an all-around dismal trading session for the stock market, with...",VRTX
268,2023-07-08,"Headline: 3 No-Brainer Stocks You Can Buy Right Now, source:Yahoo, summary: Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer stocks to buy right now.  Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie isn't currently popular with investors.  The company's shares are down by 14% year to date.",VRTX
269,2023-07-09,"Headline: Want to Get Richer? 2 Unstoppable Stocks to Invest $1,000 In This Week, source:Yahoo, summary: Airbnb (NASDAQ: ABNB) has built a business that serves the changing reality of what travel looks like in the modern, digital age.  There's certainly been a broad resurgence in leisure travel over the last 12 to 15 months as borders have reopened and pandemic-era restrictions have faded.  This has been evidenced by a considerable jump in cross-border travel, one that Airbnb continues to benefit from.",VRTX
270,2023-07-10,"Headline: Here's How Much $1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary, Headline: RBC Capital Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.86% to $344.46 Monday, on what proved to be an all-around favorable trading session for the stock market,...",VRTX
271,2023-07-11,"Headline: Sitting on Cash? These 2 Stocks Are Great Buys, source:Yahoo, summary: Coca-Cola and Vertex Pharmaceuticals are excellent choices to add to your portfolio for the long term., Headline: 2 Top Healthcare Stocks Defying the Bear Market, source:Yahoo, summary: Let's check out two top healthcare stocks that have defied the bear market -- and that could supercharge your portfolio over the long haul.  CRISPR Therapeutics (NASDAQ: CRSP) is at the start of what could be a big growth story.  The company specializes in CRISPR/Cas9 gene editing., Headline: Is Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Latest Stock Performance Being Led By Its Strong Fundamentals?, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 6.0% over the past three months. Given that the market rewards..., Headline: Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.79% to $341.74 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",VRTX
272,2023-07-12,"Headline: 3 Things About Vertex Pharmaceuticals That Smart Investors Know, source:Yahoo, summary: Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason.  The biotech company completed a regulatory submission for what may become its next blockbuster product.  Vertex and partner CRISPR Therapeutics hope to launch exa-cel, a gene-editing treatment for blood disorders, as soon as next year., Headline: 3 Biotech Stocks That AI is Loving in July, source:Yahoo, summary: Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks. I asked ChatGPT which biotech stocks it recommends for investment in July and it provided the following three companies. Let’s talk about these three AI recommended biotech stocks: Vertex (VRTX) Source: Pavel Kapysh / Shutterstock.com One of the companies ChatG",VRTX
273,2023-07-13,"Headline: 3 Pharma Stocks That AI is Loving in July, source:InvestorPlace, summary: No summary, Headline: Got $500? 3 Growth Stocks to Buy That Could Double Your Money, source:Yahoo, summary: There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good., Headline: VRTX September 1st Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: 3 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has made quite a name for itself in the market with its cystic fibrosis drugs.  In 2022, Trikafta alone brought in $7.6 billion in revenue out of Vertex's total product revenue of $8.9 billion.  The company's net profits increased 53% to $3.8 billion in 2022., Headline: ClearBridge Multi Cap Growth Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Multi Cap Growth Strategy underperformed its benchmark in the second quarter of 2023. Click here to read the full fund letter., Headline: U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln , source:Reuters, summary: An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease., Headline: U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million, source:Reuters, summary: An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.86% higher to $349.02 Thursday, on what proved to be an all-around great trading session for the stock market,..., Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $349.02, marking a +0.86% move from the previous day., Headline: 3 Pharma Stocks That AI is Loving in July, source:Yahoo, summary: When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes. And in 2023, many companies are closer than ever to a solution. So, although I know that’s not how it works, it was interesting that when ChatGPT gave me a list of pharmaceutical stocks, it included several which have partnerships with gene editing companies. It’s importan",VRTX
274,2023-07-14,"Headline: Vertex Pharmaceuticals: Buy at the High?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year.  It's not surprising Vertex has advanced.  The company is about to erase investors' one big concern about its future: its dependence on one treatment area., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.07% to $352.74 Friday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: More Challenges Await AbbVie Following A Disappointing Quarter, source:SeekingAlpha, summary: AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more.",VRTX
275,2023-07-15,"Headline: Should You Be Adding Vertex Pharmaceuticals (NASDAQ:VRTX) To Your Watchlist Today?, source:Yahoo, summary: The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...",VRTX
276,2023-07-16,"Headline: ClearBridge Aggressive Growth Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Aggressive Growth Strategy underperformed its benchmark in the second quarter. Click here to read the full fund letter.",VRTX
277,2023-07-17,"Headline: 2 Monster Stocks to Buy Without Any Hesitation, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) brings in billions of dollars annually thanks to its cystic fibrosis (CF) treatments.  Vertex's Trikafta has the ability to treat 90% of CF patients today.  Vertex also is studying another candidate in pivotal trials that could even beat Trikafta., Headline: Vertex Pharmaceuticals Unusual Options Activity For July 17, source:Benzinga, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rose 1.49% to $357.98 Monday, on what proved to be an all-around great trading session for the stock market, with the...",VRTX
278,2023-07-18,"Headline: Vortex Energy enters into Agreement to Acquire Additional Mineral License in Newfoundland, source:GlobeNewswire, summary: No summary, Headline: Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road., Headline: Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.28% higher to $358.98 Tuesday, on what proved to be an all-around favorable trading session for the stock..., Headline: 3 Tech Stocks to Watch for Groundbreaking Innovations in 2030, source:InvestorPlace, summary: No summary",VRTX
279,2023-07-19,"Headline: Coinbase Global, Moderna And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: bluebird bio gains as BofA upgrades citing FDA nod for new gene therapy, source:Seeking Alpha, summary: No summary, Headline: 3 No-Brainer Stocks to Buy With $400 Right Now, source:Yahoo, summary: Despite never knowing (with any certainty) when corrections will begin, how long they'll last, or how steep the ultimate decline will be in the major U.S. stock indexes, history has shown that every sizable drop was eventually put in the rearview mirror by a bull market rally.  With the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite still well below their all-time highs, bargains can still be had.  The first phenomenal stock that makes for a surefire buy with $400 right now is healthcare conglomerate Johnson & Johnson (NYSE: JNJ), which is perhaps better known as J&J., Headline: Cramer’s Mad Dash on Vertex: Their non-opioid pain innovation could be 'the holy grail of medical', source:CNBC, summary: CNBC’s Jim Cramer delivers his daily Mad Dash., Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry.  Let's look at three healthcare stocks that are leaders or innovators in their respective niches and could provide excellent returns in the next 10 years: Vertex Pharmaceuticals (NASDAQ: VRTX), Moderna (NASDAQ: MRNA), and Gilead Sciences (NASDAQ: GILD).  Vertex Pharmaceuticals has soundly beaten the market in the past 10 years, and the company is in an excellent position to do so in the next decade., Headline: Royalty Pharma: Not Quite In The 'Buy Zone' Yet, source:SeekingAlpha, summary: Royalty Pharma shares have fallen 45% from their all-time high. Does that make RPRX a buy? Click here for our conclusion., Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.11% to $358.57 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $358.57, moving -0.11% from the previous trading session.",VRTX
280,2023-07-20,"Headline: Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial, source:Reuters, summary: Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage trial., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.91% higher to $361.82 Thursday, on what proved to be an all-around mixed trading session for the stock market,...",VRTX
281,2023-07-21,"Headline: Vertex Pharmaceuticals price target raised to $400 from $350 at BofA, source:Thefly.com, summary: No summary, Headline: Is Now a Good Time to Buy CRISPR Therapeutics?, source:Yahoo, summary: CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation.  CRISPR and big biotech partner Vertex Pharmaceuticals submitted exa-cel, a gene editing candidate for blood disorders, to regulators in the U.S., Europe, and the U.K. And U.S. regulators expect to issue a decision on the candidate for one particular indication -- sickle cell disease -- in December.  Meanwhile, CRISPR shares have soared more than 40% since the start of the year., Headline: Vertex Pharmaceuticals (NASDAQ:VRTX) stock performs better than its underlying earnings growth over last five years, source:Yahoo, summary: The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put..., Headline: B of A Securities Maintains Buy Rating for Vertex Pharmaceuticals: Here's What You Need To Know, source:Benzinga, summary: No summary, Headline: 2 Soaring Stocks With More Upside Potential, source:Yahoo, summary: Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry.  Clinical and regulatory wins can fuel excellent stock market performances for companies in the sector in a relatively short period, say a year.  With that in mind, let's look at two biotechs that have crushed the market this year: CRISPR Therapeutics (NASDAQ: CRSP) and Krystal Biotech (NASDAQ: KRYS)., Headline: Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst, source:MarketWatch, summary: Leerink Partners analyst David Risinger raised his price target to $442 from $396. His new target indicates a 20% upside from the recent price of $365., Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.18% higher to $362.46 Friday, on what proved to be an all-around great trading session for the stock market,..., Headline: Vortex Energy Announces Further Extension of Marketing Campaign, source:GlobeNewswire, summary: No summary",VRTX
282,2023-07-22,"Headline: B of A Securities Maintains Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan, Headline: The Best Stocks to Invest $5,000 in Right Now, source:Yahoo, summary: Others could be worried about the stock market's nosebleed valuation and avoid stocks altogether.  Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't skyrocketed 50% or more as some stocks have so far in 2023.  More importantly, I think Vertex has plenty of room to run.",VRTX
283,2023-07-23,"Headline: The Power Play by The Market Herald Releases New Interviews with Gamelancer Media, Soma Gold, Pelangio Exploration and Vortex Energy Discussing Their Latest News, source:Accesswire, summary: No summary, Headline: Eaton Vance Worldwide Health Sciences Fund Buys Vertex Pharmaceuticals, Exits Dechra Pharmaceuticals, source:GuruFocus, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
284,2023-07-24,"Headline: Vortex Energy Announces Large Scale Hydrogen Storage Estimates at the Robinsons River Salt Project, source:GlobeNewswire, summary: No summary, Headline: Vertex Shares Have Been Heavily Accumulated All Year, source:Yahoo, summary: Vertex Pharmaceuticals, Inc. (VRTX) shares are up 25% in 2023. This uptrend is being powered by healthy appetite for the stock., Headline: The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023, source:Yahoo, summary: Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock? It’s a company that’s somehow involved in the creation of innovative drugs. This can be through research, development, or production. This sector saw a huge pandemic-related boost when the mRNA technology that many of them specialize in was thrust into the spotlight. The biotech industry is underpinned by some pretty undeniable growth trends. First and foremost is the aging global population. A",VRTX
285,2023-07-25,"Headline: A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings, source:Benzinga, summary: No summary, Headline: Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth, source:Yahoo, summary: Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.28% higher to $358.06 Tuesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Vertex Pharmaceuticals (VRTX) Stock Moves 0.28%: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $358.06, marking a +0.28% move from the previous day.",VRTX
286,2023-07-26,"Headline: Earnings Preview: Repligen (RGEN) Q2 Earnings Expected to Decline, source:Yahoo, summary: Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: 2 No-Brainer Cathie Wood Stocks to Buy Right Now, source:Yahoo, summary: Cathie Wood is enjoying a remarkable comeback in 2023.  Pharmaceutical behemoths Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are perfect examples.  Read on to learn more about these two low-risk Cathie Wood stocks., Headline: Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.72% to $351.91 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names, source:Yahoo, summary: The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns. In this article, I’m going to introduce you to three companies that are making waves in this field and are pioneering stocks in biotech. They are making a difference and deserve to be on your radar! Best Biotech Stocks: Regeneron (REGN) Sou, Headline: Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel On Deck, source:SeekingAlpha, summary: FDA review date of CRISPR Therapeutics exa-cel for patients with severe sickle-cell disease has been set for December 8, 2023. Find out more on CRSP stock here.",VRTX
287,2023-07-27,"Headline: 3 Biotech Stocks You Better Be Buying on Each and Every Dip, source:Yahoo, summary: Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks. Therefore, it is important to pick quality biotech stocks that have a competitive edge, solid financial position and clear growth strategy. Below are three biotech stocks that fit these criteria. These po, Headline: Could Vertex Pharmaceuticals Stock Help You Retire a Millionaire?, source:Yahoo, summary: Turning to equity markets is still one of the best ways for most people to accumulate wealth over long periods, so retirement savers should strongly consider this option.  Let's look at one biotech stock, Vertex Pharmaceuticals (NASDAQ: VRTX), and determine whether it falls in the first or the second category., Headline: Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?, source:Yahoo, summary: On Vertex's (VRTX) Q2 earnings call, investors focus will likely be on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline., Headline: Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. sank 0.65% to $349.64 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Bernstein Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary",VRTX
288,2023-07-28,"Headline: Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. rallied 1.26% to $354.05 Friday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Vertex & CRISPR Therapeutics - Partners On Exa-Cel - But Unequally Valued, source:SeekingAlpha, summary: nan, Headline: 3 Biotech Stocks to Buy Before the Breakout, source:Yahoo, summary: During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care. At the national level, the FDA has approved over-the-counter birth control pills and considered aspartame to be a carcinogen. The user count of telemedicine services continues to increase, and technological advancements in drug-making have led to the clinically testing a drug created by Artificial Intelligence in Hong Kong. These developmen",VRTX
289,2023-07-30,"Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",VRTX
290,2023-07-31,"Headline: These 2 Stocks Are Heading for a Big Moment. Time to Buy?, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories.  The biotech companies are awaiting regulatory decisions for exa-cel, their potential blockbuster treatment for blood disorders.  For Vertex, this represents a first step beyond its cystic fibrosis (CF) specialty., Headline: Rising Stars, Falling Trends: July's Industry ETF Winners And Losers, source:Benzinga, summary: No summary, Headline: Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More, source:Yahoo, summary: Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1., Headline: Vertex Pharmaceuticals reports Q2 EPS $3.52, consensus $3.88, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals raises FY23 CF product revenue to $9.7B-$9.8B, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals Non-GAAP EPS of $3.89 beats by $0.01, revenue of $2.49B beats by $70M, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary, Headline: Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary",VRTX
291,2023-08-01,"Headline: Vortex Energy Closes Purchase of Additional Mineral License in Newfoundland, source:GlobeNewswire, summary: No summary, Headline: Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested, source:Benzinga, summary: No summary, Headline: Peering Into Vertex Pharmaceuticals's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Stocks Dip, Bond Yields Rise And Dollar Gains As Investors Turn Cautious: What's Driving Markets Tuesday, source:Benzinga, summary: No summary, Headline: Vertex: Q2 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Vertex : Q2 Earnings Snapshot, source:Finnhub, summary: BOSTON  — BOSTON  — Vertex Pharmaceuticals Inc.  on Tuesday reported second-quarter profit of $915.7 million.
  The Boston-based company said it had net income of $3.52 per share. Earnings,..., Headline: Vertex Pharmaceuticals 2Q Profit Up On Higher Cystic Fibrosis Drug Revenue, source:Finnhub, summary: By Paul Ziobro 

  Vertex Pharmaceuticals posted higher second-quarter earnings, boosted by higehr sales of its cystic fibrosis drugs. 

  The Boston-based drugmaker on Tuesday reported a profit of..., Headline: Vertex Pharmaceuticals Incorporated : Q2 2023 Presentation, source:Finnhub, summary: Post PoC VX-880 - Post PoC
          
          
            VX-548  - Phase 2 VX-864  - Phase 2
          
        
      
      
        
          
            
              
                PoC:..., Headline: Vertex second quarter earnings rise, driven by treatments performance, source:Alliance News, summary: No summary, Headline: Vertex Reports Second Quarter 2023 Financial Results, source:Yahoo, summary: BOSTON, August 01, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2023 and updated its full year 2023 financial guidance., Headline: Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength, source:Reuters, summary: Vertex Pharmaceuticals raised its full-year sales forecast on Tuesday, banking on strong demand for its cystic fibrosis (CF) treatment., Headline: Cash Machine Vertex Rides A Single Drug To Its Second-Quarter Beat And Raise, source:Yahoo, summary: Vertex Pharmaceuticals rode cystic fibrosis pill Trikafta to a beat-and-raise on Tuesday, but VRTX stock inched lower., Headline: Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Top Estimates, source:Yahoo, summary: Vertex (VRTX) delivered earnings and revenue surprises of 1.04% and 3.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Dow Jones Futures Fall On U.S. Debt Downgrade; AMD, ELF Lead 5 Earnings Movers Late, source:Yahoo, summary: Futures fell as Fitch downgraded U.S. debt ratings. AMD and ELF Beauty were big earnings movers late, Headline: Vertex Pharmaceuticals Incorporated (VRTX) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:NASDAQ:VRTX) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ETCompany ParticipantsSusie Lisa - CFA, Senior Vice President of Investor..., Headline: Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: My name is Susie Lisa, and as the senior vice president of investor relations, it is my pleasure to welcome you to our second-quarter 2023 financial results conference call.  On tonight's call making prepared remarks we have Dr. Reshma Kewalramani, Vertex's CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer., Headline: Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline, source:Benzinga, summary: No summary, Headline: Bernstein Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",VRTX
292,2023-08-02,"Headline: Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Vertex Pharmaceuticals (VRTX) and IQVIA Holdings (IQV), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $399 from $384 at Barclays, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV), source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $390 from $380 at Bernstein, source:Thefly.com, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $370 from $360 at TD Cowen, source:Thefly.com, summary: No summary, Headline: Vertex Pharmaceuticals price target raised to $425 from $410 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Analysts’ Top Healthcare Picks: Tenet Healthcare (THC), Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Barclays Maintains Vertex Pharmaceuticals (VRTX) Overweight Recommendation, source:Fintel, summary: nan, Headline: Bernstein Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Reiterates Vertex Pharmaceuticals (VRTX) Buy Recommendation, source:Fintel, summary: nan, Headline: Q2 2023 Vertex Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q2 2023 Vertex Pharmaceuticals Inc Earnings Call, Headline: Wells Fargo Maintains Vertex Pharmaceuticals (VRTX) Overweight Recommendation, source:Fintel, summary: nan, Headline: BMO Capital Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: Oppenheimer Reiterates Vertex Pharmaceuticals (VRTX) Outperform Recommendation, source:Fintel, summary: nan, Headline: Vertex Stock Wavers Despite Chock-Full Calendar Of Expected Drug News, source:Yahoo, summary: Vertex Pharmaceuticals faces numerous catalysts this year and next, an analyst said Wednesday. But VRTX stock wavered., Headline: Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View, source:Yahoo, summary: Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023., Headline: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2023 Earnings Call Transcript August 1, 2023 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $3.89, expectations were $3.88. Operator: Good afternoon and welcome to the Vertex Pharmaceuticals Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn […], Headline: Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News, source:Yahoo, summary: Vertex Pharmaceuticals faces numerous catalysts this year and next, an analyst said Wednesday. And VRTX stock popped., Headline: 1 No-Brainer Cathie Wood Stock to Buy Hand Over Fist in August, source:Yahoo, summary: Cathie Wood has made a remarkable comeback in 2023 after a disappointing year for her Ark Innovation ETF in 2022.  The fund has dramatically outperformed the broader markets this year, as investors flock to buy undervalued tech and biotech stocks.  The gene-editing pioneer Crispr Therapeutics (NASDAQ: CRSP), for example, stands out as a potential gold mine for risk-tolerant investors., Headline: S&P 500 Gains and Losses Today: Weak Guidance from AMD Weighs on Chip Stocks, source:Yahoo, summary: The S&P 500 index finished 1.4% lower on August 2, 2023, after chipmaker AMD issued weaker-than-expected third-quarter guidance, which weighed on the sector., Headline: Vertex Pharmaceuticals (VRTX): A Fairly Valued Stock with Strong Growth Prospects, source:Yahoo, summary: Vertex Pharmaceuticals Inc (NASDAQ:VRTX) saw a daily gain of 3.07%, with an Earnings Per Share (EPS) (EPS) of $12.56.  Read on to discover more about Vertex Pharmaceuticals' financial performance and its value as per the GF Value Line.  Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a leading biotechnology company that focuses on the discovery and development of small-molecule drugs for treating serious diseases., Headline: Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",VRTX
293,2023-08-03,"Headline: Here's Why Investors Should Buy These 2 Medical Stocks After Earnings, source:Yahoo, summary: Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock., Headline: Maxim Group Remains a Buy on Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Morgan Stanley Maintains Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Analysts Are Bullish on Top Healthcare Stocks: Oculis Holding (OCS), Vertex Pharmaceuticals (VRTX), source:TipRanks, summary: No summary, Headline: Vertex: VX-548 preclinical studies, Phase 2, proof-of-concept results published, source:Thefly.com, summary: No summary, Headline: This Is Arguably the Single Best Stock to Buy Right Now, source:Yahoo, summary: Here are five arguments for why Vertex Pharmaceuticals (NASDAQ: VRTX) deserves the honor.  Vertex is fresh on my mind because it just reported great second-quarter results.  Vertex's net profit margin of close to 37% makes it one of the most profitable drugmakers on the planet., Headline: Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential, source:GuruFocus, summary: No summary, Headline: Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine, source:Yahoo, summary: BOSTON, August 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries., Headline: Company News for Aug 3, 2023, source:Yahoo, summary: Companies in The News Are: VRTX, DVN, AFL, HUM, Headline: Vertex Pharmaceuticals (VRTX) Gets a Hold from Robert W. Baird, source:TipRanks, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
294,2023-08-04,"Headline: 2 Nasdaq 100 Stocks That Are Surefire Buys in August and 1 to Avoid, source:Yahoo, summary: Two Nasdaq 100 components are plain-as-day bargains, while another Nasdaq 100 stock could struggle to live up to lofty expectations., Headline: Vertex Announces Publication of VX-548 Positive Phase 2 Proof-of-Concept Results in New England Journal of Medicine, source:Finnhub, summary: a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, mRNA, cell..., Headline: 12 Best Biotech ETFs To Buy, source:Yahoo, summary: In this article, we discuss 12 best biotech ETFs to buy. If you want to skip our detailed discussion on the biotech industry, head directly to 5 Best Biotech ETFs To Buy. According to Precedence Research, the worldwide biotechnology market was valued at approximately $1,224.31 billion in 2022. It is projected to reach a value […], Headline: Vertex (VRTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates, source:Yahoo, summary: Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",VRTX
295,2023-08-05,"Headline: 3 Fantastic Growth Stocks to Buy in August, source:Yahoo, summary: What's a great thing to do during the hot month of August? One option is to find somewhere cool. Another is to invest in stocks that could deliver their own kind of sizzle. We asked three Motley Fool contributors to identify some fantastic growth stocks to buy in August., Headline: 3 Top Healthcare Stocks to Buy for August, source:Yahoo, summary: Shares of Humana, Vertex Pharmaceuticals, and Idexx Laboratories have all increased by at least 20% so far this year.",VRTX
296,2023-08-06,"Headline: 2 Top Biotech Stocks to Buy in August, source:Yahoo, summary: Consider biotech giants Vertex Pharmaceuticals (NASDAQ: VRTX) and Eli Lilly (NYSE: LLY).  Vertex Pharmaceuticals is best known for its dominance of the market for therapies that treat the underlying causes of cystic fibrosis (CF).  In the second quarter, the company's top line of $2.49 billion jumped by 14% year over year., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: No summary",VRTX
297,2023-08-07,"Headline: Vertex Pharmaceuticals price target raised to $315 from $312 at Canaccord, source:Thefly.com, summary: No summary, Headline: CRISPR (CRSP) to Post Q2 Earnings: What's in the Offing?, source:Yahoo, summary: CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates., Headline: Canaccord Genuity Maintains Vertex Pharmaceuticals (VRTX) Hold Recommendation, source:Fintel, summary: nan, Headline: Why did CRISPR Therapeutics stock soar today? Q2 results, source:Seeking Alpha, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",VRTX
298,2023-08-08,"Headline: CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected, source:Yahoo, summary: CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales., Headline: Why CRISPR Therapeutics Stock Is Jumping Today, source:Yahoo, summary: Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 9.1% as of 11:31 a.m. ET on Tuesday after rising as much as 13% earlier in the day.  CRISPR Therapeutics reported second-quarter revenue of $70 million.  Credit Suisse's Richard Law reiterated a neutral rating for the gene-editing stock but increased his price target from $62 to $63., Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: No summary",VRTX
299,2023-08-09,"Headline: Is Vertex Pharmaceuticals Stock a Buy Now?, source:Yahoo, summary: As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a broad crowd of investors.  Given its collection of medicines on the market and a highly promising pipeline that's packed with some very sophisticated candidates, buying its shares today could be a great decision in five years.  In short, Vertex is exposed to an abundance of growth opportunities in the near term., Headline: 2 Great Stocks Under $100 to Buy and Hold for 10 Years, source:Yahoo, summary: Neither has performed well over the past year, but investors would do well to focus on the longer term., Headline: 2 Supercharged Growth Stocks That Could Make You Richer, source:Yahoo, summary: If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals (NASDAQ: VRTX).  Exact Sciences is the company behind Cologuard, a noninvasive test that can detect colorectal cancer and a fair amount of pre-cancerous polyps from a stool sample.  Colorectal cancer is the second-leading cause of cancer deaths in the U.S., but it can be prevented or cured if detected early., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",VRTX
300,2023-08-10,"Headline: 3 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming.  The iShares Biotechnology ETF is down more than 3% so far in 2023, and the SPDR S&P Biotech EFT is down more than 5%.  The two ETFs reflect negative market sentiment toward biotech stocks, in general, this year., Headline: 3 Explosive Stocks to Buy Right Now, source:Yahoo, summary: Some stocks are like the jack-in-the-box toy that kids play with. They wait and wait until the time is right, then they suddenly jump. Other stocks are more like the Energizer Bunny. They keep going and going., Headline: Vertex Pharmaceuticals: Strategically Positioning For Future Success, source:SeekingAlpha, summary: Vertex Pharmaceuticals showed strong Q2 '23 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and US growth. Read more here., Headline: Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?, source:Yahoo, summary: Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period.  The company is a leader in cystic fibrosis treatments with an eye for more growth and diversification in the long run.  Does Vertex have the potential to be a millionaire-making investment going forward?, Headline: Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans, source:SeekingAlpha, summary: Vertex Pharmaceuticals is performing well in cystic fibrosis market with its drug Trikafta, leading to 2023 guidance increase. Find out why VRTX stock is a Strong Buy., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",VRTX
301,2023-08-11,"Headline: Meta, Google, Tesla Lead AI Stocks And More For Weekend Watchlist, source:Yahoo, summary: Including Meta, Tesla and Google stock, this screen showcases top-rated AI stocks to watch in the Top 20 industry groups.",VRTX
302,2023-08-13,"Headline: Vertex Pharmaceuticals Still Looks Attractive, source:SeekingAlpha, summary: Vertex Pharmaceuticals' Q2 financials showed strong revenue growth and it has some undervalued pipeline opportunities. Find out why VRTX stock is a Buy., Headline: Want to Get Richer? Buy and Hold These 5 Unstoppable Stocks, source:Yahoo, summary: A recent Bankrate survey found that Americans think they'd need to make $483,000 per year on average to feel rich. Few currently earn that amount, though. No one can honestly guarantee you that you'll become rich based on that definition., Headline: Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years, source:Benzinga, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
303,2023-08-14,"Headline: Second Half Outlook For Biotech Stocks, source:SeekingAlpha, summary: Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts., Headline: Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold, source:Yahoo, summary: The market experienced a wild ride in 2022, making investors hesitant to invest in the stock market.  In this recovering market, growth stocks that are still undervalued are a good option for risk-averse investors.  CRISPR Therapeutics (NASDAQ: CRSP) is a gene-editing biotech company., Headline: Vertex Pharmaceuticals Incorporated 2023 Q2 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2023 Q2 earnings call., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",VRTX
304,2023-08-15,"Headline: 6 Pharma and Life Sciences Stocks That Are Actually Up This Year, source:MarketWatch, summary: For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market., Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",VRTX
305,2023-08-16,"Headline: Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+, source:Yahoo, summary: Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81., Headline: CRISPR Therapeutics upgraded to buy at Citi on near-term approvals, source:Seeking Alpha, summary: No summary",VRTX
306,2023-08-17,"Headline: The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023, source:InvestorPlace, summary: No summary, Headline: Vortex Energy Announces Its 2023 Fall Program on Its Robinsons River Salt Project, source:GlobeNewswire, summary: No summary, Headline: 2 Excellent Stocks to Buy and Hold Forever, source:Yahoo, summary: Let's look at two healthcare companies whose shares are worth buying and holding on to for good: Vertex Pharmaceuticals (NASDAQ: VRTX) and Novartis (NYSE: NVS).  Vertex Pharmaceuticals has been an outstanding performer over the past decade.  In October 2020, Vertex Pharmaceuticals' shares dropped like a rock after it decided to discontinue a phase 2 clinical trial for VX-864, a non-CF program targeting alpha-1 antitrypsin deficiency that many thought was promising., Headline: Vertex Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.13% higher to $343.87 Thursday, on what proved to be an all-around dismal trading session for the stock..., Headline: Peering Into Vertex Pharmaceuticals's Recent Short Interest, source:Benzinga, summary: No summary",VRTX
307,2023-08-18,"Headline: 3 Monster Stocks to Buy Without Any Hesitation, source:Yahoo, summary: Amazon (NASDAQ: AMZN) ranks as one of the biggest monster stocks on the planet with a market cap of close to $1.4 trillion.  The company is also on a roll, with its shares soaring more than 60% year to date.  Amazon has plenty of room to run., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.28% higher to $344.82 Friday, on what proved to be an all-around mixed trading session for the stock market,...",VRTX
308,2023-08-19,"Headline: 4 Superlative Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip, source:Yahoo, summary: With the Nasdaq Composite still 15% below its record-closing high, amazing deals are hiding in plain sight.",VRTX
309,2023-08-20,"Headline: Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk, source:Seeking Alpha, summary: No summary",VRTX
310,2023-08-21,"Headline: Vertex/CRISPR, bluebird sickle cell therapies could be cost-effective - ICER, source:Seeking Alpha, summary: No summary, Headline: Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner, source:TalkMarkets, summary: No summary, Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP., Headline: Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. advanced 1.72% to $350.74 Monday, on what proved to be an all-around mixed trading session for the stock market, with...",VRTX
311,2023-08-22,"Headline: Gene Therapy Breakthroughs On The Horizon, source:SeekingAlpha, summary: The Institute for Clinical and Economic Review has recently released a report about exagamglogene autotemcel from Vertex/CRISPR and lovotibeglogene autotemcel by bluebird. Read more here..., Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Investors looking to earn outsized returns over long periods (which describes most investors) would do well to consider shares of innovative companies such as CRISPR Therapeutics (NASDAQ: CRSP), Sarepta Therapeutics (NASDAQ: SRPT), and DexCom (NASDAQ: DXCM).  Gene-editing specialist CRISPR Therapeutics currently has no products on the market., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.10% to $350.40 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the...",VRTX
312,2023-08-23,"Headline: December 15th Options Now Available For Vertex Pharmaceuticals (VRTX), source:Stock Options Channel, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.06% higher to $350.60 Wednesday, on what proved to be an all-around great trading session for the stock..., Headline: Bluebird bio favored at Baird as sickle cell disease space gets busy, source:Seeking Alpha, summary: No summary",VRTX
313,2023-08-24,"Headline: 3 Clever Tricks to Find Winning Biotech Stocks, source:Yahoo, summary: Investing in biotech is not for the faint of heart, but knowing how to pick probable winners and avoid lemons can make the balance of risks and rewards look a lot more palatable.  In fact, having a playbook of clever tricks is a big part of succeeding.  Teamwork makes the dream work, and that's why most biotech players are eager to forge collaborations with other biopharma businesses, especially larger ones in big pharma., Headline: 2 No-Brainer Biotech Stocks to Buy Right Now, source:Yahoo, summary: Cystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist Exelixis (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.  Vertex is well-known for its cystic fibrosis (CF) drugs and has maintained consistent revenue and profits in recent years., Headline: Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 1.09% to $346.77 Thursday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Got $600? Here are 3 No-Brainer Stocks You Absolutely Must Buy, source:Yahoo, summary: The stock market recovered nicely from last year’s debacle. The Nasdaq Composite Index in particular went from a 34% loss in 2022 to a 29% gain so far this year. Yet even with all the major indexes trading higher than they were at the start of the year, The Dow Jones Industrial Average, S&P 500, and the Nasdaq are all well below their all-time highs of 2021. That suggests investors can still readily find no-brainer stocks to buy if they’re willing to look. And it doesn’t take a lot of money to m",VRTX
314,2023-08-25,"Headline: Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years, source:Benzinga, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.95% higher to $350.06 Friday, on what proved to be an all-around great trading session for the stock market,...",VRTX
315,2023-08-28,"Headline: Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: 3 Top Growth Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Growth stocks are back in style after getting battered in last year's downturn.  Vertex Pharmaceuticals has a significant catalyst ahead.  The company is awaiting approval for exa-cel, a treatment for sickle cell disease (SCD) and beta-thalassemia (TDT) developed with CRISPR Therapeutics., Headline: Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.44% higher to $351.60 Monday, on what proved to be an all-around positive trading session for the stock..., Headline: Crispr Therapeutics: ICER Puzzles The Prospects, source:SeekingAlpha, summary: CRISPR Therapeutics' collaboration with Vertex on gene-editing therapy for sickle cell disease and thalassemia faces uncertainty. Read here for more details.",VRTX
316,2023-08-29,"Headline: Vertex appoints Atkinson  EVP Chief Technical Operations Officer, source:Thefly.com, summary: No summary, Headline: Vertex appoints Atkinson EVP Chief Technical Operations Officer, source:Seeking Alpha, summary: No summary, Headline: Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, source:Yahoo, summary: BOSTON, August 29, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene thera, Headline: IN BRIEF: Vertex puts Atkinson in charge of technical operations, source:Alliance News, summary: No summary, Headline: Vertex Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slipped 0.10% to $351.26 Tuesday, on what proved to be an all-around positive trading session for the stock market,...",VRTX
317,2023-08-30,"Headline: Vertex Pharmaceuticals (VRTX) Receives a Hold from Jefferies, source:TipRanks, summary: No summary, Headline: Vertex (VRTX) Outperforms Industry Year to Date: Here's Why, source:Yahoo, summary: Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio., Headline: Vertex makes room in its C-suite for new technical operations role, source:Yahoo, summary: Vertex Pharmaceuticals Inc. has promoted E. Morrey Atkinson to a new role in its C-suite: chief technical operations officer., Headline: Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. shed 0.14% to $350.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, source:Yahoo, summary: BOSTON, August 30, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Morgan Stanley 21st Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat on Wednesday, September 13, 2023 at 11:30 a.m. ET.",VRTX
318,2023-08-31,"Headline: The 3 Most Promising Biotech Stocks to Own Now, source:Yahoo, summary: Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well for overall economic health and long-term growth. As policies prioritize equitable access to resources such as healthcare, the increased consumer base can stimulate demand across industries. In particular, biotech stands to benefit as advancemen, Headline: Vertex Pharmaceuticals: Critical Period For The Pipeline Is Approaching, source:SeekingAlpha, summary: Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis. Find out why I'm currently neutral on VRTX stock., Headline: Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. slid 0.69% to $348.34 Thursday, on what proved to be an all-around grim trading session for the stock market, with the...",VRTX
319,2023-09-01,"Headline: As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs, source:MarketWatch, summary: No summary, Headline: Drug Developer Stocks Are Risky. Why a Picks-and-Shovels Approach Makes Sense. , source:MarketWatch, summary: Companies like Danaher and Repligen that make the lab equipment and consumables needed to manufacture drugs can produce long-term, stable earnings in a..., Headline: Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Vertex Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Vertex Pharmaceuticals Inc. inched 0.79% higher to $351.10 Friday, on what proved to be an all-around positive trading session for the stock..., Headline: Vortex Energy Announces Further Extension of Marketing Campaign, source:GlobeNewswire, summary: No summary, Headline: Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $351.13, marking a +0.8% move from the previous day.",VRTX
